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SUMMARY
Thymidylate synthase (EC 2.1.1.45) is one of the most highly conserved enzymes. It 
is the sole de novo source of 2’-deoxythymidylate (dTMP) in a diverse range of 
organisms. Thymidylate synthase (TS) catalyses the conversion of 2’-deoxyuridylate 
(dUMP) and N5, N 10-methylene-tetrahydrofolate to dTMP and dihydrofolate. To 
date, sequences are known from 36 different species of TS. These include the human 
enzyme which is a drug target for anti-cancer agents, thymidylate synthases from 
protozoa, which are generally bifunctional with TS and dihydrofolate reductase 
present in a single protein, and TS from bacterial and viral species. TS is an essential 
enzyme to almost all living species and is encoded by several large DNA viruses, 
presumably to support an increased need for DNA synthesis during the viral life 
cycle. There are only a few organisms that adequately scavenge thymidine from their 
environment and do not require TS. The essential requirement for TS activity makes 
TS an important drug target for the development of anti-parasitic and possibly 
antiviral agents.
The work presented in this thesis identifies a mobile surface loop region of TS (the 
DRTG loop) and shows that it is important for substrate turnover. It is implicated in 
packing against the C-terminus of VZV TS facilitating efficient closing of the active 
site upon ligand binding. This loop is highly conserved throughout the TS family 
with the phage 0 3 T  and Ldactis being the most divergent species. Site-directed 
mutagenesis was used to substitute the VZV residues in the DRTG loop for their L. 
lactis counterparts. The resultant variant proteins were dysfunctional in their ability 
to complete the catalytic reaction. With the exception of G40M they could still bind 
the substrate, dUMP.
The development of a region-directed mutagenesis protocol is also described. Such 
an approach was used to select for covariant residues of the DRTG loop mutants that 
might restore activity. In this study, no covariant residues were identified. The 
validity of the protocol was however, shown by generation of several temperature 
sensitive mutants.
The C-terminal region of TS is also mobile and plays a significant role in catalysis by 
closing down the active site upon binding of ligands. Previous studies proposed a
III
unique interaction at the C-terminus of VZV TS and this has been investigated 
further. Mutations of the C-terminus of both VZV and human TS suggest that VZV 
is not unique in this respect.
Temperature sensitive mutants allow the role of amino acid residues in protein 
stability to be investigated. Several temperature sensitive mutants were generated to 
different regions of VZV TS and showed that the enzyme can tolerate many changes 
even within residues that are fully conserved within the TS family.
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o
A angstrom
A600 Absorbance at wavelength 600nm
Amp ampicillin
BrdUMP 5-bromo-2’ -deoxyuridine 5 ’ -monophosphate
BSA bovine serum albumin
C- carboxy-
CB3717 N 10-propargyl-5, 8-dideazafolate
Ci Curie
CIP calf intestinal phosphatase
dATP 2'-deoxyadenosine 5'-phosphate
dCTP 2'-deoxyadenosine 5'-phosphate
dGTP 2'-deoxyadenosine 5'-phosphate
dH20 deionised water
DMSO dimethyl sulphoxide
dsDNA double-stranded deoxyribonucleic acid
DTT dithiothreitol
dTTP 2'-deoxyadenosine 5'-phosphate
dUMP 2’-deoxyuridine 5’-monophosphate
EDTA sodium ethylenediamine tetra-acetic acid
FdUMP 5-fluoro-2’-deoxyuridine 5’ -monophosphate
HSV herpes simplex virus
IE immediate early
IPTG isopropyl-D-thiogalactoside
Km Michaelis-Menten constant
N- amino-
0 phenol
0/CHC13 phenol/chloroform 1:1 (v/v)
OD optical density
PEG polyethylene glycol
ssDNA single-stranded deoxyribonucleic acid
Tris tris(hydroxymethyl)aminomethane
Vmax initial enzyme rate at saturating substrate concentration
VZV varicella-zoster virus
AMINO ACIDS
Amino Acid Three letter code One letter code
Alanine Ala A
Arginine Arg R
Asparagine Asn N
Aspartate Asp D
Cysteine Cys C
Glutamate Glu E
Glutamine Gin Q
Glycine Gly G
Histidine His H
Isoleucine lie I
Leucine Leu L
Lysine Lys K
Methionine Met M
Phenylalanine Phe F
Proline Pro P
Serine Ser S
Threonine Thr T
Tryptophan Trp W
Tyrosine Tyr Y
Valine Val V
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INTRODUCTION
The research presented in this thesis concerns the structural flexibility of the 
thymidylate synthase of varicella zoster virus. This introduction aims to overview 
briefly the biology and molecular biology of herpesviruses and in particular varicella 
zoster virus. The latter sections of this introduction will review the structural and 
enzymatic properties of thymidylate synthase.
1. The Herpesviruses
1.1 Description and classification
Herpesviruses are found in a wide variety of host species, ranging from fish to 
humans (reviewed by Roizman, 1993 and 1996). Nearly 100 herpesviruses have been 
characterised and seven have been isolated from humans [herpes simplex virus 1 
(HSV-1), herpes simplex virus 2 (HSV-2), varicella-zoster virus (VZV), human 
cytomegalovirus (HCMV), Epstein-Barr virus (EBV) and human herpesvirus 6 and 7 
(HHV6 and HHV7)]. Herpes vims-like sequences have ben found in over 90% of 
AIDS-related Kaposi’s sarcoma tissue, indicating that an eighth human herpes vims 
(Kaposi’s sarcoma herpes vims; KSHV) may exist (Chang et al 1994). Membership 
of the family Herpesviridae is based primarily, though not exclusively, on virion 
stmcture. A typical herpes virion consists of a core containing a linear double-stranded 
DNA, an icosahedral capsid approximately 100 to 110 nm in diameter containing 162 
capsomeres, which is surrounded by an amorphous proteinaceous layer of tegument 
which in turn is enveloped in a lipid membrane containing glycoprotein spikes.
Members of the family Herpesviridae are divided into three sub-families, the 
Alphaherpesvirinae, the Betaherpesvirinae, and the Gammaherpesvirinae.
A lp h a h erp esv ir in a e  are neurotrophic vimses which establish latent infections 
primarily in sensory ganglia. They have a variable host range and relatively short 
reproductive cycle (less than 24 hours). Members of this sub-family include herpes
1
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simplex virus type 1 and type 2 (HSV-1, HSV-2), varicella-zoster virus (VZV), 
equine herpesvirus type 1 (EHV-1) and pseudorabies virus (PRV).
Betaherpesvirinae have a restricted host range and long reproductive cycle (greater 
than 24 hours). Infected cells frequently fuse and become enlarged forming giant cells 
or cytomegalia. They can establish latency in secretory glands, lymphoreticular cells, 
kidneys and other tissues. Members of this sub-family include human cytomegalovirus 
(HCMV) and murine cytomegalovirus (MCMV).
Gammaherpesvirinae have a very restricted host range, infecting only the family or 
order to which the natural host belongs. They infect and establish latency specifically 
in T or B lymphocytes. Members of this sub-family include Epstein-Barr virus (EBV), 
herpesvirus ateles (HVA) and herpesvirus saimiri (HVS).
1.2 Biological properties of herpesviruses
Seven herpesviruses which infect humans have be identified to date (see section 1.1). 
They appear to be ubiquitous and transmission is usually by contact between moist 
mucosal surfaces. Serological studies show that a large proportion of the worlds 
population have been exposed to and may be latently infected with one or more 
herpesviruses.
HSV-1 and H SV -2 usually cause cold sores and genital lesions respectively 
(reviewed by Whitley and Gnann Jr 1993). Primary infection can be asymptomatic or 
result in virus replicating at the site of infection to form a localised lesion. Virions are 
transported via the axons to the sensory ganglia that innervate that site of infection. 
Latency is established in the ganglia and the virus remains latent until reactivation. 
Reactivation can occur spontaneously to produce recurrent infection. The frequency of 
reactivation is increased by exposure to sunlight or UV light, tissue damage, immune 
suppression and physical or emotional stress. HSV-2 has long been suspected of an 
association with cervical carcinoma but its role as a causative agent of transformation is 
not clear. The virus can occasionally cause encephalitis or disseminated disease in 
newborn infants.
VZV infection has two distinct clinical manifestations: chickenpox (varicella) and 
shingles (herpes zoster). Varicella represents the primary infection, usually in
2
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childhood and zoster is caused by reactivation later in life of latent virus from sensory 
ganglia (see section 3.1 and 3.2).
H CM V infections are most often asymptomatic and latency is established in the 
absence of any associated disease (reviewed by Alford and Britt 1993). Virulence is 
seen only in the absence of a competent immune system and is a threat in utero, since it 
has the ability to cross the placenta and cause congenital infection which can lead to 
birth defects. It is frequently reactivated after organ transplants and is a common 
opportunistic infection associated with acquired immunodeficiency disease (AIDS).
EBV infects B lymphocytes in the peripheral blood and lymphoid organs causing 
infectious mononucleosis or ‘glandular fever’ (reviewed by Miller 1990). EBV is also 
associated with two specific cancers: Burkitt’s lymphoma and nasopharyngeal 
carcinoma.
H H V -6 is a lymphotrophic virus acquired by most individuals during their first two 
years of life (reviewed by Lopez and Honess 1990). It can cause exanthem subitum, a 
mild fever and rash, but in most cases seroconversion is asymptomatic.
HHV-7 was recently isolated from the T lymphocytes of a healthy individual (Frenkel 
et al 1990). The virus has not yet been associated with any disease but like HHV-6 
linked with rosola in infants (Burns et al 1994, Hidaka et al 1994, Tanaka et al 1994, 
Ueda et al 1994, Ablashi et al 1995).
KSHV (Kaposi’s sarcoma herpes virus) has recently been specultated to be involved 
in the pathogenesis of the Kaposi’s tumour (Schalling et al 1995) because these herpes 
virus-like sequences have also been found in Kaposi’s scarcoma of HIV negative 
individuals.
2. Varicella Zoster virus
As its name implies, varicella-zoster virus (VZV) produces two distinct clinical 
syndromes: chickenpox and shingles. Chickenpox (varicella) is a ubiquitous, highly 
contagious, generalised exanthem that spreads rapidly in a susceptible population and 
displays marked seasonality. Shingles (herpes zoster), in contrast, is a less common 
endemic disease that occurs usually in older or immunocompromised individuals and
3
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is characterised by a painful vesicular eruption generally limited to a single dermatome 
(reviewed by Arvin 1996, Cohen and Straus 1996).
Like other members of the a-Herpesviridae, VZV is an enveloped icosahedral virus 
that contains a double-stranded DNA genome (Almeida et al 1962). The complete 
enveloped virion measures 180 to 200 nm in diameter, while the naked capsid 
measures -95 nm in diameter. The nucleocapsid consists of 162 hexagonal capsomers 
organised in an icosahedron and is surrounded by tegument and finally by a bilayer 
membrane containing radially oriented glycoprotein projections about 8 nm long on its 
outer surface.
VZV is extremely cell-associated and is usually passaged in vitro by seeding infected 
fibroblasts, rather than cell-free virus, onto fresh monolayers. Under these conditions 
it grows relatively rapidly, yet a method for preparing high titre cell-free virus with 
reasonable infectivity still eludes us today. This problem and the lack of a suitable 
animal model for infection has resulted in an almost complete lack of VZV genetics and 
little understanding of VZV gene expression.
2.1 Genome structure
Electron microscopy (Dumas et al 1980) and restriction endonuclease cleavage profiles 
(Dumas et al 1981, Mishra et al 1984, Straus et al 1981, 1982) suggest that the VZV 
genome is approximately 80-87 xlO^ Daltons and thus is one of the smallest 
herpesvirus genomes. It has a G+C content of 46%, which is less than that of most 
herpesviruses. Restriction endonuclease mapping (Dumas et al 1981) showed that the 
genome is composed of two unique regions, U l  (-100 kbp) and Us (5.4 kbp). The 
U s region is flanked by an inverted repeat sequence R l and R s, and the location of 
each repeat is defined by I (internal) or T (terminal) called TRs/IRs which is 6.8 kbp 
(Figure 4). Restriction endonuclease profiles showed that virion DNA molecules 
contain predominately two genome isomers in approximately equal amount which 
differ in the orientation of Us (Dumas eta l 1981, Straus et al 1981, Ecker and Hymen 
1982). However, more recently it has been shown that a minor proportion (-5%) of 
genomes exist with U l inverted (Davison 1984, Kinchington et al 1985, Hayakawa 
and Hyman 1987). Thus, VZV virions contain four genome isomers: two major and 
two minor (Figure. 4). Much of the size differences between the VZV and HSV-1 
genomes may be explained in terms of smaller T R l/IR l ar*d Us regions in VZV.
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Upon entering the cell it is thought that the genome circularizes and that subsequent 
DNA synthesis occurs by a rolling circle mechanism which produces head-to-tail 
concatamers (Davison 1984). Cleavage of unit length molecules is intimately linked to 
their packaging into capsids.
100 120 140
VZV
TRL IRLIRS TRS
US
UL
HSV-1
TRL UL IRL IRS TRS
US
UL US
0—0
95%
5%
F ig u re  4 . Comparison of VZV and HSV-1 genomes
The top panel show s schem atics o f  the VZV (125kbp) and HSV-1 (152kbp) genom es and a scale in 
kbp is shown above. Inverted repeats (TRL/IRL and T R S/IR S) are show n as coloured boxes. The 
bottom  panel show s the different isom ers o f the VZV genom e; the tw o predominant form s contain the 
long segm ent in a single orientation, w hile the short segm ent is detected in an equimolar ratio in 
either o f  the tw o possible orientations, as indicated by the arrows. A sm all percentage o f  the VZV  
D NA  m olecules exist either in a circular form or with the long segm ent inverted. Data taken from 
Dumas e t a l 1981, M cGeoch et a l 1988)
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A major step in improving the understanding of VZV molecular biology was the 
sequencing of the complete genome by Davison and Scott (1986). The DNA sequence 
of the Dumas strain of VZV (Dumas et al 1981) contains 124,884 bp (Davison and 
Scott 1986) and originally 71 ATG initiated open reading frames (ORFs) likely to 
encode proteins were identified. However, a further two ORFs have been identified, 
namely ORF 9A (Barnett et al., 1992) and ORF 33.5 which encodes an N-terminal 
truncated form of ORF 33 (Telford et a l ,  1992). The arrangement in the genome of 
the 73 ORFs in VZV is shown in Figure 5. Three are present twice, being duplicated 
in IRs and TRs and two (42 and 45) are probably expressed as spliced mRNA. Thus, 
there are 68 distinct genes that are arranged compactly on both strands and with little 
extensive overlap.
2.2 Transcriptional analysis
The first transcription maps of the VZV genome came from Ostrove et al 1985 using 
overlapping cloned restriction fragments as probes in Northern blot analysis. 
Subsequently, cytoplasmic polyadenylated transcripts have also been mapped 
(Maguire and Hyman 1986) and using ssDNA probes the direction of each RNA 
species was determined (Reinhold et al 1988). In total 77 RNAs were detected and 
these studies indicated that the size and map locations of many of the VZV transcripts 
were consistent with the open reading frames predicted within the genome sequence 
(Davison and Scott 1986).
The mapping of individual open reading frames to specific genes is also being refined 
as the function of individual genes is identified (Ellis et al 1985, Keller et al 1986, 
Davison et al 1985, Ling et al 1991, 1992).
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2.3 Gene products
Studies of VZV-specific proteins has also been hampered by the difficulties associated 
with purification of VZV virions. Analysis of virus-specific proteins is further 
comfounded by the high background rate of host cell protein synthesis in the relatively 
asynchronous VZV infection. Most studies of VZV proteins have employed 
polacrylamide gel electrophoresis of solubilized proteins derived either from purified 
virions or infected cells. Virus specificity has been confirmed by immunoprecipitation. 
With the publishing of the VZV DNA sequence (Davison and Scott 1986), comparison 
of the predicted VZV ORFs with those of the more fully characterised HSV-1 proteins 
permitted many gene functions to be assigned. Additional information as to the likely 
function of the predicted VZV genes has also been gained from either sequence 
comparison with non-herpesvirus proteins or from experimental work (reviewed by 
Davison 1991). The genetic relationship between VZV and HSV-1 forms the major 
basis for the properties or functions assigned to the VZV genes in table 2.
Four of the five HSV-1 immediate early genes (i.e. those expressed in the absence of 
host protein synthesis) have VZV counterparts (genes 4, 61, 62 and 63) and these are 
likely to play roles in the regulation of VZV gene expression of similar importance to 
their HSV-1 counterparts.
Five membrane glycoproteins (gpI-gpV) were proposed from the VZV DNA sequence 
and in addition four genes (5, 13, 32 and 50) are likely to be associated with 
membranes since they are multiply hydrophobic.
VZV (like HSV-1, and a characteristic of herpesviruses not shared with other animal 
nuclear DNA viruses) specifies a large number of enzymes involved in DNA 
synthesis. The VZV pyrimidine deoxyribonucleoside kinase (dPyK) was identified on 
its homology to the HSV-1 thymidine kinase (TK). In addition to specifying a dPyK 
(gene 36) which is involved in the salvage pathway for thymidine metabolism, VZV is 
unique among the alphaherpesviruses in that it also encodes a gene for thymidylate 
synthase (TS). VZV gene 13 was predicted to encode a TS enzyme by its homology to 
non-herpesvirus TS enzymes (Davison and Scott 1986) and the ability of the VZV TS 
to compliment E.coli T h y  strains (Thompson et al 1987). Thus VZV supplements 
both pathways for providing thymidylate and it is possible that dPyK and TS are 
required at different stages of viral pathogenesis.
8
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VZV Gene HSV-1 Counterpart Protein/function
1 Function Unknown
2 — Function Unknown
3 UL55 Function Unknown
4 UL54 IE protein; Post-translational regulator of 
gene expression
5 UL53 Possible membrane protein
6 UL52 Component of DNA-helicase-primase
7 UL51 Function Unknown
8 UL50 Deoxyuridine triphosphatasae
9 UL49 Tegument protein
9A UL49A Possible membrane protein
10 UL48 Tegument protein; transactivates IE genes
11 UL47 Tegument protein
12 UL46 Modulates IE gene transactivaton by UL48 
protein
13 — Thymidylate Synthase
14 UL44 Membrane glycoprotein (gpV) -role in cell 
entry
15 UL43 Function Unknown, probable integral 
membrane protein
16 UL42 Subunit of DNA polymerase
17 UL41 Virion host shutoff protein
18 UL40 Ribonucleotide reductase small subunit 
(R2)
19 UL39 Ribonucleotide reductase large subunit 
(R l)
20 UL38 Capsid protein
21 UL37 Possible DNA binding function
22 UL36 Tegument protein
23 UL35 Capsid protein
24 UL34 Membrane-associ ated phosphoprotein
25 UL33 Role in capsid maturation/DNA packaging
26 UL32 Function Unknown
9
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VZV Gene HSV-1 Counterpart Protein/function
27 UL31 Function Unknown
28 UL30 Catalytic subunit of DNA polymerase
29 UL29 Single-stranded DNA binding protein
30 UL28 Role in capsid maturation/DNA packaging
31 UL27 Membrane glycoprotein (gpll) -role in cell 
entry
32 — Function Unknown
33 UL26 Protease involved in virion maturation
33.5 UL26.5 Internal protein of immature capsids 
(processed by UL26 in HSV-1)
34 UL25 Virion protein
35 UL24 Function Unknown
36 UL23 Thymidine kinase
37 UL22 Membrane glycoprotein (gpIII) -role in cell 
entry
38 UL21 Role in virion morphogenesis
39 UL20 Integral membrane protein; role in virion
egress
40 UL19 Major capsid protein
41 UL18 capsid protein
42+45 UL15 Possible terminase
43 UL17 Function Unknown
44 UL16 Function Unknown
46 UL14 Function Unknown
47 UL13 Tegument protein; probable protein kinase
48 UL12 DNase- role in maturation and packaging 
of DNA
49 UL11 Myristylated tegument protein- role in 
envelopment and virion transport
50 UL10 Probable integral membrane protein
51 UL9 On-binding protein; DNA helicase
52 UL8 Component of DNA helicase-primase 
complex
\
\
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VZV Gene HSV-1 Counterpart Protein/function
53 UL7 Function Unknown
54 UL6 Role in virion morphogenesis
55 UL5 Component of DNA helicase-primase 
complex
56 UL4 Function Unknown
57 — Function Unknown
58 UL3 Function Unknown
59 UL2 Uracil-DNA glycosylase
60 UL1 Function Unknown
61/71 RL2 IE protein; transcriptional regulator
62 RSI IE protein; transcriptional regulator
63/70 US1 IE protein; transcriptional regulator
64/69 US2 Virion protein
65 US9 Tegument protein
66 US3 Protein kinase
67 US7 Membrane glycoprotein (gpIV)
68 US8 Membrane glycoprotein (gpl)
T ab le  2. Functions or putative properties of VZV proteins 
D ata taken from  D avison 1991, 1993; Ostrove 1990; M cG eoch e t a l  1993.
One important feature of gene 13 is that it is one of the five VZV genes (1, 2, 13, 32 
and 57) with no HSV-1 counterpart. The only other herpesviruses possessing a TS 
gene are members of the subgroup gammaherpesviruses typified by herpesvirus 
saimiri (Honess et al 1986). In the same way that the TS gene was identified by its 
homology to non-herpesvirus proteins, the products of two VZV genes 47 and 66, 
encode proteins with homology to serine-threonine protein kinases (McGeoch and 
Davison 1986, Smith and Smith 1989). VZV also encodes a ribonucleotide reductase 
(genes 18 and 19) which catalyses the conversion of ribonucleoside diphosphates to 
their corresponding deoxyribonucleotides. Furthermore VZV encodes a deoxyuridine 
triphosphatase (dUTPase) an enzyme that catalyses the conversion of deoxyuridine 
triphosphate (dUTP) to its corresponding monophosphate (dUMP) with the 
concomitant release of pyrophosphate.
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2.4 Regulation of gene expression
Understanding of the temporal expression of VZV genes is still in its infancy and like 
many of the experiments with VZV has been hampered by the difficulty of inducing 
co-ordinate infections and in obtaining cell-free virus of sufficiently high titre. It is still 
not clear whether VZV follows a distinct cascade pattern during which the three classes 
of genes (immediate early, early and late) are sequentially expressed as found in other 
herpesviruses such as HSV-1.
Four of the five immediate early HSV-1 genes have VZV counterparts, they are genes 
4, 61, 62 and 63.
The product of VZV gene 4 is the sequence homologue of HSV-1 Vmw63 sharing 
29% amino acid homology (McGeoch et al 1988). However, VZV gene 4 only 
partially complements an HSV-1 virus with a ts lesion in Vmw63 when supplied by 
co-infection with VZV or from a transformed cell line (Felser et al 1987, Moriuchi et al
1994). Furthermore, the cell line expressing VZV gene 4 fails to complement an HSV- 
1 virus carrying a Vmw63 deletion mutation (Moriuchi et al 1994). VZV gene 4 was 
found by transient transfection analysis to activate expression of a variety of VZV and 
cellular genes both alone and in synergy with the product of VZV gene 62. This 
transactivation by gene 4 shows a degree of selectivity, as only IE gene 62 and a 
selection of putative early VZV genes were activated (Inchauspe et al 1989, Inchauspe 
and Ostrove 1989, Perera et al 1992, Defechereux et al 1993, Moriuchi et al 1994). 
The regulatory functions of gene 4 appeared to influence both transcriptional and post- 
transcriptional events, as the increase in reporter mRNA levels following transfection 
of a plasmid expressing gene 4 could not alone account for the high levels of reporter 
enzyme activity (Defechereux et al 1993). Therefore, in common both VZV gene 4 and 
its HSV-1 counterpart appear to influence pre-mRNA processing. Thus despite the 
functional similarities of these transcriptional activator proteins, their precise 
mechanisms of action differ.
The VZV gene 61 product shows limited sequence homology to HSV-1 VmwllO 
(encoded by the HSV-1 IE1 gene) but in contrast to IE1, gene 61 is only represented 
once in the viral genome. The gene 61 protein has recently been characterised as a 
nuclear, phosphorylated heterogeneous species of 62-65 kD (Stevenson et al 1992). 
Even though sequence similarities between HSV-1 VmwllO and VZV gene 61 are 
confined to the N-terminus, to sequences spanning the VmwllO zinc-finger, a stable 
cell line expressing gene 61 is able to complement a Vmwl 10 deletion mutant HSV-1
12
Introduction
virus (Moriuchi et al 1992). Transient assays have demonstrated VZV gene 61 to be a 
potent trans-repressor or activator of gene 4 and gene 62 mediated activation, 
depending on the cell type used (Nagpal and Ostrove 1991, Perera et al 1992a). The 
evidence so far suggests that VZV gene 61 may be important for up-regulating VZV 
gene expression at an early stage in the viral life cycle.
The product of VZV gene 62 is the sequence homologue and functional counterpart of 
the product of HSV-1 gene IE3, Vmwl75. Transient transfection assays have been 
used to demonstrate that VZV gene 62 is a potent transactivator of all classes of VZV 
promoters and also heterologous promoters at the transcriptional level (Everett 1984, 
Inchauspe et al 1989, Cabirac et al 1990, Inchauspe and Ostrove 1989, Perera et aL 
1992a, 1992b). Like its HSV-1 counterpart protein VZV gene 62 negatively 
autoregulates its own expression in transient transfection assays, although this appears 
to occur in a cell type dependent manner (Disney et al 1990, Perera et al 1992b). The 
high abundance of VZV gene 62 within the virion tegument (Kinchington et al 1992) 
may have implications for VZV gene regulation, following release from the tegument, 
gene 62 may activate the other IE promoters in advance of de novo viral protein 
synthesis, playing a role analogous to HSV-1 Vmw65.
The product of VZV gene 63 shows partial sequence homology to HSV-1 Vmw68 
(encoded by HSV-1 gene IE4), although VZV gene 63 is diploid in contrast to HSV-1. 
As is the case with HSV-1 Vmw68, the functions of the VZV protein are poorly 
understood. A transient transfection study of gene 63 function reports that VZV gene 
63 inhibits expression of VZV gene 62, activates early but has no effect on putative 
late VZV promoters (Jackers et al 1992). However, a more recent study (Kost et al
1995) demonstrated that gene 63 exerts only minimal effects on immediate early and 
early promotors and in contrast to the work of Jackers et al it did not directly inhibit 
the expression of gene 62. A study of the functional interplay between gene 63 and the 
other VZV IE proteins is required before speculation as to its likely role in infection.
2.5 DNA replication
VZV is genetically related to other alphaherpesvirinae such as the two serotypes of 
herpes simplex virus (HSV-1 and HSV-2) and pseudorabies virus (PRV). A model for 
VZV DNA replication has been proposed by Davison (1984) based upon the structural 
features of the viral genome and experimentally supported views of PRV and HSV-1 
DNA replication.
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Linear VZV DNA in one of its four isomeric forms (Figure 4) circularizes, probably 
by direct ligation of the termini to produce a novel L-S joint identical in sequence to the 
normal L-S joint in the linear genome. After circularization limited replication of 
circular molecules occurs, and segment inversion takes place by intramolecular 
recombination between inverted repeats. DNA replication proceeds by the generation 
of head-to-tail concatamers, perhaps by a rolling circle mechanism, as has been shown 
for PRV and HSV-1 (Ben-Porat and Rixon 1979, Jacob et al 1979). Finally the 
concatamers are cleaved specifically to generate unit length genomes for encapsidation. 
Cleavage usually occurs at the novel L-S joint but occasionally at the normal L-S joint, 
generating the major and minor genome arrangements.
The biochemical processes of viral DNA replication are unlikely to differ markedly 
between VZV and HSV-1 because each of the seven HSV-1 genes that are essential for 
HSV-1 DNA replication (Wu et al 1988) have VZV sequence homologues; VZV genes 
6, 16, 28, 29, 51, 52 and 55 (Davison and Scott 1986). Only one of these, the product 
of gene 51, has been extensively characterized in any detail (Stow et al 1990). This 
protein, the counterpart of HSV-1 gene UL9, has been shown to bind to VZV origin 
of replication, (Stow et al 1990). A VZV origin of replication has been identified 
within each copy of the genome short repeat, in a position analogous to that occupied 
by one of the HSV-1 replication origins (ORIs) (Stow and Davison, 1986). No VZV 
counterpart of the HSV-1 ORIl origin of replication has been identified to date, 
perhaps because its putative location in the long unique segment of the VZV genome is 
highly unstable on cloning (Davison and Scott, 1986) and it is therefore possible that 
such an element may have become deleted.
2.6 Latency
Both HSV and VZV have a propensity to establish long term latency as a consequence 
of primary infection and to emerge from latency and again cause clinically important 
disease. In addition, each virus can produce vesicular mucocutaneous eruptions during 
both primary and reactivation disease. Despite these shared properties, important 
differences remain between HSV and VZV. The clinical characteristics (reviewed by 
Meier and Straus, 1992) that distinguish the reactivation infection caused by these 
viruses highlight their many unique biological properties. Table 3 illustrates some of 
these clinical characteristics and they imply that each virus has evolved a unique 
strategy to ensure the establishment, maintenance, and reactivation of latency.
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Feature VZV HSV
Frequency of recurrences in 
lifetime
Usually once To several hundred
Likelihood of recurrence Increases with age Decreases over time
Distribution Dermatome Focal lesion
Associated pain Severe pain Mild dysesthesia
T a b l e  3 .  Features of VZV and HSV reactivation infections (adapted from Croen and 
Straus 1991)
Animal models and neuronal cell culture systems have permitted a detailed analysis of 
the pathway to HSV latency and subsequent reactivation. Initial mucocutaneous 
infection with HSV-1 entails viral multiplication in epithelial cells that extends locally 
to involve the distal sensory nerves. Upon entering the nerve the nucleocapsid is 
transported to the neuronal cell body residing in the sensory ganglia. Once in the 
ganglia the pattern of gene expression changes dramatically. All genes responsible for 
viral reproduction are shut off except for one duplicated region of the genome that 
remains transcriptionally active, producing a family of RNAs referred to as the latency- 
associated transcripts (LATs) which are anti-sense, relative to the Vmwl 10 mRNA.
The cellular location of HSV latency has been determined by in situ hybridisation 
analyses using nucleic acid probes that specifically detect the LATs (Stevens et al 
1987, Dealty et al 1988, Croen et al 1987, 1991, and Stroope et al 1984) and 
revealed that HSV-1 and HSV-2 LATs persist at high levels in neuronal nuclei. When 
reactivation occurs, the virus resumes widespread transcriptional activity to produce 
progeny vims that is then transported centrifugally via the axon to the epithelial surface 
where it multiplies and spreads.
Little is known about the mechanism by which VZV establishes latency in sensory 
ganglia. By analogy to HSV, it is thought that VZV travels by route of sensory nerves 
using axonal transport. Detailed analysis of ganglia latently infected with VZV (Croen 
et al 1988) has shown that many regions of the genome appear not to be expressed 
during latency. Using unidirectional probes five regions of the genome appear to be
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transcribed during latency. Potential transcripts contained in these regions include gene 
3 (unknown function), gene 4 (transcriptional activator homologue of HSV-1 
Vmw63), gene 5 (Possible membrane protein), gene 6 (DNA helicase-primase 
complex) and gene 8 (deoxyuridine triphosphatase) or gene 29 (major DNA binding 
protein), gene 30 (role in capsid maturation/DNA packaging), gene 31 (gpll), gene 32 
(unknown function) and gene 62 (transcriptional activator, homologue of HSV-1 
Vmwl75) assuming that transcription in the ganglion cell is in the same direction as 
that which occurs during a productive virus infection. Further work involving 
explantation and in vitro cultivation (Vafai et al 1988) detected, by 
immunoprecipitation, seven “VZV specific” polypeptides of 35, 36, 45, 100, 140, 170 
and 200 kDa. VZV genes 62 and 63 are predicted to encode proteins of 140 kDa and 
30 kDa respectively and thus the polypeptides of similar size detected in these 
experiments may be related to the products of genes 62 and 63.
Interestingly, studies to date confirm that VZV lacks a transcript comparable to the 
LATs of HSV-1 and HSV-2 (Croen et al 1988, Vafai et al 1988, Croen and Straus 
1991). The latency transcripts of bovine herpesvirus (BHV) and pseudorabies virus 
(PRV) are antisense to another immediate early gene, in each case one equivalent to the 
Vmwl75 of HSV. VZV possesses a Vmwl75 homologue (gene 62), but transcripts to 
this gene have not been detected during latent VZV infections (Croen and Strauss 
1991).
Clearly VZV has a unique pattern of gene activity that sets it apart from the other 
neurotrophic herpesvirus.
The cellular location of VZV latency has been analysed by in situ hybridisation and 
found to be the neuronal cell (Hyman et al 1983, Gilden et al 1987) and more 
recently in non-neuronal cells immediately surrounding the neuron (Croen et al 1988). 
The phenotype of the non-neuronal cell latently infected with VZV has not been 
determined with certainty, but its morphology and proximity to neuronal cells suggest 
it is a satellite cell. These cells structurally resemble Schwann cells and indeed may be 
the ganglion equivalent of the Schwann cell.
In summary comparative analysis of epidemiology, clinical presentation, pathogenesis, 
and molecular biology of HSV and VZV latency reveals striking differences. Data 
suggest that clinicoepidemiologic features that distinguish these viruses are attributable 
to their different cellular sites of viral persistence and molecular strategies used to 
modulate latency. Central to this is the presumed cellular sites of latency (Figure 6a 
and 6b). A neuronal cell latently infected with HSV is subject to repeated provocations
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from variety of stimuli acting centrally or peripherally upon the neuron so as to trigger 
viral reactivation. This reactivation process remains confined to the immediate area of 
the involved neuron thus causing minimal neuralgia and localised mucocutaneous 
eruptions (Figure 6a).
Neuronal Cell
Satellite Cell
Sensory Nerve 
Ganglion
Skin
Neuronal Cell
Satellite Cell
Sensory Nerve 
Ganglion
Skin
F i g u r e  6 a  Schematic of hypothetical model of HSV latency and reactivation
The lop  panel show s latent HSV infection o f  neuronal ce lls  and the bottom panel show s reactivation 
o f HSV and axonal transport to a sm all area o f  the skin. Depicted in red is the presence o f  virus and in 
yellow  areas o f productive viral replication. Adapted from M eier and Straus 1992.
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In contrast, latent VZV appears to reside in the satellite cell, which may be less readily 
influenced by stimuli that perturb neurons. Nevertheless, viral reactivation may occur 
eventually, yielding extensive viral proliferation and cell-to-cell spread.
Neuronal Cell
Satellite Cell
Sensory Nerve 
Ganglion
Skin
Neuronal Cell Satellite Cell
Sensory Nerve 
Ganglion
Skin
F i g u r e  6  b  Schematic of hypothetical model of VZV latency and reactivation
The top panel show s latent VZV infection o f non-neuronal ce lls  (satellite cells) and the bottom  panel 
show s reactivation o f  VZV , spread to non-neuronal and neuronal ce lls , and transport via axons to a 
large part o f  the dermatome. Depicted in red is the presence o f  virus and in yellow  areas o f  productive 
viral replication. Adapted from Meier and Straus 1992.
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In the process, numerous neurons are infected, leading to dermatomal vesicular 
eruptions (Figure 6b). The cumulative damage to the ganglion and its neural 
projections is substantial, potentially causing troublesome neuralgia.
2.7 VZV growth in animal models
Varicella-zoster virus is highly species-specific and has been demonstrated to naturally 
infect only humans and great apes. Simian varicella, a group of antigenically related 
agents distinct from VZV, infects cercopithecoids producing severe varicella-like 
disease but does not infect humanoids. Seroconversion following inoculation of VZV 
in small laboratory animals has been demonstrated in the rat, rabbit, and guinea pig 
(reviewed by Myers and Connelly 1992); however, animal-to-animal spread, viremia, 
and exanthem have been demonstrated only in guinea pigs. Both humoral and cellular 
immune responses to VZV infection have also been examined in the guinea pig and 
rabbit. Animal models of VZV persistence have been elusive although persistence may 
be established in the rat. Naturally occurring varicella of a gorilla has been documented 
with virus recovered from vesicular lesions (Myers et al 1987). This model was 
predictably too unfriendly to pursue further.
2.8 VZV growth in vitro
V Z V  has been propagated in a variety of primary cell lines, usually of human or simian 
origin, although continuous cell lines such as Vero or human melanoma cells have also 
been employed with equal success. However, even cultured cells derived from the 
natural host are considered to be only partially permissive for VZV growth as they do 
not readily support the production of cell-free infectious virus (Weller and Witton, 
1958). The investigation of all aspects of VZV biology and structure have been 
significantly impaired by the inability to isolate stable, high titre stocks of cell-free 
virus. Consequently VZV growth in tissue culture is very poorly characterised.
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3. Biology of varicella-zoster virus
3.1 Varicella: Pathogenesis and Disease
Knowledge of the pathogenesis of varicella comes primarily from analogy with other 
viral exanthems because the clinical disease is quite benign and no suitable 
experimental models are available.
The virus apparently enters through the mucosa of the upper respiratory tract and 
oropharynx or via the conjuctiva. Viral replication begins at the primary inoculation 
site, and subsequently virus disseminates via the bloodstream and lymphatics. After 
this primary viraemia the virus is then taken up by cells of the reticuloendothelial 
system, where it undergoes multiple cycles of replication, and in most cases, 
overwhelms the immune system to develop extensive secondary viraemia. This 
secondary viremia is associated with prodomal symptoms, which are then followed by 
cutaneous and mucosal lesions (Gelb 1993). These lesions appear in successive crops, 
probably reflecting cyclic viremia. The viremic phase is terminated in about three days 
by specific humoral and cellular responses, after which no new lesions appear but 
existing vesicles may continue to enlarge.
The rash of varicella is the most typical feature of the disease which usually begins 
after an incubation of 14 or 15 days. These lesions dry and the crusts fall off in one to 
three weeks. Successive crops of lesions appear over two to four days with lesions 
tending to appear first on the scalp and trunk spreading to the extremities. The 
distribution is predominately central, with the greatest density of lesions found on the 
trunk, which correlates with later presentation of herpes zoster. The illness is generally 
benign and while new lesions continue to appear is accompanied by a mild fever 
(Broughtion 1966). The most marked symptom is pruritus, which lasts throughout the 
vesicular stage. Increased severity of the disease is more common in adults and in the 
immunocompromi sed.
The most common complication of varicella (in the normal host) is bacterial 
superinfection of the skin lesions, which can lead to scarring and rarely septicaemia or 
metastatic infections elsewhere (Bullowa and Wishik 1935) but it usually responds to 
antibiotics. Increased severity of disease is more common in adults and in the 
immunocompromised. Varicella pneumonia is the most common serious complication
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in adults with mortality in the range 10% to 40% (Guess 1986). Pregnant women are 
at greater risk of varicella pneumonia than other adults, with a reported incidence of 
symptomatic pneumonia of almost 10% (Paryani and Arvin 1986). The severity and 
complications of varicella are significantly increased in immunocompromised patients, 
particularly leukaemics, those receiving immunosuppresive chemotherapy or with 
acquired immunological deficiencies (Feldman et al 1975, Krugman et al 1977). Fatal 
cases have widespread visceral dissemination, varicella pneumonia, and often 
encephalitis which is responsible for 20% of hospitalizations with varicella (Fleisher et 
al 1981, Feldman et al 1975).
3.2 Zoster: Pathogenesis and Disease
The pathogenesis of herpes zoster is also not well understood. The current model of 
zoster pathogenesis is based primarily on clinical and epidemiological data as well as 
on analogy with recurrent HSV infections (Hope-Simpson 1965). Once in the 
ganglion, the virus sets up a latent infection or is actually a persistent infection in 
which some VZV is constantly being produced. In either case, the infection remains 
quiescent until reactivation in the form of herpes zoster. These reversions are sporadic 
and infrequent. There is no temporal or spatial relationship to clinical varicella, and all 
evidence points to endogenous reactivation of virus in a previously infected host. 
When herpes zoster does appear, it occurs with the greatest frequency in those 
dermatomes in which the rash of varicella is most dense. The mechanism of 
reactivation is unclear and many conditions have been associated with the appearance 
of herpes zoster such as Hodgkin’s disease and other lymphomas, immunosuppresive 
drugs and trauma to the spinal cord and adjacent structures (Gelb 1993). Since many 
of these precipitating conditions are associated with immunosuppression, it led to the 
proposal (Hope-Simpson 1965) that it is the deterioration of host defences below the 
level of containment that allows VZV to begin active replication in the sensory ganglia. 
The tiny dose of infectious virus that results is immediately contained by circulating 
antibody or cell-mediated immunity. When host defences deteriorate to the point that 
VZV replication can no longer be contained, extensive viral multiplication occurs in the 
ganglion, producing severe neuronal necrosis and intense inflammation, often with 
associated neuralgia. Infectious virus then spreads antidromically down the sensory 
nerve and infects the skin, where it produces the characteristic clustered vesicles of 
herpes zoster. Occasionally, the immune response is able to abort the cutaneous 
lesions, but not the necrosis and inflammatory response in the ganglion. This results in 
radicular pain and associated skin lesions
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The rash of herpes zoster is usually preceded by pain and paresthesias in the involved 
dermatome. This begins several days before the eruption and ranges from mild itching 
or tingling to severe pain. The eruption of herpes zoster is characteristically unilateral, 
does not cross the midline, and is limited to the cutaneous innervation of a single 
sensory ganglion. The lesions are typically varicelliform and may be scattered in 
patches within the involved dermatome or so numerous as to form an almost confluent 
plaque. Crusts may take a week to form and persist an additional two to three weeks. 
Dermal involvement is more common in zoster and there is a greater propensity for 
scarring (Gelb 1993).
The most common complication of herpes zoster is post-herpetic neuralgia, which 
occurs in 50% of patients older than 60 years of age, but rarely in those under 40 
years. It is especially common with ophthalmic zoster (de Morgas and Kierland 1957) 
and is often difficult to treat. The incidence of true post-herpetic neuralgia (pain lasting 
more than one month) is estimated to between 9 and 14%. It resolves within two 
months in about 50% of patients and within one year in 70-80%. The pain can last a 
decade or more in a small fraction of patients. As in varicella, there may be superficial 
gangrene with delayed healing or secondary bacterial infection. Severe eye 
involvement may lead to corneal opacification or secondary bacterial panophthalmitis. 
Most other complications of herpes zoster are related to virus spread. As with 
varicella, herpes zoster tends to be much more severe (as well as more common) in 
immunocompromised individuals or those with malignancies.
4. Antiviral Strategies
There has always been considerable interest in specific anti-VZV therapy because 
varicella, particularly in the immunocompromised, can cause significant morbidity and 
even mortality. The current approach to the management of varicella-zoster virus 
infections involves choices among various therapeutic and preventive strategies (the 
most simplest being isolation of infectious individuals).
4.1 VZV immune globulin and zoster immune plasma
Initial attempts at passive immunization employed large doses of standard immune 
serum globulin (ISG). This could attenuate but not prevent varicella in normal children 
if given within three days of exposure (Ross 1962). Administration of varicella-zoster
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immune globulin (VZIG), a high titre VZV antibody preparation, was able to prevent 
varicella in normal children under similar circumstances(Brunell et al 1969), as well as 
modify disease in immunosupressed children (Gershon et al 1974, Zaia et al 1983). 
Zoster-immune plasma (ZIP), VZV convalescent plasma, will also modify or prevent 
varicella in susceptible high-risk children (Geiser et al 1975). Unfortunately VZIG 
does not modify zoster infections.
4.2 Vaccination
An alternative approach to post-exposure prophylaxis is the use of the live (Oka strain) 
attenuated varicella vaccine (Takahashi et al 1974, 1975). If administered within 72 
hours of exposure this vaccine is able to prevent clinical varicella in normal susceptible 
children (reviewed by Gershon et al 1993). Although questions have been raised about 
persistence of immunity, degree of attenuation, risk of secondary spread, possible 
oncogenicity, and potential for reactivation as herpes zoster, the vaccine appears both 
safe and effective even in immunocompromised patients (Gelb 1993).
4.3 Antiviral compounds and resistance
Compared to the remarkable progress made in the treatment of bacterial infections over 
the past four decades, advances in the chemotherapy of viral diseases have occurred at 
a slower pace. Only a few antiviral agents of proven clinical value for a limited number 
of indications are available (reviewed by Whitley and Gnann Jr 1993).
Three antiviral compounds have been proven efficacious in varicella: leukocyte 
interferon, vidarabine and acyclovir. Human leukocyte or alpha-interferon has 
favourably altered varicella in children with cancer (Arvin et al 1982). However, it 
must be given parenterally and has several associated toxicides. Consequently, most 
studies have employed either of the two nucleoside analogues. Vidarabine (adenosine 
arabinoside) has proven efficacy in both varicella and zoster and also has some toxicity 
(Whitley et al 1982, Whitley and Alford 1981). Acyclovir (a guanosine derivative with 
an acyclic side chain) has largely superseded vidarabine for most applications. It has 
been shown to prevent the development of pneumonitis and systemic infection in 
immunosuppressed children with varicella (Prober et al 1982). Several nucleoside 
analogues (such as bromovinyl arabinosyl uracil [BV-araU], fluroiodoarabinosyl 
cytosine and its analogues and phosphonate methyl derivatives) have been shown to 
have antiviral activity in vitro and many are undergoing further investigation or are in
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clinical trials (Whitley and Gnann Jr 1993, Cameron 1993). Antiviral compounds are 
not always beneficial, cytosine arabinoside and iododeoxyuridine, for example, have 
proven too toxic for systemic use in VZV infections and may actually worsen the 
disease (Gelb 1993).
The use and possible overuse of VZV-specific antivirals raises the question of antiviral 
drug resistance. As with herpes simplex virus, acyclovir-resistant varicella-zoster 
viruses can be readily selected in the laboratory by growth in the presence of acyclovir, 
and the first observation of a clinical isolate resistant to acyclovir has been reported 
(Averett et al 1987). The mechanisms by which the virus becomes resistant are the 
same as with herpes simplex virus, namely, mutation of the viral thymidine kinase or 
polymerase genes. Unlike herpes simplex virus, however, varicella-zoster virus 
disseminates readily, and the spread of resistant virus in immunosuppressed patients 
could result in increased visceral disease.
5. Thymidylate synthase
Thymidylate synthase (EC 2.1.1.45) is one of the most highly conserved enzymes 
with a evolutionary period of -23 million years -  the meantime it took to accept a 
single amino acid change during the divergent evolution of TS (Stroud and Finer- 
Moore 1993). Thymidylate synthase (TS) is the sole de novo source of 2’- 
deoxythymidylate (dTMP) in a diverse range of organisms. TS catalyses the 
conversion of 2’ -deoxy uridyl ate (dUMP) and N 5, N 10-methylene-tetrahydrofolate to 
dTMP and dihydrofolate (reviewed by Carreras and Santi 1995). To date, sequences 
are known from 36 different species of TS. These include the human enzyme; which is 
a drug target for anti-cancer agents; thymidylate synthases from protozoa, which are 
generally bifunctional (Ivanetich and Santi 1990), with TS and dihydrofolate reductase 
present in a single protein, and TS from bacterial and viral species. TS is an essential 
enzyme to almost all living species and is coded for within several large DNA viruses, 
presumably to support an increased need for DNA synthesis during the viral life cycle. 
There are only a few organisms that adequately scavenge thymidine from their 
environment and do not require TS (Stroud and Finer-Moore 1993). The essential 
requirement for TS activity makes TS an important drug target for the development of 
anti-parasitic, anti-fungal, and possibly antiviral agents.
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5.1 The thymidylate cycle
Efficient DNA synthesis requires the presence of adequate pools of the four 
2 ’-deoxyribonucleotides, dATP, dCTP, dGTP and dTTP. The first three of these are 
synthesised by direct reduction of their corresponding ribonucleotides in a reaction 
catalysed by ribonucleotide reductase (Figure 7). In eukaryotes and certain 
prokaryotes, reduction occurs at the diphosphate level and is followed by 
phosphorylation of the dNDPs to dNTPs by the enzyme nucleoside diphosphate 
kinase. In other prokaryotic organisms reduction occurs at the triphosphate level. 
Ribonucleotide reductase also mediates the synthesis of the 2’-deoxyribonucleotide 
dUTP. As dTTP has no ribonucleotide counterpart, it cannot be synthesised in the 
same way. Instead, it is synthesised de novo , commencing with the formation of 
thymidylate (dTMP) from deoxyuridylate (dUMP) in a reaction catalysed by 
thymidylate synthase (Figure 8).
Deoxyuridylate is provided by the hydrolysis of dUTP, catalysed by deoxyuridylate 
triphosphate dephosphohydrolase (dUTPase) or by the deamination of deoxycytidylate 
(dCMP). dTMP can also be formed by a salvage pathway where thymidine kinase 
catalyses the phosphorylation of thymidine. The phosphorylation of dTMP to dTDP is 
catalysed by thymidylate kinase and nucleoside diphosphate kinase catalyses the 
phosphorylation of dTDP to form dTTP.
The thymidylate cycle involves three enzymes, thymidylate synthase, dihydrofolate 
reductase and serine trans-hydroxymethylase (Figure 7). Thymidylate synthase 
(methylenetetrahydrofolate: deoxy uridine-5’ -monophosphate C-methyltransferase) 
catalyses the de novo synthesis of thymidylate via the reductive methylation of 
deoxyuridylate with the concomitant conversion of the cofactor N 5, N 10-methylene- 
tetrahydrofolate to dihydrofolate. This reaction is the only one in nature that results in 
the production of dihydrofolate, an oxidised form of folate that cannot be used in any 
biological process. To regenerate the reduced folate pools, dihydrofolate is converted 
to tetrahydrofolate by dihydrofolate reductase (DHFR), a reaction essential for the 
maintenance of these pools and thus cell viability. The enzyme serine 
trans-hydroxymethylase completes the thymidylate cycle by catalysing the formation of 
N5, N 10-methylene-tetrahydrofolate. The pivotal roles played both by TS and DHFR 
in DNA precursor synthesis has lead to their wide recognition as target enzymes for 
drugs aimed at the treatment of both infectious and proliferative diseases.
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F i g u r e  7 . The Thymidylate cycle
The fo llow in g  abbreviations are used: H2  Folate- dihydrofolate; H4  Folate- tetrahydrofolate; C H 2 H4  
Folate- N 5N 10-methylene-tetrahydrofolate. Standard abbreviations are used for nucleotides. Adapted 
from L ew is and Dunlap 1981.
5.2 TS from different sources
Thymidylate synthase is a ubiquitous enzyme found in all cellular organisms and coded 
by some large DNA viruses. The first studies of TS were performed on the enzyme 
isolated from the b a c t e r i u m  Lactobacillus casei (Friedkin et al 1962, Blakley 1963).
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enzyme isolated from the bacterium Lactobacillus casei (Friedkin et al 1962, Blakley 
1963). The isolation of a methoxotrexate resistant L.casei strain, that over-produced 
TS and DHFR, meant that large amounts of highly purified enzyme were available for 
study (Crusberg et al 1970) and has resulted in the L.casei enzyme becoming the most 
extensively studied TS from all sources (Santi and Danenberg 1984). The over­
production of both TS and DHFR suggests that the genes encoding these two enzymes 
are closely linked. The genes encoding TS and DHFR are also closely linked in 
Bacillus subtilis and Staphylococcus aureus.(Piggot and Hoch 1985, Burdeska et al
1990). In contrast the genes for TS (thyA) and DHFR (frd) are widely separated on 
the E.coli chromosome (Bachmann 1983). However, the two enzymes have been 
proposed to form part of a multi-enzyme complex that is responsible for channelling 
newly synthesised dNTPs into replicating DNA (Mathews et al 1978, 1988). The gene 
coding for TS in Lactococcus lactis can complement the growth of an E.coli thy A  
strain, and its predicted amino acid sequence is the most widely diverged TS sequence 
known (Ross etal  1990).
TS and DHFR from bacte riophage  T4 form part of a multi-enzyme aggregate, 
comprising both T4 and E.coli proteins and termed the dNTP synthetase complex 
(Mathews et al 1978, 1988, Moen et al 1988). This complex produces dNTPs in a 
manner tightly co-ordinated with DNA replication (Allen et al 1980, Chiu et al 1982, 
Mathews et al 1988, Moen et al 1988). In addition to their catalytic roles, the two 
enzymes act as structural components of the T4 virion base plate (Capco et al 1973), 
an example of an enzyme with a stable protein fold being recruited into a structural 
role. 03T  is a phage of B.subtilis and can complement T h y  auxotrophs upon 
lysogeny because it encodes a thymidylate synthase. It is a product of the thyP3 gene 
(Tucker et al 1969) and is functional when cloned in E.coli (Duncan et al 1977, Ehrlich 
et al 1976).
TS gene expression in m am m alian cells is tightly regulated with respect to the 
proliferative state of the cell (Conrad 1971, Navalgund et al 1980). In human, mouse 
and Chinese hamster, TS enzyme and mRNA levels are low in quiescent cells but 
increase approximately 20-fold on stimulation to re-enter the cell cycle. In human and 
mouse cells, the increase in mRNA levels alone is not sufficient to explain the increase 
seen in TS activity, thus implying some form of post-transcriptional control 
mechanism (Ayusawa et al 1986, Jenh et al 1985). Studies by Chu and co-workers 
using a cell-free rabbit reticulocyte model system and in vitro gel retardation assays 
demonstrated that the translation of human TS mRNA is controlled by its own protein 
product through an autoregulatory feedback mechanism (Chu et al 1991, 1993). This
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negative autoregulatory mechanism has recently been demonstrated in Escherichia coli 
(Voeller et al 1995).
Thymidylate synthase has so far been found in five herpesviruses, HVS (Honess et 
al 1986), VZV (Thompson et al 1987), HVA (Richter et al 1988) and herpesvirus 
eotus 2 (Bob Honess, personal communication) and equine herpesvirus 2 (Telford et 
al 1995). All of these viruses have A+T rich genomes and this observation coupled 
with the fact that TS has not been found in any of the G+C rich viruses studied to date, 
led to speculation that TS may form part of a virus specific replication complex. This 
could influence the supply of thymidylate directed towards DNA replication and 
contribute to the non selected bias in base substitutions that have produced the A+T 
rich coding sequences of some subgroups of herpesviruses (Honess 1984, Honess et 
al 1986). However, a virally encoded TS gene is not a prerequisite for an A+T rich 
genome, as several other herpesviruses with such a genome composition lack TS 
(Lawrence et al 1990, Neipel et al 1991). Interestingly, the TS from VZV is highly 
homologous to eukaryotic and prokaryotic thymidylate synthases. The origins of the 
VZV TS gene (and those of the other herpesviruses) remains uncertain as there is no 
methodology to determine unambiguously whether the TS gene is an ancestral feature 
lost during divergence to herpesvirus families, or whether it has since been acquired 
after divergence. Incidently, it is also unclear as to whether TS is essential for growth 
of VZV in normal tissue culture since VZV also encodes a thymidine kinase (TK). TK 
is involved in the thymidine salvage pathway perhaps negating the dependence on a 
virally encoded thymidylate synthase. However, TK mutants of VZV and HSV-1 are 
viable in tissue culture (Dubbs and Kitt 1974, Shiraki et al 1983) indicating that TS 
may also be dispensable.
In protozoa, TS exists on the same polypeptide as DHFR. The DHFR domain forms 
the amino terminus, TS the carboxy terminus and a junction peptide links the two 
domains to form a single protein, whose size is species dependent, usually falling in 
the range 110 to 140kDa (Ivanetich and Santi 1990). One immediately apparent 
biological advantage of a bifunctional DHFR/TS is metabolic channelling of 
dihydrofolate as is seen with the Leishmania tropica enzyme. Dihydrofolate produced 
by the TS component of the bifunctional enzyme is channelled to DHFR faster than it 
is released into the medium, thus the net rate of the sequential reactions is governed by 
the rate of TS (Meek et al 1985). This arrangement also results in both activities being 
co-ordinately regulated, resulting in optimal dTMP synthesis when required.
Y east cells lack thymidine kinase and are impermeable to thymine derivatives 
including thymidylate, thus their only source of thymine nucleotides is from
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thymidylate produced de novo by TS (Bisson and Thorner 1977). TS specific mRNA 
production peaks in Saccharomyces cerevisiae at the time during the cell cycle when 
TS levels are at their highest, a point that immediately precedes maximal rates of DNA 
synthesis during S-phase (Storms et al 1984). TS is thought to be a component of a 
multi-enzyme complex found in yeast, similar to those involved in dNTP synthesis 
seen in other organisms, although only some of its components have been identified 
(Jazwinski and Edelman 1984, Mathews et al 1988).
Early analysis of TS and DHFR in higher p l a n t s  was limited to a handful of 
investigations that described the preliminary measurements of TS activity and the 
purification of DHFR from carrot and soybean cells (Ohyama 1976). More recently, 
two groups have produced conflicting reports concerning the nature of TS and DHFR 
expressed in carrot cells. Nielson and Celia (1988) reported the proposal that TS and 
DHFR from domesticated carrot cells (.Daucas carota) may exist as a bifunctional 
enzyme, similar to, albeit larger than, those found in protozoa. In contrast, Goodman 
and co-workers have described TS activity (in wild carrots) assigned to a different 
polypeptide to that of DHFR (Toth et al 1987). A DHFR-TS gene has recently been 
cloned from Arabidopsis thaliana (Lazar et al 1993) and immunochemical analysis 
reveals the presence of a bifunctional DHFR-TS in nicotiana plumbaginifolia and 
Oryza sativa (Balestrazzi et al 1995). Bachmann and Follmann (1987) have also 
copurified a bifunctional DHFR-TS enzyme from the algae Scenedesmus obliquus 
indicating that a bifunctional protein is ubiquitous in plant cells.
6 . Amino acid sequence homology
The amino acid sequences of TS have been determined from organisms as diverse as 
humans, bacteriophage and, more recently plants (see Appendix I).
6.1 The conservation paradox
A particularly striking feature of thymidylate synthase is its high degree of amino acid 
sequence conservation, approximately 10% (27 out of a core of 275 residues) are 
absolutely conserved in the 36 known TS sequences, with a further 165 residues 
(60%) being greater than 80% conserved. If the two most divergent TS sequences, 
those of L.lactis and bacteriophage 03T  are excluded, the degree of conservation rises 
to 24% (61 out of a core of 275 residues). Such a degree of amino acid homology
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places TS amongst the most highly conserved enzymes, a group that includes proteins 
such as the cytochromes. This contrasts with dihydrofolate reductase, the enzyme 
which regenerates the folate cofactor oxidised by TS, although amino acid sequences 
have been reported from a much smaller group of organisms; only 6% of residues (11  
residues from a core of approximately 170) are completely conserved, a further 41 
residues (24%) being greater than 80% conserved ( Lagosky et al 1987). The high 
degree of conservation in TS, at the level of the primary structure, is also evident at the 
tertiary-structure level, A comparison of the three-dimensional structure of the native 
enzymes from E.coli and L.casei showed that they are 89% conserved in terms of 
corresponding atom types (3824 common atoms out of 4300; E.coli TS), despite 
sharing only 60% amino acid identity (Perry et al 1990). It has been suggested that 
some reasons why TS is so highly conserved are related to the chemical reaction 
catalysed and the conformational dynamics that occur during catalysis (Finer-Moore et 
al 1990). Conservation may also be due to the need to maintain interactions with other 
enzymes such as DHFR.
Mutagenesis studies (Maley and Maley 1988, Dev et al 1988, Michaels et al 1990, 
Climie et al 1990, LaPat-Polasko 1990) on the TS of several organisms particularly 
from L.casei and E.coli have revealed a conservation paradox, such that, almost all the 
conserved residues (except at least 8 critical residues including the catalytic cysteine 
residue-C183 in VZV TS) can be substituted without severe disruption to the activity 
of the enzyme. Why these residues have been conserved throughout evolution, yet are 
not essential to the function of the enzyme, is not fully understood.
7. Catalytic mechanism of TS
Thymidylate synthase catalyses the conversion of 2’-deoxyuridylate (dUMP) and N 5, 
N 10-methylene-tetrahydrofolate (CH2H4 folate) to 2’-deoxythymidylate (dTMP) and 
dihydrofolate (Figure 8). The source of the methyl group for transfer to dUMP, the 
cofactor CH2H4 folate, plays a dual role. First, it is a one-carbon donor, and then 
reductant of the transferred methylene at different steps in the reaction. The major 
chemical steps in the methylation reaction have been deduced using chemical models as 
well as by studying the structures and kinetics of the formation of reaction 
intermediates (Santi and Danenberg 1984).
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F igure  8 The catalytic mechanism of Thymidylate synthase (adapted from Hardy et 
al 1987). R= deoxy ribose-5’-phosphate.
A  more detailed reaction m echanism  is given in Stroud and Finer-M oore 1993
The catalytic mechanism of TS involves the initial formation of a covalent bond 
between the 6-position of dUMP and a catalytic thiol (Cysteine 183 in VZV TS) of the 
enzyme (Figure 8). Formation of this binary complex serves to activate the 5-position 
of dUMP. After the CH2H4 folate binds, its imidazolidine ring opens, giving a 
reactive iminium ion that condenses with the activated C-5 of dUMP. Subsequent to 
formation of the ternary covalent complex, (3 elimination and hydride-transfer reactions 
occur to generate the methylated pyrimidine, the oxidised cofactor, and the catalytically 
active enzyme.
TS is an obligate dimer of identical subunits that are related by a twofold axis of 
rotation (Figure 9). The structure of TS shows why it is an obligate dimer, as 
components of each monomer contribute to each of two active sites. There is no
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conclusive evidence for cooperativity between the monomers in the dimer (Stroud and 
Finer-Moore 1993). However, as ligand binding induces large conformational changes 
(see section 7.3) that extend throughout the protein, the ligand affinities will depend on 
the liganded state at both active sites.
F i g u r e  9  Thymidylate synthase dimer
The view  is directly down the dimer interface between the 2 monom ers. P-strands are coloured yellow , 
a -h e lices  are red, connecting loops w hite and both the substrate and cofactor are depicted as space 
filling models.
7.1 Residues involved in catalysis
The first crystal structure of TS, that of the L.casei enzyme, revealed structural details 
of the ligand binding site. Subsequent crystallographic studies of complexes of TS that 
are analogues of reaction intermediates or ligands have provided useful information on 
residues involved in catalysis (for a full review see Stroud and Finer-Moore 1993, 
Carreras and Santi 1995). A summary of specific contacts between ligands and protein 
in the covalent ternary complex is outlined below. All residue numbers are for the
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L.casei enzyme with the VZV residue number in brackets, primed numbers indicate 
residues from the other monomer of the dimeric protein (see Appendix I).
Four highly conserved arginines, two from each monomer, provide a favourable, 
positively charged binding surface for the phosphate anion. These four arginines, Arg- 
23 [38], Arg-218 [207], Arg-178’ [163’] and Arg-179’ [164’], as well as Ser~219 
[208] are involved in an extensive hydrogen bonding network around the phosphate. 
Each arginine forms at least one hydrogen bond to the phosphate oxygens.
Arginine-23 [38] is also hydrogen bonded to the COOH terminus of the protein. 
Arginine-218 [207] is hydrogen bonded to the carbonyls of residues Pro-196 [181] 
and Arg-178’ [163]. Arginine-178’ [163] is hydrogen bonded to the hydroxyl of 
Tyr-261 [246].
Invariant Tyr-261 [246] andHis-259 [244] are the primary contacts to the ribose ring 
of dUMP, they are hydrogen bonded to 0 -3 ’ on the ribose ring. Hydrogen bonds 
between the pyrimidine of dUMP and invariant Asn-229 [214] and the main chain 
amide of Asp-221 [206] are the only other hydrogen bonded contacts between dUMP 
and the protein. Asparagine-229 [214] is hydrogen bonded to both 0-4  and N-3 of 
dUMP. Cys-198 [183] (the active-site sulfhydryl) forms a covalent bond to C-5 of 
dUMP linking it to the methylene group and N-5 of the cofactor.
The only protein side chain to hydrogen bond to the folate cofactor is that of invariant 
Asp-221 [206]. Other hydrogen bonds involving the cofactor are made either with 
water or backbone atoms. The exocyclic amino group on the pterin ring is hydrogen 
bonded to the terminal carbonyl residue (315 [301]) in the protein.
The PABA ring lies in a hydrophobic pocket surrounded by the side chains of the 
highly conserved residues Ile-81 [96], Leu-224 [209], Phe-228 [213] and Val-314 
[Met 299; only the bacteria, phage <D3T and 7>z4003 do not have methionine at this 
position]. The pocket is formed in part by movement of the carboxy terminus on 
ligand binding. Phe-228 [213] and Leu-224 [209] are within van der Waals contact of 
the PABA ring. Trp-82 [97] and Trp-85 [Tyr 100] are just below the PABA ring, 
stacked against the pterin ring.
The cofactor is normally linked to a linear sequence of as many as seven glutamate 
residues that are y-1 inked or a-linked to the PABA ring and to each other. The crystal 
structure of the E.coli enzyme reveals that interactions betwen protein and 
poly glutamyl moiety are primarily electrostatic (Kamb et al 1992b). The only three
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clearly discernable hydrogen bonds between the tetraglutamyl group and the protein 
are mediated by ordered water.
7.2 Ordered binding of ligands
Initial experimental investigation using monoglutamylated cofactor provided evidence 
that the ligands bind in an ordered fashion in which dUMP binds first, followed by 
cofactor, and that cofactor leaves before dTMP in bi-bi reaction sequence (Lorenson et 
al 1967, Danenberg and Danenberg 1978). These results may be explained in part by 
the fact that dUMP is an important binding surface for the pterin ring.
However, the intracellular pool of folates consists mainly of polyglutamylated 
molecules. Polyglutamyl folates have affinities for TS that are in some cases more than 
400-fold greater than that of the monoglutamyl form (Lu et al 1984). Under certain 
reaction conditions, the increased binding affinity of polyglutamyl folates for TS 
results in random binding order of ligands (Ghose et al 1990). Crystal structures of the 
enzyme are consistent with the observation of random binding of ligands under certain 
reaction conditions (Kamb et al 1992a).
7.3 Conformational changes upon ligand binding
Conformational changes of a protein in response to the binding of ligands is now a 
well-established phenomenon and is often necessary to account for effects such as 
cooperativity and allosteric control of enzyme reactions.
A series of conformational changes have been associated with the catalytic reaction 
performed by thymidyalte synthase. Early evidence for a conformational change upon 
ligation with both substrate and cofactor came from a number of groups (Galivin et al 
1975, Leary etal 1975, Donato et al 1976). On complexation, aromatic groups on the 
protein (tyrosine and tryptophan residues) and of the folate chromophore were 
perturbed, as detected by Raman spectroscopy, circular dichroism, ultraviolet 
spectroscopy and fluorescent spectroscopy. In both human and L.casei TS, the stokes 
radius decreased by 3.5% upon formation of the TS*FdUMP*CH2H4 folate complex 
(Lockshin and Danenberg 1980). The structures of native, unliganded TS from 
L.casei, E.coli phage T4 and human present large cavernous openings that close down 
progressively as ligands bind. In the binary complex formed as the substrate dUMP 
binds, the active sites remain open and very close to the unliganded state (Finer-Moore
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et al 1993). On the other hand, the binding of a folate analogue (CB3717) by itself 
serves to sequester the reactants from solution (Kamb et al 1992a). These results 
demonstrate that structure change during catalysis is triggered mainly by the binding of 
cofactor, and not by dUMP.
The dramatic changes in the spectra and hydrodynamic behaviour of Lcasei TS on 
formation of ternary complexes suggest large conformational differences between 
unliganded TS and TS in ternary complexex with substrate and cofactor analogues. In 
fact, the differences between Pj-bound E.coli TS and TS#dUMP#CB3717, although 
quite extensive, are not particularly large (Montfort et al 1990). Segments of helices,
o
p-sheet and loops move toward the active site, usually less than 1 A, to accommodate 
ligand binding. The ligand binding side chains do not themselves change conformation 
as the active site closes. The greatest segmental shift is in residues 312-316 (Lcasei 
TS) at the carboxy terminus and the surface loop containing arginine-21 (the DRTG 
loop). These residues become more ordered in the ternary complex and move more 
than 4A into the active site, forming an important binding determinant for the cofactor 
(see section 8.4).
8. Structural features of TS
Prior to X-ray crystallographic studies, the structure of TS was mainly predicted using 
the technique of circular dichroism (Manavalan et al 1986). The understanding of 
many facets of TS function and dynamic behaviour during catalysis have been 
significantly enhanced by X-ray crystallographic studies.
8.1 X-ray crystallographic structures of bacterial TS
In the past 6 years, the 3-dimensional structures of TS from various sources in several 
forms have been solved. Refined TS crystal structures include unliganded (Pi-bound) 
TS from Lcasei (Hardy et al 1987, Finer-Moore et al 1993), E.coli (Perry et al 1990, 
Mathews et al 1990), Phage T4 (Finer-Moore et al 1994), Leishmania major 
(Knighton et al 1994), human species (Schiffer et al 1991, Robert Stroud, personal 
communication), and pneumocystis carinii (Perry and Stroud personal 
communication); binary complexes of TS with dUMP (Finer-Moore et al 1993) and 
with a polyglutamylated cofactor analogue (Kamb et al 1992a), ternary complexes that 
are analogues of the steady-state intermediate (Mathews et al 1990a; 1990b, Montfort
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et al 1990, Kamb 1992b), and a product complex of TS with dTMP and dihydrofolate 
(Fauman et al 1994). Crystallisation of human TS (Schiffer et al 1991) is the first 
example of TS crystallisation from phosphate and/or substrate free medium, thus 
representing true native enzyme. Indeed, the addition of phosphate to the suspension 
cracks the crystals, suggesting that a possible induced conformational change takes 
place. Sequence similarity would suggest that all TS structures will be similar.
8.2 General structural features
Structural studies of TS have revealed several novel and interesting features. TS is an 
obligate dimer of identical subunits that are related by a two-fold axis of rotation. The 
structure of TS shows why it is an obligate dimer (Figure 10), as components of each 
monomer contribute to each of two active sites. The dimer interface is formed by a 
back-to-back apposition of two five-stranded (or six) (3-sheets with a unique right- 
handed twist of one sheet relative to the other (Hardy et al 1987). Three contiguous 13- 
strands bend sharply away from the remainder of the sheet in a (3-kink and form one 
wall of the large active site cavity. The cavity is lined by many conserved side chains, 
including the active site cysteine. Two layers of helices and loops pack on top of the 
central (3-sheet.
Several species of TS contain insertions and there are six sites where these inserts are 
found around the TS core. They are all present in surface loops or in a smaller 
‘variable’ domain. For example, L.casei contains a 50 amino acid insertion which is 
arranged as three short a-helices within the variable domain (Hardy et al 1987). As 
these insertions are not present in all species (and found in non core regions) they 
cannot be relevant to fundamental aspects of structure or function. Perhaps they serve 
roles specific to individual organisms (such as DHFR binding) or have become 
redundant features during evolution.
8.3 Notable structural features of TS
(3-sheet interfaces have previously only been described with a left-handed twist. One 
consequence of this unique right-handed twist is the formation of a [3-kink that 
facilitates the close packing of the two |3-sheets. Hardy and co-workers (1987) 
described an aligned discontinuity in P-strands i, ii and iii of the Lcasei enzyme at 
residues Gly-33, Ala-258, and Gln-217 twisting the bottom left comer of the sheet 
outward. Although distorted, hydrogen bonding between the three anomalous residues
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is preserved through the bend. The p-kink structure also serves as one of the major 
hinge points around which segments of secondary structure move during catalysis 
(Perry et al 1990; see section 7.3).
F i g u r e  1 0 . Different views of thymidylate synthase
The dimer (A ), a m onom er o f  TS (B) and the same monom er rotated through 90° (C) to g ive our 
standard v iew  o f  a TS monomer.
fTstrands are coloured yellow , a -h e lices  are red, connecting loops w hite and both substrate and cofactor 
depicted as space fillin g  models.
A core structural element around which the protein is folded is the J - h e l i x  (Figure 
11a, lib ) . This is a six-turn unusually hydrophobic a-helix, even more so than some 
membrane spanning helices, and is almost inaccessible to solvent, it sits on top of the 
P-sheet, is flanked by the amphiphatic a-helices A and H, and is capped by helix B.
The a c t i v e  s i t e  is a shallow cavity which contains the catalytic cysteine residue, the 
left wall of the cavity is formed by the sharply turning part of P-strands ii and iii, and
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the loop connecting a-helix A and (3-strand i. The ceiling is composed of residues 
from the solvent exposed N-terminus of the J-helix and the right-hand wall by the end 
of (3-strand iv. The back of the cavity is formed by four residues of the (3-sheet of the 
other monomer, one of which Arg-179’ (L.casei enzyme) protrudes directly into the 
cavity, explaining why TS is an obligate dimer.
F i g u r e  1 1 a .  A monomer of thymidylate synthase
(T strands are coloured yellow , a -h elices are red, connecting loops w hite. The central J helix is green, 
and the active site cysteine is blue. The C-terminal residue and the DRTG loop  are coloured cyan, 
substrate and cofactor are not shown for clarity.
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F i g u r e  l i b .  A dimer of E. coli thymidylate synthase
One m onom er is show n in light purple the other light blue. The P-strands and a -h e lices  are numbered. 
Image kindly provided by RM Stroud.
8.4 Segmental accommodation
The conformational changes associated with the catalytic reaction performed by 
thymidylate synthase have attempted to be understood by comparing the differences 
between the structures of the unliganded and ligand bound ffoms of E.coli TS (Finer- 
Moore et al 1990, Mathews et al 1990a; 1990b, Montfort et al 1990, Perry et al 1990). 
To quantitate conformational change, a core of a-carbon residues whose mutual 
disposition remains unchanged (± 0.5A) between liganded and unliganded enzyme 
was identified. This core o f 155 a-carbon atoms differs from most non-core residues
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in that they have shifted between 0.5 to 1.25A (Figure 12). In contrast to the domain 
shifts seen in proteins such as hexokinase (Anderson et al 1978) or citrate synthase 
(Remington et al 1982), the changes in TS are due to s e g m e n t a l  a c c o m m o d a t i o n ,  
where a-helices, p-strands and connecting loops undergo concerted movement 
towards the active centre (Mathews et al 1990b, Montfort et al 1990).
F i g u r e  1 2 .  Seqmental accomodation by TS
A  single m onom er o f  E. co li TS is illustrated in the sam e orientation as in figure 11. R esidues show n in 
yellow  deviate from their original position by less than 0 .5 A  upon ligand binding, whereas residues 
show n in blue undergo substantial m ovem ent. Reproduced from Finer-M oore et al 1990.
The P-kink acts as one of several hinge points around which other segments of 
secondary structure move. The central J-helix pivots around a central point such that
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the N-terminal end moves approximately 0.5A towards the active centre. This in turn, 
causes the region of (3-strands i, ii and iii below the (3-kink to move towards the same 
location. The region containing the active site residue (Cys-183 in VZV TS) moves 
inward while the loop containing the two arginine residues (Arg-163’ and Arg-164’, 
VZV TS) also moves inwards. The two largest shifts involve the loop (the DRTG 
loop) containing Arg-38 and Thr-39 (VZV TS) that moves up to interact with the C- 
terminus, and the movement of the four C-terminal residues, in the unliganded 
structure, these four residues point out into the solvent, suggesting they are disordered 
(Mathews et al 1990a). However, on binding of ligands, this region moves
o
approximately 4.0A, sequestering several water molecules, to anchor the cofactor in 
place. This directs the exact alignment of substrate and cofactor to allow the formation 
of the observed H-bonds in this region of the crystal structure (Finer-Moore et al 
1990, Mathews et al 1990a; 1990b, Montfort et al 1990)
8.5 Structural plasticity and covariant accommodation
The introduction of amino acid substitutions by site-directed mutagenesis affects 
protein function in an, as yet, poorly understood manner. The variations are often 
tolerated by adjustment of neighbouring residues and can result in unexpected 
properties. The accommodation of substitutions is due to the s tru c tu ra l p la s tic ity  
of the protein, the ability of a protein to adopt to changes in its primary structure, 
whilst maintaining the integrity of its tertiary structure. Several hundred site-directed 
mutations have been made in TS (Maley and Maley 1988, Dev et al 1988, Michaels et 
al 1990, Climie et al 1990, LaPat-Polasko 1990). Highly conserved active-site 
residues have been replaced by several other amino acids, though generally the protein 
remains active for several of the substitutions made at any position. Thus there is 
plasticity of function as well as structure
Structural plasticity, in response to substitutions, could feasibley be quantitatively 
described by two approaches. The first is comparison of structures of many 
site-directed mutations of a single protein, while the second approach is to compare 
two structures that differ at many positions in an attempt to generalise the effects of 
substitutions. The first approach suffers because each mutation at a single locus is a 
special case; substitutions at a particular site may produce no change elsewhere, or 
large and distant changes. This approach also requires the determination of many 
structures.
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The second approach using the structures of the unliganded TS from Lcasei and 
E.coli has proved more fruitful (Perry et al 1990). This species comparison of 
thymidylate synthase has served to map the tolerance of this protein toward mutation. 
A detailed study of the buried region of TS from both structures demonstrate three 
mechanisms by which mutations are accommodated (Perry et al 1990).
The first is the occurrence of local change, wherby large effects observed close to the 
site of mutation dissipate as a function of distance. This is usually achieved by a 
mechanism that involves local rearrangements, often the repacking of adjacent 
residues, with only minimal effects on the overall architecture of the protein. This local 
flexibility permits relief of strain at the protein surface (Perry et al 1990).
The second mechanism by which plastic adaptation can occur is by systematic shifts in 
individual elements of secondary structure, particularly in helices, where clusters of 
tightly packed, nonpolar residues change position in a concerted fashion. Several of 
the helical regions of TS, which contain the largest structural differences between the 
enzyme from Lcasei and E.coli, have been accommodated in this way. The
‘ensemble’ movement of helices B, C and G is the most prominent example of this
process, where these structures have shifted together as a unit in the L.casei structure, 
relative to E.coli. This movement has occurred to accommodate the interactions 
between the three-helix unit and helix-D of L.casei, a helix that is absent from E.coli 
TS (Perry et al 1990).
The final mechanism is c o v a r i a n t  a c c o m m o d a t i o n  where multiple sequence
changes combine to minimise the distortion of the main chain atoms and
simultaneously preserve the volume of the packed side-chains. An example of 
covariant accommodation in TS is found the (3-sheet, structurally the most conserved 
region of the TS protein. At the centre of (3-strand ii, Phe-255 of L.casei is substituted 
by glycine in E.coli . The ‘space’ produced by mutation of the larger Phe residue to 
glycine is ‘filled’ by the concomitant mutation of His-253 to tryptophan and Ala-258 to 
threonine. This corresponds to net difference of only a single atom in these three 
residues. The position of the main chain a-carbon atoms are essentially unchanged. 
Generally, it has been found that when a substitution introduces three or more heavy 
atoms (carbon, oxygen, sulphur or nitrogen), this nearly always results in a second, or 
covariant change nearby (Perry et al 1990). Experimental data obtained from 
mutagenesis studies of the hydrophobic core of bacteriophage lambda repressor 
protein demonstrate that where a mutation increases the volume of the core in excess of 
the permitted level, second site mutations that can reduce the net volume of the core 
can restore activity (Lim and Sauer 1991).
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For thymidylate synthase this suggests that in evolution, a certain degree of variation 
in sequence can be tolerated by plastic adaptation in structure, but the larger 
substitutions are generally compensated by covariant changes.
8.6 VZV TS model
Two models of the VZV thymidylate synthase, one of the ternary complex and the 
other of the native enzyme with bound phosphate (figure 12), have been constructed 
by Celia Schiffer and Robert Stroud (personal communication). The models are based 
upon the coordinates of the ternary complex of E.coli TS with CB3717 and dUMP 
(Montfort et al 1990) and the coordinates of the E.coli TS structure with bound 
phosphate respectively (Perry et al 1990). All residues from the E.coli sequence that 
differed from the equivalent residue of the VZV sequence were subsituted by the latter 
using the graphics programme INSIGHT (Dayringer et al 1986). The substituted 
residues were positioned in a conformation which overlapped as much as possible 
with that of the residue existing in the E.coli structure. Where a VZV residue was 
larger than one it replaced, it was placed in a conformation which corresponds to that 
most frequently found for that amino acid in protein structures. The model lacks the 
first 19 amino acids from the VZV sequence, and the two short insertion sequences 
common to all eukaryotic thymidylate synthases (residues 105-116 and 134-141; VZV 
numbering), that are not found in the E.coli enzyme. At the time the model was 
generated, these regions of the human TS being studied by this group (Schiffer et al
1991) were unresolved. The model of the VZV native TS was refined by 200 cycles of 
conjugate gradient minimization with the refinement package of XPLOR (Briinger et al 
1987), clearing up the bad contacts generated by the amino acid substitutions. The 
minimization resulted in a root mean square (RMS) shift of 0.38A of the a-carbons. 
The model of the VZV ternary complex was refined with 150 cycles of XPLOR. Due 
to difficulties in the initial stage of energy minimization, the a-carbon atoms were 
constrained to stay fixed, thus allowing only movement of side chains to remove any 
energetically unfavourable contacts.
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8.7 Human thymidylate synthase
Recently the crystal structure of unliganded human TS was resolved (Schiffer et al 
1995) providing the first three-dimensional view of a mammalian TS. The structure 
follows those of the bacterial systems which is as expected due to the high degree of 
sequence identitiy.
As described for other thymidylate synthases human TS has 2 insertions, and they are 
present as a-helices and lie close together on the outside of the protein. No homolgous 
insertions are present in prokaryotes suggestingthey are eukaryotic specific insertions 
and have a eukaryotic specific function (Hardy et al 1987, Perry et al 1990). Human 
TS also has a unique amino terminal sequence which is 27 residues longer than Lcasei 
(see Appendix I). It consists of 8 proline and 7 charged residues and is predicted to 
have a randomly coiled structure suggesting a unique function to the human TS. This 
may well enable human TS to interact with other proteins in the cell, some of which 
are involved in DNA synthesis. Perhaps the charged nature of this region allows it to 
interact with its own mRNA and negatively autoregulate its translation.
Although human TS has a similar overall fold to the bacterial enzymes it has a major 
divergence in the structure of the active site. Despite the high sequence homology 
between the Lcasei and the human sequence in this region the humam thymidylate 
synthases entire active site is twisted 180° relative to the Lcasei enzyme. This 180° 
twist buries the active site cysteine residue in the (3-sheet dimer interface and upon 
ligand binding this catalytically crucial residue must ‘untwist’ 180°. It appears that in 
addition to the normal conformational changes that occur (as in all species of 
thymidylate synthase), which sequester solvent, orientate the substrate and cofactor, 
the human TS must also reorientate the active site cysteine. It has been suggested that 
one possible function for such an orientation of the active site may be to protect the 
catalytic cysteine from being modified in the cell (Schiffer et al 1995). However, such 
a reorientation may be energetically unfavourable and the highly conserved nature of 
the thymidylate synthases lends strength to the notion that all the structures would have 
a similar (if not identical) core structure. As to why the human TS thus has a different 
active site orientation to all other crystal strcutures of TS remains open to question.
Indeed, since its publication the human TS structural coordinates have been 
withdrawn, indicating a problem with the solved structure, perhaps with the active site 
cysteine.
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8.8 The C-terminus of VZV is unique
Carboxypeptidase cleavage of the L.casei C-terminal valine from a single subunit of 
TS completely inactivates the enzyme and decreases its affinity for CH2H4 folate (Aull 
et al 1974). Subsequent mutagenesis of this residue confirms that the Lcasei 
C-terminal residue is cruical for catalysis (Climie et al 1990).
In contrast to such bacterial enzymes removal of the C-terminal residue from VZV TS 
(L301A) does not inactivate the enzyme. This mutant retains a significant amount (3%) 
of wild-type activity, and in addition has normal debromination activity (Harrison et al 
1995). This suggests a different mechanism of interaction at the C-terminus.
In L.casei TS the carboxylate group of the C-terminal residue makes four hydrogen 
bond contacts (Figure 13). They are to arginine 23, threonine 24, tryptophan 85 and 
one to the PABA ring of the folate cofactor. In VZV TS arginine 38 and threonine 39 
(equivalent to R23 and T24 in L.casei ) form virtualy identical H-bonds to the 
carboxylate group of the C-terminal residue. However, a H-bond equivalent to the one 
between the C-terminal residue of Lcasei and W85 is not found in the VZV TS model. 
This is because the equivalent to W85 from L.casei TS is tyrosine 100 in VZV TS 
(Figure 13). The hydroxyl group of Y100 can act as a H-bond donor and acceptor, 
however, it could not be positioned such that its hydroxyl group was able to form a 
H-bond with the carboxylate group of the C-terminal amino acid of VZV TS, without 
significant diruption to the rest of the protein.
A comparison of all the TS sequences at the position equivalent to Y100 reveals the 
presence of asparagine in phage T4 and all the eukaryotic thymidylate synthases, 
whilst tryptophan is found at this position in TS from all other organisms. Modelling 
of this asparagine residue in the E.coli structure (replacement of W83, equivalent to 
W85 in L c a se i) has shown that asparagine allows the formation of an H-bond to the 
C-terminal carboxylate of similar length to that of wild-type. This suggests that 
asparagine could form a H-bond to the carboxylate group of the C-terminal residue in 
all other TS enzymes. Asparagine at this position may play an analogous role to the 
conserved tryptophan in TS from prokaryotes.
Removal of the C-terminal residue of E.coli (1264A) and L.casei (V316A) inactivate 
the enzyme by destroying the H-bonds occuring in this region and presumably prevent 
the tight closing down of the active site. The VZV model suggests retention of activity 
in the mutant L301A must be due to another interaction at the C-terminus which can
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still close down the active site, if only partially. The candidate residue for such an 
interaction is tyrosine 100, since it is not found in other thymidylate synthases.
L .case i
VZV
Figure 13 Interactions at the C-terminus of L.casei and VZV thymidylate 
synthase
Hydrophobic interactions could be mportant in C-terminus of VZV TS as they may 
occur between the side chains of isoleucine 99 and tyrosine 100 and the side chains of 
the C-terminal residues methionine 299 and leucine 301. Removal of the C-terminal 
residue does not inactivat the enzyme because presumably the remaining three residues 
(199, Y 100 and M299) can still interact, and this hydrophobic packing holds the two 
sides of the active site together. Additionally, the aromatic ring structure of Y 100 may 
also help stabilise binding of the cofactor in an analogous manner to that seen by 
tryptophan. Further support for the observation that hydrophobic packing is important 
(more so, perhaps, than H-bonds) in the C-terminus of VZV TS is that E.coli and 
L.casei TS both have a valine residue as the position equivalent to M299 in VZV. 
They also have a hydrophillic glutamate residue at the position equivalent to 199. These
,  PABA ring of folate
V316 /
0 = 0 R23
W85 T24
, PABA ring of folate
L301 ✓
c^=o-- R38
Y100 T39
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residues may be sufficient to prevent significant hydrophobic interactions in the 
bacterial enzymes. So in part the tyrosine at position 100 is responsible for the residual 
activity in the VZV TS mutant V313A.
This has led to the proposal that hydrophobic interactions are more imortant for the 
stabilisation of the VZV ternary complex (Harrison et al 1995).
Contrastingly, this tyrosine 100 residue is either a tryptophan in almost all prokaryotes 
or an asparagine in eukaryotes (and phage T4) suggesting that removal of their C- 
terminal residue will result in inactive proteins. Indee VZV TS appears unique in this 
respect.
8.9 The DRTG loop of VZV
Below the C-terminal region of TS is a highly mobile loop. This loop consist of 
aspartic acid 37, arginine 38, threonine 49 and glycine 40 and as such has been named 
the DRTG loop. The D37 residue is fully conserved, while the remaining residues are 
almost completely conserved, the few exceptions being Ldactis and phage 03T . The 
loop moves along with the C-terminus upon binding of substrate and cofactor helping 
to sequester solvent forming the closed ternary from of the enzyme. Arginine 38 has 
also been implicated (by virtue of its equivalent residue; R23; in Lcasei ) in 
coordinating the phosphate of the substrate. Threonine 39 and arginine 38 make 
hydrogen contacts to the COOH terminus of the protein. Little is known in detail about 
this loop region of TS.
9. Thymidylate synthase inhibitors
Because of its central position in the pathway of DNA biosynthesis, thymidylate 
synthase is an important target enzyme in cancer chemotherapy, anti-parasitic, anti- 
fungal and possibly anti-viral therapies. Analogues of either substrate or cofactor are 
potential inhibitors of this enzyme, and as such, a large number of dUMP and 
N5, N 10-methylene-tetrahydrofolate anologues have been synthesised and evaluated 
as candidate inhibitors. Some of these inhibitors, for example, FdUMP and CB3717 
(10-propargyl-5, 8-dideazafolic acid), have been of great value in elucidating certain 
aspects of the mechanism of action and structure of this enzyme.
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9.1 Cofactor analogues
Folate analogues have several advantages over nucleoside analogues for 
chemotherapeutic use. These include a better specificity; in that the analogue pteroyl- 
hexaglutamate could inhibit bacteriophage T2 thymidylate synthase at a concentration 
100-fold lower than that required to inhibit E.coli TS (Maley et al 1979); a decreased 
susceptibility to metabolic degradation and they appear to pose no significant risk of 
mutagenicity or carcinogenicity as they are not incorporated into RNA or DNA 
(Keyomarsi and Moran 1990). Moreover, the high levels of dUMP found in many 
tumours (that would reduce the effects of nucleotide analogues such as FdUMP) 
would potentiate binding of folate analogues (Danenberg and Lockshin 1982, Myers et 
al 1974, Keyomarsi and Moran 1988, 1990, Pogolotti et al 1986). Conversely, the 
existence of low levels of N5, N 10-methylene-tetrahydrofolate in many tumours 
would result in little competition for exogenous anti-folate analogues binding to TS 
(Houghton et al 1981, Evans et al 1981, Jackson et al 1983).
Several folate analogues have been shown to inhibit TS. The first were the 2-amino-4- 
hydroquinazolines (Bird et al 1970) and folylpolyglutamates (Kisliuk et al 1974). 10- 
propargyl-5, 8-dideazafolate (CB3717) is one of the most studied compounds to 
emerge from the investigation of folate analogue inhibitors of TS (Figure 14). CB3717 
has a K, value of lxlO '9 M for TS isolated from murine leukemia L1210 cells (Jones 
et al 1981). Phase I and II clinical trials have shown that CB3717 has demonstrable 
clinical activity against ovarian, breast and liver cancers, but the occurrence of renal 
toxicity in a sporadic, unpredictable and life-threatening manner, has precluded its 
further development as an anti-cancer drug (Harrap et al 1989). Inhibition of 
thymidylate synthase is not due to CB3717 itself, but potentiated by intracellular 
polyglutamation. However, CB3717 has been used as a parent compound to identify 
derivatives wich retain the useful therapeutic properties but which are devoid of its 
major toxicity. Indeed several derivatives with such properties have been synthesised 
and include C2-desamino, C2-methyl and C2-methoxy derivatives (Harrap et al 1989).
Dihydrofolate can inhibit thymidylate synthase directly when it accumulates at high 
levels due to inhibition of dihydrofolate reductase (Bunni et al 1988, Seither et al 
1991). Direct inhibition of thymidylate synthase due to build up of dihydrofolate is a 
major cause of growth inhibition, depletion of tetrahydrofolate also plays a role (Chu 
et al 1990). This has led to the suggestion that inhibition of de novo thymidylate 
synthase is a multifactorial process (Chu et al 1990).
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HN.
HC
NH NH
COOH COOH COOH COOH
F i g u r e  1 4 .  Methylene tetrahydrofolate (A), and 10-propargyl-5,8-dideazafolate 
(CB3717), a folate analogue inhibitor of thymidylate synthase (B).
9.2 Nucleoside analogues
As with the folate cofactor thymidylate synthase can also be inhibited by analogues of 
the substrate dUMP. Most of the nucleoside compounds studied are 5-substituted-2’- 
deoxyuridine analogues (Figure 15). For these analogues to exert their inhibitory effect 
in vivo, they must first be enzymatically activated by thymidine kinase.
The requirement for phosphorylation has been shown in vivo by the fact that 
mutations in the activation step lead to resistance to these analogues, and deoxyuridine 
itself is not a substrate for the purified enzyme (Reyes and Heidelberger 1965). 5- 
fluro-2’-deoxyuridine (FUdR), 5-(trifluro-methyl)-2’-deoxyuridine (CF3UdR), 
trifluorthymidine (TFT), 5-nitro-2’-deoxyuridine (NO2-IMR) and 5-ethynyl-2’- 
deoxyuridine (EYUdR) have consistently emerged as the most potent thymidylate 
synthase inhibitors in both in vitro and in vivo experiments with nucleoside analogues 
(Balzarini et al 1982, Lewis and Dunlap 1981). The mode of action of these 
compounds is now reasonably well understood. FdUMP, the active form of FUdR, 
forms a covalent ternary complex with thymidylate synthase in the presence of the 
cofactor N5, N 10-methylene-tetrahydrofolate, which is similar to the catalytic 
intermediate (Lewis and Dunlap 1981). This complex is stable and terminates the 
reaction because the fluorine atom cannot be abstracted, as normally occurs with the 
C-5 hydrogen in the native reaction. This is presumably due to the strength of the
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C5-F bond (Santi and Danenberg 1984). In contrast to FdUMP, CF3-dUMP and 
N02-dUMP can inhibit thymidylate synthase in the absence of the folate cofactor, and 
this ability is thought to the basis of their tight binding to, and inhibition of, TS 
(Danenberg et al 1974, Wayata et al 1980). EYUdR is a potent inhibitor of S-49 
murine lymphoma cells and like FUdR, inhibits thymidylate synthase only in the 
presence of the folate cofactor (Barr et al 1981).
CF C = C H
HN H NHN
HO HOHO'
OH OHOH
CF3UdR
5-(trifluro-methyl)-
2’-deoxyuridine
FUdR
5-fluro-2’-
deoxyuridine
EYUdR
5-ethynyl-2'-
deoxyuridine
F i g u r e  1 5 .  5-substituted deoxyuridine analogue inihibitors of T S
CH
HN
B1CH9CNHCH'
OH
BAT
5-bromoacetamido-2’-deoxythymidine
F i g u r e  1 6 .  5’-haloacetamido-2’-deoxyuridine analogue inhibitors of TS
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A novel group of nucleoside analogues, the 5’-haloacetamido-2’-deoxythymidines 
(Figure 16), do not require phosphorylation or the cofactor to inhibit thymidylate 
synthase (Santi et al 1986). Three compounds 5’-bromo-, 5’-chloro-, 5’-iodo- 
acetamido-2’-deoxythymidines (BAT, CAT and IAT respectively) inhibit TS from 
L1210 cells (Sani et al 1986). Kinetic studies with BAT suggest that it acted as a 
competitive inhibitor with dUMP
9.3 Bisubstrate analogues
In addition to folate and nucleoside only analogues a class of thymidylate synthase 
inhibitors are available which consist of a folate molecule covalently linked to a 
nucleoside analogue. These so-called bisubstrate analogues are designed to mimic the 
non-enzymic portion of the catalytic intermediate of the TS reaction, and have been 
shown to inhibit thymidylate synthase (Park et al 1979, Amamath et al 1984). N5- 
dUMP-8-deazatetrahydrofolate (Figure 17) inhibits purified TS from murine leukemic 
L1210 cells as does N5-dUMP-N10-propargyl-deazatetrahydrofolate its analogue. 
Both these compounds inhibit TS in a competitive manner with respect to dUMP 
(Veda et al 1986). These workers have also shown that rather than entering into the 
active site of the enzyme to produce an inhibitory ternary complex, these compounds 
inhibit TS by blocking the nucleotide and folate binding sites.
O C - N H - C H - C O O H
c h 2c h 2 - c o o h
HN
o-— p-o—
OH
F i g u r e  1 7 .  N5-dUMP-8-deazatetrahydrofolate, a bisubstrate inhibitor of T S
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9.4 Oligopeptide inhibitors
Recently, oligopeptides have been shown to inhibit several enzymes and the mode of 
inhibition is discussed more fully in section 10.
9.5 Anti-sense oligonucleotides
An alternative aproach to the inhibition of enzyme function other than the use of drugs 
is to specifically inhibit enzyme synthesis. The use of anti-sense 
oligodeoxynucleotides (oligos) to arrest translation of specific mRNA molecules 
(Helene and Toulme 1990) has recently been directed to the DHFR-TS mRNA of the 
parasite Plasmodium falciparum. A 49mer targetted to the conserved region of 
thymidylate synthase gave 50% inhibition at 6(iM and 90% inhibition at 45fiM 
(Sartorius and Franklin 1991a). Such a oligo is very specific to the DHFR-TS mRNA 
of P. falciparum. It also differs considerably from the human TS mRNA, sharing 59% 
(29 out of 49) nucleotide sequence identity (Ayusawa et al 1986). However, the fact 
that certain useful modifications such as the use of methylphosphonates or poly (L- 
lysine) conjugates cannot be used for long oligos, may delay their development as anti- 
malarial drugs (Sartorius and Franklin 1991b).
10. Disruption of protein-protein interactions
Many biological processes rely on the specific interactions between two 
macromolecules and could, in principle, be inhibited by interfering with that 
interaction. Recognition sites on proteins are specific, and there are various examples 
of peptides, derived from the recognition site on one of the ligands, which retain 
sufficient structure to compete with the whole protein for a binding site.
Essential interactions between viral protein subunits are potential targets for antiviral 
agents. Interactions involving virus proteins that can be specifically inhibited have 
been reviewed by Marsden (1992). Described below are some examples of disruption 
of viral protein interactions.
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10.1 HSV ribonucleotide reductase
The best studied examples of protein complexes which can be disrupted by a peptide 
from one of the subunits are the ribonucleotide reductases from HSV and Escherichia 
coli. These enzymes catalyse the reduction of all four ribonucleotides to 
deoxyribonucleotides utilizing nucleoside diphosphates as substrates. The 
deoxyribonucleotides are phosphorylated and incorporated into DNA. Both the E.coli 
and HSV enzymes are heterodimers containing two molecules of a large subunit (R l) 
and two molecules of a small subunit (R2).
A nonapeptide (YAGAVVNDL) corresponding to the carboxy-terminus of HSV R2 
specifically inhibits the viral enzyme and not the cellular ribonucleotide reductase 
(Dutia et al 1986, Cohen et al 1986). The peptide acts by competing for the R2 
binding site on the Rl protein, and thus inhibits the normal association of the two 
subunits. The mammalian and E.coli enzymes can be similarly inhibited by their 
corresponding C-terminal peptides (Yang et al 1990, Cosentino et al 1991).
Although effective at inhibiting HSV ribonucleotide reductase enzyme activity in vitro, 
the YAGAVVNDL peptide does not inhibit virus growth in tissue culture, probably 
because it is too large to cross the cell membrane (Dutia et al 1986). However, it does 
provide a starting point from which therapeutically useful compounds could be 
developed.
10.2 FI protein of Paramyxoviridae
Membrane fusion by Paramyxoviridae is an example of a virus-host cell interaction 
that can be disrupted by a peptide fragment of the virus component. Paramyxoviridae 
— the family to which measles and mumps viruses belong—  have two surface 
glycoproteins: an attachment protein and a fusion (F) protein. The F protein is made 
fusogenic by proteolytic cleavage of an inactive precursor (Fo) to give two disulphide- 
linked polypeptides, Fj and F2. The newly generated N-terminus of F i is very 
hydrophobic and can insert into cell membranes (reviewd by Kingsbury 1990). Short 
peptides with amino acid sequences similar to the N-terminal region of Fi specifically 
inhibit virus-induced cell fusion and virus infection (Nicolaides et al 1968, Miller et aL 
1968, Richardson et al 1980, Richardson and Choppin 1983). The cell membrane 
components of this interaction are as yet undetermined.
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10.3 The a-TIF-Oct-1 transcription complex
The HSV-1 virion protein a-TIF (Vmw65, VP 16) plays a central role in the assembly 
of a virus-specific transcription complex responsible for the expression of IE genes. 
The complex (Figure 18) is composed of a-TIF and at least two cellular proteins: the 
cellular transcription factor Oct-1 (OTF-1, NFIII, TRF) and the complex forming 
factor CCF(HCF, V C A F -l.C l)
Oct-1
ATGCTAATGARAT TATA
HCF
Oct-1
AT GCTA AT GAR A TATA[
F ig u re  18 A model for the a-TIF-Oct-1 transcription complex formation and 
transcriptional activation
T his schem atic diagram depicts interactions that have been experim entally observed between the 
various protein com ponents o f the immediate early com plex and the basal transcription machinery. 
F ollow ing  release o f the viral DNA from the capsid, the octamer sites o f  the IE promoters become 
occupied by Oct-1. Independently, V m w 65 com plexes to HCF, and this heterocom plex then recognises 
Oct-1 in the context o f the flanking GARAT signal to form the immediate-early com plex. The 
V m w 65 acidic activation region is now positioned to activate transcription by prom oting assem bly o f  
the transcription com plex at the TATA box, through interactions w ith the basal transcription factors. 
Figure com piled and adapted from O ’Hare 1993, and Goodrich et a l 1993
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Formation of the complex can be inhibited by peptides corresponding to a region of a -  
TIF involved in the interaction (Haigh et al 1990, Hayes and O’Hare 1993). The 
region of a-TIF encompassing amino acids residues 360-388 was found by mutational 
analysis, to be critical for complex assembly (Greaves and O’Hare 1990). A peptide 
corresponding to amino acids 360-373 was found to inhibit complex assembly without 
affecting the DNA-binding property of Oct-1 (Haigh et al 1990). The peptide, 
proposed to act by competing with a-TIF for binding to the cellular components of the 
complex, inhibited complex formation when added to nuclear extracts prior to the 
addition of a-TIF, but was not able to disrupt pre-formed complex (Haigh et al 1990). 
By using overlapping peptides, the inhibitory sequence has been narrowed down to 
eight amino acids, REHAYSRA, corresponding to residues 360-367 (Hayes and 
O’Hare 1993). It remains to be tested whether the presence of this peptide in a cell 
prevents the expression of IE genes upon HSV-1 infection.
10.4 Influenza virus haemagglutinin
Influenza A, an orthomyxovirus, contains two membrane glycoproteins, 
haemagglutinin (HA) and neuraminidase (N). HA consists of two disulphide-linked 
chains, HA] and HA2. The protein is anchored in the cell membrane close to the C- 
terminus of HA2, with a short (11 amino acid residue) region on the internal side of 
the membrane. Virion assembly is poorly characterised, but appears to involve 
interactions between viral matrix proteins, the nucleocapsid and the cytoplasmic 
domains of the viral glycoproteins at the plasma membrane.
A 10 amino acid peptide (NGSLQCRICI), corresponding to the cytoplasmic domain 
of HA2, was shown to inhibit the release of infectious virions when added to the 
culture medium during infection (Collier et al 1991). The peptide acted specifically on 
influenza virus and had no other effect on two other enveloped RNA viruses, Sindbis 
and vesicular stomatitis vims. It was postulated to cross the plasma membrane and act 
by competing with the haemagglutinin for sites recognised by nucleocapsids or matrix 
protein.
10.5 VZV thymidylate synthase
Recently, oligopeptides have been shown to inhibit VZV thymidylate synthase activity. 
A linear pentadecapeptide corresponding to the amino acid sequence of p-strand i 
(LPPCHTLCQFYVANG) inhibits TS in vitro (IC50 = 50pM). Amino and carboxy
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terminal deletions of this peptide have defined the active core as CHTLCQFY, which 
corresponds precisely to those amino acids at the interface of the two monomers (HS 
Marsden and R Thompson, personal communication). These oligopeptides are thought 
to disrupt activity by preventing the correct formation of the dimer.
11. Aims of the project
The aim of this project was to investigate the role of structurally mobile regions of 
VZV thymidylate synthase using site-directed and region-directed mutagenesis. The 
regions chosen were the DRTG loop and the C-terminus. The loop, along with the C- 
terminus shows a dramatic movement upon ligand binding and is highly conserved 
within members of the TS family. The L. lactis enzyme displays significant variation 
in this region. Our aim was to substitute VZV residues in the DRTG loop for their L. 
lactis counterparts. It was anticipated that such mutants would be inactive and then 
they would allow selection for covariant residues that might restore enzyme activity.
The C-terminal region places a significant role in catalysis by closing the active site and 
sequestering ligands from solvent. Previous studies had suggested that the VZV 
enzyme might be unique among the TS family in terms of the interactions at the C- 
terminus (Harrison 1992, Harrison et al 1995). We aimed to extend these studies and 
to include the human TS with a view to probing the species specific differences.
A variety of folate analogues and a substrate-folate mimic were tested to examine the 
effect of amino acid substitutions on the enzyme’s sensitivity to such inhibitors. The 
potential for peptide inhibition of the C-terminal interactions will be explored.
MATERIALS
1. Bacteria and bacteriophage strains
S t r a i n  G e n o t y p e
BW313 relAX, spoTX, dut-\, ung-\, Hfr KL16(P045)
NM522 supE, thi, A (Lac-proAB), DhssdI5(r, n r) [F’,/?re>AB, lacYX
ZDM15]
X2913 thy A  A 152
BL21 (DE3) F-, ompT, hsdSB, gal, dcm, (DE3)
TGI supEAA, hsd5, thi 1, A(Lac-proAB)/ F ’|7raD36, p roA B +, lacl% lacZ
M15]
thy A  derivatives were made of strains NM522 and BL21 (DE3) 
Bacteriophage M13 R408 and M l3 K07 were laboratory stocks.
2. Bacterial growth media
Liquid media (all per litre unless stated otherwise):
Luria-Bertani Medium ILB) 2xYT Medium f2YT!
NaCl lOg
Bactopeptone lOg
Yeast extract 5g
Adjusted to pH 7.0 prior to 
sterilisation
All LB media (both liquid and solid) was supplemented with lOOjxg/ml thymidine 
unless otherwise stated.
Bactotryptone 16g 
Yeast extract lOg
NaCl 5g
Adjusted to pH 7.0 prior to 
sterilisation
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Minimal Medium fM9) per 400ml M9Tx41 salts per 1000ml
dH20 300ml Na2HPO4.7H20 24g
M9[x4] salts 100ml KH2PO4 12g
15% casamino acids 20ml NH4CI 4g
20% glucose 4ml NaCl2 2g
1M mgCl2 500jil
0 .8mg/ml thiamine lOOjLtl
Solid media:
LB
As above except supplemented with 15g Bacto-agar 
M9
As above except 300ml dH20 replaced by 300ml 2% Bacto-agar
3. Plasmids
pAD768 VZV TS containing BamHI/Hindlll fragment cloned into pBS"
constructed by Harrison 1992
pAD876 Human TS containing Sacl/Hindlll fragment of pHTS-pUC19
cloned into pBS“
Plasmids constructed by Harrison 1992
4. Chemicals and reagents
Unless specifically stated below, all chemicals were purchased from BDH chemicals 
Ltd, Poole, Dorset, or from Sigma (London) Ltd.
Ammonium persulphate (APS) Bio-Rad Laboratories, Richmond,
California, USA.
N,N,N',N-tetramethylethylenediamine Bio-Rad Laboratories, Richmond,
(TEMED) California, USA.
Ampicillin Smithkline and Beecham.
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Bactopeptone
Bio-Rad protein assay reagent
Casamino acids 
Deoxynucleoside triphosphates 
Ecoscint A
Kanamycin 
Organic solvents 
Replicote™
Wacker solution
Difco.
Bio-Rad Laboratories, Richmond, 
California, USA.
Difco.
Pharmacia LKB, Uppsala, Sweden.
National Diagnostics, Manville, New 
Jersey, USA.
Sigma.
May and Baker.
BDH.
Wacker Chemical company.
5. Sequencing solutions
Labelling mix 1,5|lM dGTP, 1,5|iM dTTP, 1,5|lM dCTP
Termination mix: G  contained 8p,M ddGTP, 80|iM dGTP, 80(lM
dATP ,80(iM dTTP, 80|iM dCTP, 50mM NaCl
A  contained 8(i.M ddATP, 80pM dGTP, 80|iM 
dATP ,80|nM dTTP, 80^M dCTP, 50mM NaCl
T  contained 8ji.M ddTTP, 80pM dGTP, 80p,M 
dATP ,80pM dTTP, 80|iM dCTP, 50mM NaCl
C  contained 8pM ddCTP, 80jiM dGTP, 80jiM 
dATP ,80pM dTTP, 80pM dCTP, 50mM NaCl
Annealing buffer (5xTM) 0.1M tris pH 8.0, 0.1M MgCl2
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Stop solution 95% deionised formamide, 20mM EDTA pH 7.5,
0.05% Xylene cyanol FF, 0.05% bromophenol 
blue
Wacker solution (5ml) 25|il Wacker silane GF38, 1 50jll1 10% acetic acid,
5ml ethanol
6. Radiochemicals
All radiochemicals were purchased from Amersham International Ltd, Maidstone, 
UK.
Nucleotide
[a 35S]dATP
5-[3H]dUMP
Activity 
37TBq/mmol 
622GB q/mmol
Concentration 
1 mC i/mmol 
16.8Ci/mmol
Code 
S J 1304 
TRK287
7. Enzymes
Restriction enzymes
T4 polynucleotide kinase 
T4 gene 32 protein
Klenow fragment of DNA polymerase I 
Sequenase™
Boehringer Mannheim, Lewes, E. 
Sussex, UK.
New England Biolabs, Bishops 
Stortford, UK.
New England Biolabs, Bishops 
Stortford, UK.
Pharmacia LKB, Uppsala, Sweden.
Purified in house by Moira Watson 
from E.coli cells expressing a plasmid 
construct (Joyce & Grindley, 1983).
United States Biochemicals.
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8. Miscellaneous materials
Kodak X-Omat Film 
Whatman Paper
S-Sepharose
Hydroxylapatite
9. Buffers and solutions
5x Electrode buffer 
Boiling mix 
Coomasie blue stain
Destain solution 
Enzyme dilution buffer 
Ligase buffer (BM)
Ligase buffer (BRL)
Loading buffer
Kodak Ltd, UK.
Whatman International Ltd, 
Maidstone, UK.
Pharmacia LKB, Uppsala, Sweden. 
BDH
4.5g tris base, 21.6g glycine, 1.5g SDS 
made to 300ml with dH20
80mM Tris pH 6.8, 2% SDS, 0.1M 
DTT, 20% glycerol, Bromophenol blue
1.25g Coomasie blue, 228ml methanol, 
45ml acetic acid, made to 500ml with 
dH20
50% dH20, 40% methanol, 10% acetic 
acid
130mM Tris pH 7.5, 0.125mM DTT, 
0.15% BSA
66mM tris pH 7.5, ImM DTT, 5mM 
MgCl2, ImM ATP
50mM tris pH 7.6, ImM DTT, lOmM 
MgCl2, ImM ATP, 5% (w/v) PEG
8000 (or 6000)
15% ficoll, Bromophenol blue in 
lxTBE
Materials
Lysozyme solution 
0/CHC13
Oligo elution buffer 
Oligo loading buffer 
Potassium acetate solution 
Reaction buffer (debromination assay)
Sonication buffer 
Spectrophotomemtric assay buffer
STET buffer
Stop solution (tritium release)
TBE
TE
TES buffer 
TM buffer
0.4% egg white lysozyme, 50mM 
glucose, 25mM tris pH 8.0, lOmM 
EDTA
Phenol/chloroform 1:1 (v/v)
500mM ammonium acetate, lOmM 
MgCl2, ImM EDTA, 0.1% SDS
90% (v/v) deionised formamide in 
lxTBE
60ml 5M potassium acetate, 11.5ml 
glacial acetic acid, 28.5ml dH2 0
200mM N-methylmorpholine 
hydrochloride pH 7.4, 25mM MgCl2, 
ImM EDTA, 75mM 
p-mercaptoethanol
50mM tris pH 7.4, lOmM DTT, 0.1% 
(v/v) Triton X-100
50mM TES, 25mM MgCl2, 6.5mM 
HCHO, ImM EDTA, 75mM
(3 -mere aptoeth an ol
8% sucrose, 50mM tris pH 8.0, 40mM 
EDTA, 1% Triton X-100
3 volumes 33% TCA, 1 volume 
5 mg/ml dUMP
90mM Tris, 90mM boric acid. ImM 
EDTA
lOmM Tris-Cl pH 8.0, ImM EDTA
50mM tris pH 7.4, 5mM EDTA, 
50mM NaCl 2
0 .1M tris pH 8.0, 0.1M MgCl2
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TSB
[2x] assay mix (tritium release assay)
7.4mll LB, 2ml 50% PEG 4000, lOOpl 
1M MgSC>4/lM  MgCl2, 500|il DMSO
128miM NaF, 260mM Tris-HCl pH 
7.5, 64mM sucrose, 0.3% (w/v) BSA, 
0.25mM DTT, 38mM HCHO, 2mM 
tetrah^drofolate
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1. Growth and maintenance of bacteria and 
bacteriophage
1.1 Overnight cultures
An isolated single colony was inoculated into 5ml LB, supplemented with the 
appropriate antibiotics and thymidine. The culture was incubated with vigorous 
shaking at 37°C overnight.
1.2 Bacterial glycerol stocks
A 15ml overnight culture of the appropriate clone was set up in a universal. Cells 
were harvested by centrifugation at 7000rpm for 5 minutes in a Beckman centrifuge. 
The cell pellet was resuspended in 5ml of 2% bactopeptone. To this 5ml 80% 
glycerol and 40|il 25mg/ml thymidine were added, mixed and stored at -70°C.
1.3 Antibiotics
Antibiotics were used at the following final concentrations, unless otherwise stated. 
Ampicillin (Amp) 100|!g/m; Kanamycin (Km) 75pg/m l
1.4 Titration of helper phage R408
10ml of 2YT broth was inoculated with 1ml of an overnight culture of TGI cells and 
incubated at 37°C with vigorous shaking for 1 hour. 3ml aliquots of molten top agar 
were equilibrated to 45°C in a waterbath. A series of 1 in 10 dilutions of the helper 
phage was made in T2 buffer. To the equilibrated top agar was added 200pl of 
NM522 T h y  cells and lOOpl of the diluted helper phage (in the range 10^ to 1012). 
The top agar was mixed together and immediately poured on to LB plates. After the 
top agar layer had solidified the plates were incubated overnight at 37°C. Helper 
phage plaques were counted the next day and the titre calculated.
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1.5 Growth of helper phage
Four individual plaque plugs of helper phage were inoculated into 100ml 2YT broth 
containing exponentially growing E.coli NM522 T h y  cells. This was incubated with 
vigorous shaking at 37°C overnight. The overnight culture was cleared of bacteria by 
centrifugation at 9K at 4°C for 10 minutes. The supernatant was decanted to a fresh 
tube and recleared by a further centrifugation step. This supernatant was heat- 
inactivated at 55°C for 20 minutes, allowed to cool to room temperature and stored at 
4°C. The titre of the helper phage was determined as described above.
2. Bacterial manipulation
2.1 Transformation (Chung and Miller, 1988)
20ml of LB was inoculated with 1ml of an overnight of the appropriate bacterial 
strain and incubated at 37°C with vigorous shaking until A600 was ~ 0.5. Cells were
pelleted by centrifugation at 7K/10 minutes at 4°C and resuspended in 2ml 
transformation storage buffer (TSB). The resuspended cells were made competent by 
incubation on ice for 15 minutes.
10 to lOOng of DNA was added to 1OOpl competent cells and incubated on ice for 30 
minutes. 900pl of LB (supplemented with thymidine) was added to the cells and 
incubated at 37°C for 1 to 1V2 hours. 1 OOpil was spread on to LB plates 
supplemented with ampicillin and thymidine and incubated at 37°C overnight. Both a 
positive (~10ng plasmid DNA) and a negative (no DNA) control was always 
included in a transformation experiment.
3. DNA isolation
3.1 Mini-prep plasmid DNA preparation (Hattori et al, 1986)
A fresh single colony (or 50pl of an overnight culture) harbouring the desired 
plasmid was picked and inoculated into 5ml LB supplemented with the appropriate 
antibiotics and thymidine. The culture was incubated at 37°C with vigorous shaking 
overnight. Cells were pelleted by centrifugation of D /2 ml in a microfuge for 2 
minutes at full speed. The cell pellet was resuspended and lysed with lOOpl
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lysozyme solution at room temperature for 5 minutes. 200|il 0.2M NaOH/l%SDS 
was added and incubated on ice for 5 minutes. 1 50jll1  of potassium acetate solution 
was added, mixed gently and incubated for a further 5 minutes on ice. The cell debris 
was removed by centrifugation at 12K for 10 minutes (microfuge) and the 
supernatant removed to a fresh tube. The supernatant was 0 /CHCI3 extracted and
the aqueous layer removed. The DNA was precipitated with 2 volumes ethanol by 
incubation at room temperature for 15-30 minutes followed by centrifugation at 12K 
for 5 minutes. The DNA pellet was washed with 70% ethanol, dried under vacuum 
and resuspended in an appropriate volume of TE buffer.
3.2 STET lysis plasmid DNA preparation
D /2 ml of an overnight culture was centrifuged (12K/40 seconds) to pellet the cells. 
The cell pellet was resuspended in 200pl STET buffer and 20jll1  lysozyme (25mg/ml) 
added. The solution was boiled for 2 minutes and centrifuged (12K/10 minutes). The 
supernatant was removed and to it added Vjo volume 3M sodium acetate and 2
volumes isopropanol. The DNA was precipitated by centrifugation at 12K for 10 
minutes, the pellet dried under vacuum and resuspended in 2 0 jll1 dH20.
3.3 Qiagen™ plasmid preparation
100ml of LB supplemented with ampicillin was inoculated with 10ml of an 
overnight culture of the appropriate plasmid containing E.coli strain and incubated 
overnight at 37°C with vigorous shaking.
The plasmid was isolated from the bacteria as described in the MIDI protocol of the 
Qiagen™ handbook.
3.4 Plasmid DNA sequencing preparation
DNA was extracted from cells as described in section 3.1 with the pellet being 
resuspended in a final volume of 50pl TE buffer. RNase was added to a final 
concentration of 10jag/ml and incubated at 37°C for 30 minutes. The DNA vas 
precipitated by incubation on ice for 1 hour with 30(0.1 20% PEG 6000/2.5M NaCl 
followed by centrifugation at 12K for 5 minutes. The DNA pellet was washed with 
70% ethanol, dried under vacuum and resuspended in 18(0.1 TE buffer. The DNA vas 
denatured by the addition of 2pl 2M NaOH and incubation for 5 minutes at room
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temperature. 8pJ 5M ammonium acetate, IOOjlxI ethanol was added and incubated in a 
dry ice bath for 5 minutes followed by centrifugation. The pellet was wahed with 
70% ethanol, dried under vacuum and resuspended in 10-20jal dH20 . 5jil was used 
directly for sequencing.
3.5 ssDNA sequencing preparation
A single colony was inoculated into 5ml 2YT broth containing ampicillin (75|Xg/ml), 
thymidine (lOOjig/ml) and M l3 K07 helper phage (2x10^ pfu/ml) and incubated at 
37°C with vigorous shaking for 2 hours. Kanamycin was added to a final 
concentration of 70pg/ml and the culture incubated at 37°C with vigorous shaking 
overnight.
3x 1 ]/2 ml of the culture was centrifuged at 12K for 10 minutes in a microfuge to 
pellet the cells. 1ml of the supernatant was transferred to a fresh eppendorf tube and 
300pl 2.5M NaCl/20% PEG added, vortexed and incubated on ice for 15 minutes. 
The phage was pelleted by centrifugation in a microfuge (12K for 5 minutes) and the 
supernatant discarded. The phage pelleted was resuspended in 400pl 0.3M sodium 
acetate and an equal volume of 0 /CHCI3 added, vortexed vigorously and
microfuged for 5 minutes. The top aqueous layer was transferred to a fresh 
eppendorf tube and 1 ml ethanol added, vortexed and incubated at room temperature 
for 30 minutes. The ssDNA was pelleted by centrifugation at 12K for 5 minutes 
(microfuge) and the supernatant carefully discarded. The 3 ssDNA pellets were dried 
under vacuum (5 minutes in a speedivac), resuspended in 5-25pl TE buffer and 
stored at -20°C until needed.
3.6 Uracil-ssDNA preparation (Kiinkel, 1985; Kiinkel et a l , 1987)
10ml of 2YT broth supplemented with the appropriate antibiotics and uridine 
(100pg/ml) was inoculated with 50pl glycerol stock of E.coli strain BW313 Dut~ 
Ung” harbouring the required plasmid. The culture was incubated at 37°C with 
vigorous shaking overnight. The overnight culture was added to 200ml of 2YT 
supplemented with the appropriate antibiotics and uridine (100|ig/ml) in a 2L baffled 
flask and incubated at 37°C with vigorous shaking until A^OO was 9.5. At this point
M l3 R408 helper phage was added to a final pfu/ml of 5x 109 and the culture 
incubated at 37°C with vigorous shaking for a further 8 hours. The cells were 
pelleted by centrifugation at 7K for 20 minutes using a Sorvall GS3 rotor and the
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supernatant kept. The supernatant was centrifuged one final time. To the supernatant 
V4 volume of 3.75M ammonium acetate/20% PEG 6000 was added, mixed, split in 
two and incubated on ice for V2 hour. Phage was precipitated by centrifugation at 9K 
for 30 minutes using a Sorvall GS3 rotor. The phage pellet was allowed to air dry for 
ten minutes and then resuspended in TE buffer (400jil per pellet). The protein was 
removed by chloroform extracting twice and 0/CHCl? extracting 3 to 6 times or until
the interface became clear. The aqueous phase was chloroform extracted one final 
time and to it added 0.36 volumes 7.5M ammonium acetate and 2.5 volumes ethanol 
followed by incubation on ice for 20 minutes. The ssDNA was pelleted by 
centrifugation at 12K for 20 minutes, washed with 70% ethanol and dried under 
vacuum. The lyophilised pellet was resuspended in 50(il dH20. This ssDNA template
was checked to ensure it was enriched with uracil by transforming it into a D ut+ 
Ung+ host and a Dut Ung host (see section 2.1). Uracil-enriched DNA gave no 
colonies in the Dut+ Ung+ host. The concentration of ssDNA produced was estimated 
spectrophotometrical ly *.
* 1 A26O u n i t  -  4 0 |H g /m l  ssDNA
4. DNA manipulations
4.1 Restriction enzyme digests
Restriction enzyme digests were usually carried out in 1 0  to 50jll1  reaction volumes. 
Restriction enzyme buffers are available commercially at lOx concentration and 
were diluted accordingly. Enzymes were added at 1 to 1 0  units (U) per |ig DNA and 
incubations performed at 37°C for 3 hours or overnight.
When mini or STET prep DNA was digested, RNase was added to a final 
concentration of lOOmg/ml for the last hour of the incubation. Digested DNA to be 
used in cloning experiments was always 0/CHCl^ extracted (to remove the
restriction enzymes) and ethanol precipitated prior to use.
4.2 Isolation of DNA from agarose gels
DNA was isolated from agarose using a Pharmacia Sephaglass™ kit as per the 
manufacturers instructions
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4.3 DNA ligations
Ligations were usually performed in a total volume of 10|il. lOOng of vector and 
17ng insert DNA were mixed with 2(lx1 5 x  ligation buffer (BRL) or lp l lOx LB 
(Boehringer-Mannheim), 1 unit T4 DNA ligase and the volume made up to lOpl 
with dH20. The ligation mix was incubated at 16°C overnight. l-5(il of the ligated
DNA was used for transformation of E.coli.
5. Oligonucleotides
5.1 Synthesis and purification
Oligonucleotides were synthesised on a Biosearch 8600 DNA synthesiser by Dr John 
McLaughlin or on a Cruachem PS250 DNA synthesiser by myself.
Oligonucleotides were provided still attached to the column upon which they were 
synthesised. Oligonucleotides were removed from the column by flushing the 
column with one column volume (~0.25ml) of concentrated ammonia solution, and 
incubating at room temperature for 20 minutes. This process was repeated until 
1.5ml of concentrated ammonia had been flushed through the column. 
Oligonucleotides from the Biosearch machine were already provided in 1ml of 
ammonia solution.
The oligonucleotide containing ammonia solution was heated at 55°C for 5 hours and 
subsequently lyophilised overnight. The lyophilised pellet was resuspended in 50(0.1 
dH20 and this crude preparation stored at -20°C until needed.
10 to 25 |il of the crude preparation was mixed with an equal volume of loading 
buffer without any dyes (lxTBE, 90% deionised formamide) and boiled for 2  
minutes. The sample was loaded on to a 15% polyacrylamide gel along with 5 to 
lOp.1 formamide dyes (in a separate well) as a marker track. Electrophoresis was 
performed at 250V in lxTBE buffer. For oligonucleotides of length 15 to 30 bases 
the bromophenol blue band was allowed to migrate approximately 7cm down the gel 
(~1 hour). For oligonucleotides 30 to 60 bases in length the bromophenol blue band 
was allowed to migrate to approximately the end of the gel ( - 2 - 3  hours).
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To isolate the oligonucleotide the gel was removed from the glass plates and 
wrapped in cling film. The DNA was visualised using the shadow casting technique, 
which involved illumination of the gel whilst on a thin layer chromatography (TLC) 
plate using a short-wave UV lamp. The DNA appears as a dark band against a 
uniform green fluorescent background. The largest moving band at the top of the gel 
was excised and cut into several smaller pieces prior to being eluted in 1/2ml oligo 
elution buffer by overnight incubation at 37°C. The eluted oligonucleotide was 
centrifuged at full speed in a microfuge for 5  minutes to remove any acrylamide. The 
supernatant was carefully removed to another eppendorf tube and ethanol 
precipitated. The DNA pellet was resuspended in 50|LLl of dH20, its concentration
determined spectrophotmetrically* and stored at -20°C prior to use.
* 1 A26O und = 20|ig/ml oligonucleotide
5.2 Spiked oligonucleotides
Spiked oligonucleotides were synthesised on the Biosearch 8600 DNA synthesiser 
using phosphoramidite mixes containing 96% of the normal nucleotide and 1.33% 
each of the other three nucleotides.
5.3 Oligonucleotide sequences
A complete list and sequences of all the oligonucleotides used in this project are 
shown below.
VZV TS Site-directed mutagenesis oligonucleotides
Sequence Mutation
CCT-GTT-CC A-TCG-CGT R38G
CGT-TCC-GAT-TCC-TTG-TCG-ATC-GCG-TTT T39Q
T A A-CGT-TCC-GAT-CAT-TGT-TCG-ATC-GCG G40M
AG A-T A A-CGT-T CC-GGC-G AT-TCC-TGT-T CG 41A42
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AGA-TAA-CGT-TCC-GGC-TCC-TGT-TCG I41A
AAT-CCA-TTA-AGC-AAG-AGC-CAT A302
A AT-CC A-TT A-T CC-A AG-AGC-C AT G302
Human TS Site-directed, mutagenesis oligonucleotides
Sequence
G-GAA-ATG-GCT-TAA-TAG-GGT-GC
Mutation
V313A
The numbering system refers to the VZV (or Human) TS gene, with nucleotide +1 
referring to the A in the ATG codon specifying the first methionine residue.
Spiked oligonucleotides
Number Sequence targeted
R O 1 C A A- ATT-GT A-TCG- AGC-TTG-C AT-TCC-AA A-
TAA-AGA-TAA-CGT-TCC-GAT-TCC-TGT-TCG- 
ATC
Size
57mer
R 05 ATT-CCA-AGA-CGA-TAT-AAT-CAT-TCG-TCG- 
GCT-TTC-TGG-GTT-TGT-TTT -A AT
48mer
R 07 GTT-TGC-AAC-GTA-AAA-CTG-ACA-TAA-CGT- 
GTC-ACA-TGG-AGG-TAG-TAC
45mer
R 08 CAT - ATC-CCC-CGA-TCT-CTG-GT A-T AC-TTG- 48mer
GC A-GG A-T A A-TTC-ACC-GTT-TGC
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RO 10 T AA-ATC-TCC-GGT-TTT-AAG-TCC-TGT - AAC- 54mer
ATG-CGC-T AC-T AT-GT A-GGT-A AG-AAG-TGC
5.4 Sequencing oligonucleotides
Sequence
GTC-T GT-GT A-T AT-CAT 
CC A-TTG-T AT-GA A-TT A 
TTT -A AT-TGT-ATC-T AT 
CCA-CGA-CGG-CCC-TCC
GGA-CC A-CTT-GGC-CTG 
GT A-CCT-GGG-GC A-GAT 
AAG-AGC-TGT-CTT-CCA 
GAC-ACC-ATC-AAA-ACC 
GCT-C AC-GT A-C AT-GAT 
CTC-AGG-ATT-CTT-CG A 
A AG-GGT - AC A-ATC-CGC 
TTC-ATC-TCT-C AG-GCT 
GCC-GCA-GCG-GAG-GAT 
CTG-CTG-ACA-ACC-AAA
6 . Mutagenesis
6.1 Oligonucleotide site directed mutagenesis
Oligonucleotides were used to introduce specific mutations at defined sites within a 
TS gene. The strand selection scheme of Kiinkel was employed using a uracil- 
enriched template strand which is degraded in a Ung+ host strain.
500pmole oligonucleotide was phosphorylated in 20pl ligation buffer containing 10 
units of T4 polynucleotide kinase at 37°C for 30 minutes. The T4 kinase was 
inactivated by incubation at 65°C for 15 minutes. The phosphorylated 
oligonucleotide was diluted with dH20 to a final concentration of 5pmole/jil. Ip]
Number
59
60 
61 
62
HP1
HP2
HP3
HP4
HP5
HP6
HP7
HP8
HP9
HP10
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phosphorylated oligonucleotide was annealed to O.lpmole U-ssDNA in 10|Lil TM 
buffer at 37°C for 30 minutes. The annealed oligo was filled in by the addition o f ljil 
5mM dNTP (a 5mM solution of all four dNTP’s), 5 units Klenow fragment of DNA 
polymerase I, 1 unit of T4 polynucleotide kinase, 2.0pg gene 32 protein in 20|il 
ligation buffer.
6.2 Region directed mutagenesis
Spiked oligonucleotides were designed to have on average two base changes per 
oligonucleotide. They were used to introduce random mutations to a targeted region 
of the TS gene. As for site-directed mutagenesis the strand selection scheme of 
Kiinkel was employed using a uracil-enriched template strand which is degraded in a 
Ung+ host strain.
Mutagenesis was performed as outlined for site-directed mutagenesis (see section 
6 . 1).
6.3 Temperature sensitive mutations
Spiked oligonucleotides were used to probe for residues involved in protein stability. 
Mutagenesis was performed as outlined for site-directed mutagenesis. Colonies were 
patched on to minimal media (M9) with or without thymidine and grown at 30°C, 
37°C and 42°C.
7. Mutant screening
7.1 Restriction digests
Potential mutations were screened by restriction digest analysis prior to sequencing 
to remove those clones that did not give the correct restriction pattern and thus did 
not contain the plasmid of interest.
Restriction analysis was performed as described in section 4.1.
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7.2 Growth complementation assays
1 to 5 j l x 1 mutagenised DNA was used to transform a suitable E.coli thyA strain. 
Transformants were picked, using sterile tooth picks, and patched onto M9 plates 
and M9 plates supplemented with thymine 5Q|ig/ml and incubated overnight. 
Appropriate clones were used to set up overnightt cultures and mini-prep (or STET 
prep) DNA prepared for restriction digest analysis. Both Thy+ and Thy- clones with 
the correct restriction pattern were sequenced. In  all cases the entire TS coding 
region was sequenced for each clone.
7.3 DNA sequencing
All DNA sequencing was performed in a 96) well m icro-titre plate using a 
Sequenase™ kit. 3pl (~10-30ng) sequencing prinner, was annealed to O.l-l.Opg of 
DNA (ssDNA or dsDNA) in 1 OjllI lx reaction buiffer by incubating at 37°C for 30 
minutes in an eppendorf tube. The annealed reactkon mix was transferred to a micro- 
titre plate and 1 jLil DTT, 2jil label mix (previously (diluted 1 in 3), 1-2jli1 [a 35S]dATP, 
and 2jll1 Sequenase enzyme (previously diluted 1 im 8) added. The plate was spun in a 
centrifuge IK for 30 seconds to mix the reagents aind incubated at room temperature 
for 1 minute. 3 .5jll1 of this mix was transferred to ai separate well containing 2.5jll1 of 
ddGTP. This was repeated for the other three didieoxy termination mixes (ddATP, 
ddTTP, ddCTP) and the plate sealed with a plate sealer (Flow Laboratories Ltd or 
Corning) and incubated for at 37°C 15 minutes. T o  the sequencing reaction 2jil of 
stop solution was added and the plate boiled for 2 minutes prior to loading 3jll1 on to 
a polyacrylamide gel.
Sequencing reactions were resolved on a 4% acrydamide, 7.7M urea, */2X TBE gel. 
Prior to use both plates were washed in 100% ethamol. If the gel was to be oven dried 
then the front plate was coated in Replicote™ them washed once with 100% ethanol. 
The back plate was coated with ~5ml Wacker soluition and then washed 5 times with 
100% ethanol prior to the gel being poured. If th© gel was to be transferred to 3M 
paper then both plates were coated with ReplicoUe™ and washed once with 100% 
ethanol before the plate was poured. Electrophcoresis was performed at 40W in 
lxTBE. For normal runs the bromophenol blue was used as a marker to terminate 
electrophoresis. For longer runs the gel was run for' a further 1-2 hours.
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8 . Mutant characterisation
8.1 Crude TS extracts
300ml LB supplemented with the appropriate antibiotics and thymidine was 
inoculated with 10ml of an overnight culture of the appropriate clone and incubated 
at 37°C with vigorous shaking until A600 ~ 0.3. A small volume of culture was 
removed and kept on ice for a phenotype check (see later). The cells were pelleted by 
centrifugation at 7K/10 minutes (Sorvall GS3 rotor) at 4°C. The pellets were drained 
resuspended in 10ml TES buffer, and vortexed to disrupt any lumps. The cells were 
pelleted once more (MSE bench top centrifuge) by centrifugation at 3K for 10 
minutes at 4°C. The pellet was resuspended in 2 volumes of sonication buffer and 
sonicated (Branson Sonifier with the microprobe setting on 3). Sonication was 
performed in 10 second bursts three times with 30 seconds cooling between each 
burst. The sonicated extract was transferred to an eppendorf tube(s) and spun at 10K 
for 10 minutes in a pre-cooled (4°C) Beckman SS34 rotor. The supernatant was 
removed to fresh tubes and its protein concentration determined prior to being snap 
frozen in a dry ice/ethanol bath, and stored at -70°C.
To check the phenotype of the extract a drained loop full of the culture was streaked 
to single colonies on a LB agar plate (supplemented with thymidine only)and 
incubated at 37°C overnight. Single colonies were then patched on to M9, M9 plus 
thymidine and LB (supplemented with ampicillin and thymidine) agar plates and 
incubated at 37°C overnight.
8.2 Protein concentration determination
A modified version of the Bradford assay was used to determine the protein 
concentration of crude and purified protein extracts. Assays were performed in 
micro-titre plates using an Anthos HTII plate reader at wavelength 620nm.
To a series of wells 400|al of Bradford reagent was added and to these lOjal BSA 
protein standard was mixed. l-10|i.l of the test protein was added to a well and mixed 
prior to reading the plate. The plate reader read the plate and determined the protein 
concentration of the test protein from the standard curve it plotted.
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8.3 Tritium release assay
This assay follows the release of radioactivity from 5-[3H] dUMP to the solvent. 
Unreacted substrate is absorbed to charcoal, removed by centrifugation and the 
radioactivity in the supernatant determined by scintillation counting.
TS extract was mixed with 20jil [2x] assay mix, 0.4jnCi 5-[3H] dUMP and dH20 in a 
total volume of 40jal and incubated at 30°C for 15 minutes. The reaction was 
terminated by addition of stop solution and 1 80(li1 2% charcoal suspension. The 
sample was vortexed and centrifuged for 2 minutes following which 500|il 
supernatant was removed and added to 5ml Ecoscint A prior to liquid scintillation 
counting in a Beckman LS5000CE scintillation counter. A total counts control was 
included using 5jjJ sonication buffer instead of extract and adding 940 |lU dH20
instead of charcoal suspension. A background control was also included by replacing 
extract with 5jnl sonication buffer and this value subtracted from all experimental 
values. Assays were performed in duplicate on two or more independent extracts for 
each clone. The amount of extract used was adjusted so that less than 30-60% of the 
total counts are released. This ensures that assays are in the linear region of the 
reaction curve.
The amount of dTMP generated is directly equivalent to the amount of [3H] released 
during the assay. The amount of [5-3H] dUMP added to the reaction in pmol can be 
calculated from its specific activity. The total counts represents the equivalent 
amount of product (dTMP)
dTMP produced = P CPM x pmol [5-3H] dUMP added 
Total CPM
From protein concentration, the specific activity of TS in the crude extracts can be 
expressed in terms of pmol dTMP produced per jig protein per minute.
8.4 Debromination assay
This assay follows the reduction in absorbance at 285nm caused by the release of 
bromine from 5-BrdUMP (Garret et al 1979). It represents the first stage of the TS
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reaction and as such does not require the presence of folate cofactor. Reactions were 
perform ed in Hellma quartz microcells containing 250jil reaction buffer (2x 
strength), 5|il 4mM 5-BrdUMP (40pM final concentration), l-5|xl of crude extract 
and dH20 to final volume of 500jil. Absorbance change was monitored using a Cecil
CE595 double beam spectrophotometer (zeroed on the cuvettes before adding 
extract) and displayed on a chart recorder. Reactions were run for 15 minutes to 20 
minutes at room temperature. An extract of wild-type VZV TS was included in each 
batch of assays and assays were performed in duplicate on two or more independent 
extracts for each clone. To compare extracts initial rates were calculated and 
expressed as mOD/min/pg protein.
9. Peptide inhibition of TS
Peptides that potentially inhibited VZV TS were tested essentially the same as for 
the tritium release assay (see section 8.3).
Peptides were preincubated with the enzyme, in a reaction mix that did not contain 
folate or 5-[3H]dUMP, for 15 minutes prior to their addition. The tritium release 
assay was then performed as section 8.3.
Peptides were tested in duplicate in a range of concentrations ranging from 0.2mM to 
2.0mM and with varying preincubation and assay temperatures (30° or 42°C).
Peptides were made and purified by Gillian McVey by continuos-flow Fmoc 
chemistry using a Novabiochem peptide synthesiser. Purification was by reverse 
phase chromatography on a Beckman System Gold HPLC using a Dynamax 300A 
C8 preparative column. Lyophilised pellets were stored at -20°C.
10. Purification of mutant proteins
10.1 T7 expression vector
To enable large quantities of protein to be purified from a bacterial culture system 
the TS gene was cloned in to the T7 vector pET8c. This vector when transformed in 
to the host E.coli strain BL21 (DE3) is inducible by IPTG allowing high levels of 
protein to be expressed.
Prior to transformation into BL21 (DE3) cells the TS containing pET8c vector was 
first transformed into E.coli strain NM522 Thy, and a STET lysis DNA preparation
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made for restriction digest analysis. This DNA was then transformed into BL21 
(DE3) cells.
10.2 Growth and extraction of TS
A fresh single colony was picked into 50ml LB supplemented with the appropriate 
antibiotics and thymidine and incubated at 37°C with vigorous shaking overnight. 
5ml of the overnight culture was used to inoculate 750ml LB supplemented with the 
appropriate antibiotics and thymidine in a 2L baffled flask. A total of 6L (8 flasks) 
was inoculated and incubated at 37°C with vigorous shaking until the A630~ 0.5. At
this point 1ml was transferred to a universal and incubated at 37°C as before. To the 
flasks IPTG was added to a final concentration of 0.2mM and incubation at 37°C 
continued for a further 3-5 hours. 1ml of the induced culture was removed to a 
universal and along with the previous 1ml sample processed (as described in section 
10.3) to check for protein induction.
The induced culture was centrifuged at 9K for 10 minutes (4°C) and the resulting 
pellets were resuspended in a total of 10ml TES buffer. A further 10ml of TES buffer 
was added and the suspension vortexed to disrupt any lumps. The cells were once 
again pelleted by centrifugation at 9K for 5 minutes (4°C) and the supernatant 
discarded. The bacterial pellet was resuspended in 10ml 50mM potassium phosphate 
buffer pH 7.0 and vortexed vigorously prior to sonication. Sonication was performed 
(using a Branson sonifier) with the microprobe on setting 5 and entailed five 15 
second bursts with 30 seconds cooling between each burst. The sonicated sample 
was centrifuged at 18K for 30 minutes (4°C) and the supernatant removed. The 
remaining cells were resuspended in a further 5ml 50mM potassium phosphate 
buffer pH 7.0 and re-sonicated. The two supernatants were combined and stored at 
4°C prior to purification.
10.3 Protein mini-gel electrophoresis
SDS polyacrylamide gel electrophoresis was performed using a Bio-Rad MINI- 
PROTEAN™ II kit. Gels were cast according to the manufacturers instructions and 
consisted of a separating gel (12% acrylamide, 0.37M tris pH 8.8) and a stacking gel 
(4% acrylamide, 0.125M tris pH 6.8).
Bacterial cultures to be tested were initially pelleted by centrifugation of 1ml of the 
appropriate culture in a microfuge (full speed) for 1 minute. The supernatant was 
removed and the pellet resuspended in 50pl dH20 and then 50jil of boiling mix
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added. The sample was boiled for 2 minutes prior to loading on the gel. Purified 
protein samples to be tested were mixed with a equal volume of boiling mix and 
boiled as before. Electrophoresis was performed at 450V in lx  electrode buffer for 
45 minutes or until the bromophenol blue dye front had reached the bottom of the 
gel. The acrylamide gel was removed from the casting plates and the top stacking 
layer carefully discarded. The gel was stained using a coomassie blue stain for 20 
minutes. The gel was then destained for 20 minutes, the destain discarded and the 
process repeated.
Destained gels were air dried overnight between a sheet of porous polythene.
10.4 Hydroxyl apatite chromatography
All chromatographic procedures were performed at 4°C. A 30ml column was poured 
by resuspending ~12g hydroxylapatite in 6x column volume of 50mM potassium 
phosphate buffer pH 7.0 and mixing by gentle swirling. The hydroxylapatite was 
allowed to settle and the buffer decanted, fresh buffer was added and the process 
repeated. The washed hydroxylapatite was finally resuspended in an equal volume of 
50mM potassium phosphate buffer pH 7.0 and poured in to the column. Two bed 
volumes of 50mM potassium phosphate buffer pH 7.0 were pumped through the 
column at 1 ml/minute to wash and equilibrate the column.
Samples were kept from all stages of the chromatography (loading, washing and 
eluting) for analysis on a protein mini-gel (see section 10.3). The supernatant usually 
appeared viscous after sonication and was thus diluted two times with 50mM 
potassium phosphate buffer pH 7.0 prior to loading on to the column at V2 
ml/minute, and the flow through collected. The unbound protein was removed by 
washing (1 ml/minute) the column with increasing phosphate concentrations. The 
first was 2 volumes 50mM potassium phosphate buffer pH 7.0 and the second 2 
volumes lOOmM potassium phosphate buffer pH 7.0. The TS protein was eluted 
from the hydroxylapatite by washing the column in 2 volumes 300mM potassium 
phosphate buffer pH 7.0 at 1 ml/minute.
The partially purified TS protein was cut by ammonium sulphate precipitation to 
reduce its volume and then dialysed reduce the phosphate concentration to 50mM 
prior to purifying further on a S-sepharose column.
i1
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10.5 Ammonium sulphate precipitation and dialysis
TS protein was precipitated with 70% ammonium sulphate by adding it slowly to the 
protein solution while stirring on ice. The solution was then stirred on ice for a 
further 30 minutes. The precipitate was pelleted by centrifugation (4°C) at 18K for 
30 minutes. The pellets were resuspended carefully without frothing in a minimal 
volume of 50mM potassium phosphate buffer pH 7.0. The protein solution was 
dialysed overnight against 1 litre of 50mM potassium phosphate buffer pH 7.0 using 
Spectra/Por (Mol Wt. cut off 10, 000) dialysis tubing. The dialysed protein solution 
was centrifuged (microfuge) to remove any sediment and the supernatant kept ready 
to load on to an S-sepharose column.
10.6 S-sepharose chromatography
All chromatographic procedures were performed at 4°C. A 10ml S-sepharose column 
was poured. As before samples were kept from all stages of the chromatography 
(loading, washing and eluting) for analysis on a protein mini-gel. The column was 
washed and equilibrated with 6 bed volumes of 50mM potassium phosphate buffer 
pH 7.0 at 1 ml/minute. The dialysed protein sample was loaded directly on to the top 
of the column and pumped on at 1 ml/minute. The unbound protein was washed from 
the column with 2 volumes 50mM potassium phosphate buffer pH 7.0. The TS 
protein was eluted from the column using a salt gradient (50mM potassium 
phosphate buffer pH 7.0 to 50mM potassium phosphate buffer pH 7.0 plus 400mM 
KC1). The gradient was applied using a mixing chamber (20ml of each buffer in a 
separate chamber) at ]/2 per minute, and fractions collected every 2 minutes.
The Bradford assay was used to visualise which fractions contained the TS protein. 
These fractions were tested for activity (tritium release assay) and stored at -70°C 
until needed.
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11. Kinetic characterisation of mutants
11.1 Kinetic parameter determination
Steady-state kinetic constants were determined using the spectrophotometric assay as 
described (Pogolotti et al 1986). Reactions of 200p,l volume were set up in 
microplate wells at room temperature and the change in absorption at 340nm was 
monitored on an Anthos Labtec HTII microplate reader. When the concentration of 
dUMP was varied, (CH2H4-folate was constant at 550jaM; when CH2H 4-folate was 
varied, the dUMP concentration was 225pM.
12. Computing and molecular modelling
Computer analysis of DNA and protein sequences were perform ed on the 
M icroVax II computer in this institute using the software package from the 
University of Wisconsin Genetics Computer Group (GCG Inc., Madison, Wis.). The 
models of the VZV TS native enzyme and ternary complex were visualised and 
manipulated using INSIGHT® II (Biosym technologies) run on a Silicon Graphics 
Indigo Workstation and a Iris Workstation.
81
RESULTS AND DISCUSSION
The research presented in this thesis concerns two areas of structural flexibility in the 
thymidylate synthase of varicella zoster virus, namely the DRTG loop and the C- 
terminus. The results and discussion are divided into individual sections which detail 
the experiments for both the DRTG loop and C-terminus and discuss the outcome.
1. The DRTG surface loop of VZV TS
The conservation paradox that exists for members of the TS family (in that there are 
many residues fully conserved which can be substituted without loss of catalytic 
activity) remains unresolved. Previous work has centred on replacing these 
conserved residues one by one and observing the affect they have on catalysis, 
providing evidence for the role many residues have in the structure and function of 
TS.
Two observations prior to the start of this work showed that thymidylate synthase 
structurally was a highly flexible enzyme (Finer-Moore et al 1990) and that the L. 
lactis enyzme was the most widely diverged TS sequence known (Ross et al 1990). 
Why this enzyme is divergent is not known, one possibility is that the divergent 
residues of the L. lactis enzyme may cluster within particular structural regions of the 
protein. Clustering may provide insight into mutational hot-spots within a protein 
where the structure can tolerate some change without affecting function. Initial 
thoughts were that these may cluster on the surface of the protein and in particular 
within a region that is involved in dihydrofolate reductase (DHFR) binding, as some 
other species such as the protozoa, produce a bifunctional TS-DHFR enzyme. All the 
divergent (differing from those in VZV) amino acid residues of L. lactis were 
substituted into the VZV model. Detailed examination of this structure did not show 
any reasonable clustering with most of the changes seeming to be distributed 
throughout the enzyme. The L. lactis enzyme can be considered to be the result of an 
elegant yet ‘natural’ mutagenesis experiment that has shown that a large number of 
conserved amino acids can be substituted en masse without inactivating the enzyme.
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The absence of obvious ‘hot-spots’ leaves the possibility of covariance where 
multiple sequence changes combine to minimize distortion and side-chain packing 
clashes on the overall structure. Using sequence data a highly conserved surface loop 
was identified on the VZV enzyme. This loop consists of five residues (Glu 37, 
Arg38, Thr39, Gly40, Ile41) and is located between alpha helix A and beta strand i 
(Figure 19, appendix I, and figurella, l ib  of introduction). Figure 11a and l ib  are 
also contained loose in the back of this thesis for easy reference. This surface loop 
(named the DRTG loop, because it starts with a fully conserved glutamate (D) 
residue) is highly mobile moving approximately 4A upon binding of ligands. With 
the exception of TS from phage <1>3T and L. lactis the DRTG loop is fully conserved 
across all published TS sequences. The initial aim of this work was two fold, firstly 
to examine the basis for the effect whereby a conformational mobile region might 
affect catalysis and secondly, if this region does affect catalysis can we discover 
covariant residues which minimise this effect. Our approach was to “lacticise” the 
VZV protein by replacing residues in the DRTG loop with those from L. lactis.
Beta
29 helix A | 38 | strand i
VZV I R Y G V R K R ..........................................D R T G I G T L S
L.lactis L D N G V F S E N A R P K Y K D G Q M A N S K Y
Figure 19. Partial sequence alignment of VZV and L. lactis TS 
The DRTG loop is shown in bold and the variant L. lactis residues in red.
1.1 DRTG loop mutant construction
To examine the effect upon catalysis of mutating the DRTG loop of VZV 
thymidylate synthase the corresponding L. lactis residues were substituted into the 
VZV protein.
Plasmid pAD768 (Harrison, 1992; see materials section 3) a pBS" backbone vector 
containing VZV TS was used to construct all the VZV mutants during this study. 
This vector confers ampicillin resistance and contains the bacteriophage fl origin of 
replication to allow ssDNA selection . TS is expressed from a tac promoter.
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Site-directed mutagenesis was used (using the appropriate primers 1-5, see section 
5.3 of the methods section) to construct the mutants R38G, T39Q, G40M, 141A 
(where the first letter represents the wild-type amino acid, followed by its position 
and the final letter the substituted amino acid). In addition to the four mutants 
outlined above, an insertion mutation was made fortuitously using an incorrectly 
designed oligo. This mutant, 41A42, corresponded to the insertion of alanine 
between residues 41 and 42.
The strand selection procedure of Kiinkel (Kiinkel, 1985; Kiinkel et al, 1987) for 
mutant enrichment was used for both site-directed and random mutagenesis. The 
method uses a ssDNA template that contains a number of uracil residues instead of 
thymine. This uracil-enriched ssDNA (U-ssDNA) is produced in an E.coli dut" ung" 
strain. These strains lack the enzymes dUTPase and uracil N-glycosylase. Lack of 
dUTPase activity leads to raised levels of dUTP and results in increased 
incorporation of uracil into DNA instead of thymine. The lack of uracil 
N-glycosylase, which normally removes uracil from DNA, means that the uracil is 
stably incorporated. The resultant U-ssDNA molecule can be used as a template for 
in vitro mutagenesis reactions as the coding potential of uracil is the same as that of 
thymine. The completely double stranded molecule, the product of the in vitro 
mutagenesis reaction, has a parental strand that contains both uracil and thymine 
residues, whilst the newly synthesised mutant strand contains only thymine residues. 
When wild-type E.coli strains (i.e. dut+ ung+) are transformed with this double­
stranded mutant DNA, there is a strong in vivo biological selection against the 
replication of the parental template strand that results in the production of 
predominately mutant dsDNA molecules. The high efficiency of mutant production 
(typically >70%) allows the screening of site-directed mutants by DNA sequencing 
or the generation of highly mutated DNA libraries by random mutagenesis.
The strand selection efficiency was confirmed in that ssDNA (normal thymine 
containing DNA) was capable of transforming both E.coli BW313 (dut" Ung") and 
NM522 (dut+ ung+), whereas U-ssDNA could transform E.coli BW313, but not 
NM522.
Our experimental system involved expressing the VZV TS gene via the tac promoter 
in Thy" E.coli strains. The wild-type VZV enzyme is active and can complement the 
Thy" phenotype allowing growth in the absence of exogenous thymidine or thymine.
A qualitative assay for TS activity in vivo involves complementation of growth of 
Thy" E.coli in the absence of thymine. Although this method provides a rapid genetic
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method for the assessment of whether or not TS is active, it is sensitive to the level 
and activity of the expressed enzyme and is not quantitative. The minimum level of 
TS that can be detected corresponds to about 1% of wild-type activity 
(approximately 0.002 U/mg in soluble extracts).
Because of its high degree of conservation we anticipated that the DRTG loop 
mutants would be inactive. Colonies that were phenotypically Thy" in E.coli strain 
NM522 Thy" were picked and grown overnight. DNA was isolated from each culture 
by either a mini-prep or STET lysis preparation and restriction digested with EcoRI. 
Colonies that yielded a restriction profile the same as that of wild-type (pAD768) 
DNA (Figure 20) were glycerol stocked and sequenced.
1 2 3 4  +  6 7 8 9  10
F i g u r e  2 0 .  Restriction analysis of Thy" clones after mutagenesis
D N A  digested with 10U EcoRI for 3 hours. Lanes 1, 3, 8 , 9  and 10 show positive restriction profiles
comparable to that o f the control (+). Lanes 2, 4 , 6 , and 7 show  a negative restriction profile.
Mutations were initially identified by sequencing across the loop region using primer 
62 (Figure 21). That no further changes were introduced during the mutagenesis step 
was confirmed by sequencing the complete TS gene with primers 59-62 (see 
methods section 5.4).
Phenotype was assigned on the basis of growth on minimal media (M9) in the 
absence of thymidine, where strong growth is Thy+, no growth Thy" and weak 
growth Thy+/'. E.coli strain NM522 T h y  contains a point mutation in TS, whereas 
X2913 has its TS deleted. Mutants are selected initially in NM522 Thy" because 
X2913 transform poorly. However, to exclude the possibility that the host strain TS 
may have reverted (by correction of its point mutation), enzyme characterisation is 
performed in the strain X2913.
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R38G
F i g u r e  2 1 .  Sequence analysis of clones showing mutant R38G and 141A 
The nucleotide change for each mutant is shown underlined and in bold.
Upon transforming the mutants into X2913 (to enable enzymatic characterisation-see 
below) some of the mutants (except G40M and 41A42) became Thy+ (Table 4). This 
phenotype change is thought to be due to the differences in the level of expression of 
lac repressor in these two different strains. The lacIQ strain (NM522) producing 
approximately 10 times more repressor than the lacl+ strain (X2913).
86
Results and Discussion
Mutant
Phenotype
NM522 
(lacIQ )
X2913
(lacl+)
R38G Thy- Thy+
T39Q T h y Thy+
G40M T h y T h y
141A T h y Thy+
41A42 T h y T h y
T a b l e  4 .  Phenotype of VZV DRTG loop mutants in two different strains of E. coli 
cells. All variants were derivatives o f pA D 768 expressed  in E. coli.
1.2 Enzymatic properties of the DRTG mutants
Transformation of the DRTG loop mutants into E. coli strain X2913 (a strain deleted 
for E. coli TS) has enabled characterisation of the enzymatic properties of each 
mutant from a crude extract (see methods section 8.1) in the absence of any E. coli 
TS protein.
Two convenient assay systems for thymidylate synthase are available which monitor 
different parts of the catalytic mechanism. The partial reaction involves the binding 
of substrate dUMP in the a b s e n c e  of cofactor and can be monitored by following the 
debromination of 5-Br-dUMP. The debromination assay was used to monitor the 
ability of each DRTG loop mutant to participate in the partial reaction (and hence 
bind the substrate dUMP and activate the C-5 position for subsequent substitution). 
Figure 22 shows a typical debromination result. However, the reaction is slow 
compared to dTMP formation and the assay suffers from low sensitivity.
Two independent extracts were assayed at lleast in triplicate and the results for the 
DRTG surface loop mutants are summarised in table 5.
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F i g u r e  22. A typical debromination assay
W ild-type TS (A ), and 2 different extracts o f  R38G (B and C ) are shown. Chart recorder speed was 
120 seconds/cm , recorder range 1. Reaction rates were obtained by determ ining the change in mOD  
units per minute (by drawing a tangent line through the linear part o f  the trace). Rates were divided by 
the amount o f protein added to the reaction in fig  to give m O D/m in///g. The loss o f  absorbance at 
285nm  is due to the debromination o f  5-BrdUM P.
The complete reaction of thymidylate synthase (i.e. substrate turnover) can be 
monitored by an assay in which 3H is released from [5-3H] dUMP into solvent upon 
the formation of dTMP. The tritium release assay is performed in the p r e s e n c e  of 
folate cofactor and is highly sensitive detecting as little as 10~8 U/mg TS activity.
The results of the two assays on the mutant proteins have provided new data about 
the role of the DRTG loop in the catalytic mechanism of thymidylate synthase (Table 
5). The mutant protein R38G has an approximate 10-fold decrease over wild-type 
activity for the complete reaction (tritium release assay), T39Q has a 100-fold 
reduction and 141A an approximately 6-fold reduction. The mutants G40M and 
41A42 have a much greater effect on catalysis with an approximately 140-fold and 
125-fold reduction respectively, an almost total inhibition of the complete reaction. 
However when the data for the debromination assay is examined (Table 5) it can be
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seen that with the exception of G40M all the mutants have a less than 3-fold 
reduction in their activity in the partial reaction.
Expressed
enzyme
Tritium release 
assay 
pmol/min/]Hg
% Wild Type Debromination
assay
mOD/min/jig
% Wild Type
pAD768 (WT) 160.7 ±9.8 100.0 0.19 ±0.02 100.0
R38G 21.1 ± 1.1 13.1 0.07 ± 0.02 36.8
T39Q 2.2 ±0.5 1.3 0.10 ±0.02 52.6
G40M 1.1 ±0.5 0.7 0.00 ± 0.0 0.0
141A 24.2 ± 2.0 15.1 0.19 ±0.02 100.0
41A42 1.3 ±0.1 0.8 0.09 ± 0.01 47.4
T a b l e  5  TS assays (tritium release and debromination) from crude extracts of 
wild-type VZV TS and variants with mutations the DRTG loop region.
A ctiv ities are given as m eans ±  standard error o f  the mean. A ll variants w ere derivatives o f  p A D 768  
expressed  in E. co li strain %2913. %2913 not expressing TS exhibits no activity in either assay (R. 
Thom pson, personal com m unication).
The low sensitivity (approximately 5-10% of wild-type levels) of the debromination 
assay is highlighted by the mutant G40M. It is inactive in this assay and thus would 
appear not to be able to bind substrate. In contrast however, it is active (0.7%) in the 
tritium release assay (which is highly sensitive) and thus this mutant must be able to 
bind substrate for the complete reaction to take place.
These data suggests that the ability of the DRTG loop mutants to debrominate 
substrate is not adversely affected and thus they can bind the substrate dUMP albeit 
slightly less than wild-type. In contrast, the tritium release assay reveals that the 
DRTG loop mutants are drastically impaired in their ability to turnover substrate. 
Without the final step of the catalytic reaction occurring these mutant proteins are 
unable to produce the product dTMP with any great efficiency, leading to their Thy' 
phenotype.
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In conclusion, the DRTG loop region of VZV thymidylate synthase may not play a 
role in substrate binding but is important for substrate turnover. These results are 
complementary to those obtained by Carreras et al (1992) who found that the C- 
terminus of L. casei thymidylate synthase is not needed for debromination.
1.3 Kinetics
The above characterisation of the DRTG surface mutants of VZV thymidylate 
synthase were carried out using crude extracts. In order to obtain a detailed kinetic 
characterisation, high levels of purified protein were produced by cloning the VZV 
TS gene into a T7 expression vector for ease of purification.
The open reading frame (of the mutant TS proteins R38G, T39Q, G40M and wild- 
type) was subcloned from the pBS" based vector pAD768 into the pET based vector 
pET8C as detailed in figure 23.
FI C-) originA m p
BamH 1
 EcoR 1
\N c o  IT3
VZV TS
T7colEJ ori
'Hindlll
EcoR 1
Ncol and 
EcoRI
Digestion
VZV TS
IcoRI
-Ncol
T7 V  
T7
Digestion
Ap
EcoRI
ORI
LcoRI
A m p
T7
VZV TS
pETFJ
T 7^,
ORI-
Ncol
i Figure 23. Strategy for construction of the pET8c based expression vectors
I
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The TS gene was ligated into the T7 vector pET8c as described in the materials and 
methods (section 4.3) and transformed into E.coli BL21 (DE3). Clones were 
analysed by restriction digestion. However, transforming pET8c directly into E.coli 
strain BL21 (DE3) proved problematic in that very few colonies were recovered. 
Those that were gave a restriction profile different to that of the parental backbone 
control, indicative of the loss of an EcoRI or Ncol restriction site. To overcome this 
problem the ligated vector was transformed initially into E.coli strain NM522 Thy". 
Clones from this strain were analysed as before and those that were correct re­
transformed into E.coli strain BL21 (DE3). Transferring the cloned vector directly 
into BL21 (DE3) cells was unsuccessful probably due to the restriction status of the 
E.coli strain used to make the original vector. The small amounts of DNA from the 
cloning would not be sufficient to overcome the restriction difference of the two 
strains (NM522 cells, a K strain and BL21 (DE3), a B strain) for direct 
transformation, hence large amounts of DNA were produced by first transforming 
the clone into NM522 cells. This strategy of transforming the vector between two 
strains was successful. Hundreds of colonies were recovered in BL21 (DE3) and the 
majority had the correct restriction profile.
Analysis of clones revealing the correct restriction pattern were test-induced with 
IPTG. Clones that induced produced a protein of approximately 39K (Figure 24).
1 2 3 4 5 6 7 8  +
F i g u r e  2 4 .  Test induction of R38G mutant clones of TS with IPTG
Lanes 1, 3, 5 and 7 are uninduced, lanes 2, 4 , 6 , and 8  are induced. An arrowhead indicates the TS  
band. A positive induction o f  w ild-type TS is shown (+) as a control. Proteins were separated on a 
12% acrylamide SD S gel.
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1 2 3 4 5 M M
Crude 
\]A 5iA
94K
67K
m.
43K
<  <
30K
20K
Figure 25. Purification of R38G TS by hydroxylapatite chromatography 
Lane l=crude extract, 2=colum n flow  through, 3=50m M  K P 0 4 wash, 4=100m M  K P 0 4 wash, 
5=300m M  K P 0 4 wash, M =m olecular w eight markers (from top to bottom show ing, 94K , 67K , 43K , 
30K , 20K ). The final tw o lanes show different amounts o f  the crude extract. The thym idylate synthase 
band is indicated by an arrow head. Note that the load was cycled through the colum n several tim es 
prior to elution.
A 6000ml culture was centrifuged and sonicated prior to purification (see section 10 
of methods). The first step in the purification process was hydroxylapatite 
chromatography. Hydroxylapatite consits of a calcium phosphate powder which can 
bind proteins and was chosen for the first step in the purification process for two 
reasons. Firstly, it does bind TS with some slight selectivity, while not binding the 
majority of proteins contained in the bacterial extract. TS probably binds to 
hydroxylapatite due to its phosphate ‘binding’ pocket, which co-ordinates the 
phosphate of dUMP in the wild-type situation. The second reason is that 
hydroxylapatite is relatively cheap and thus disposable. This is useful as it prevents 
the potential cross contamination of one mutant with another that can occur when 
columns are re-used. Each step of the purification was monitored by protein mini-gel 
analysis of the appropriate collected fractions (Figure 25). Cycling the load several
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times through the column can reduce the amount of TS that elutes in the flow 
through.
After hydroxylapatite chromatography the TS was precipitated with ammonium 
sulphate and then dialysed over night against 1 litre of 50mM potassium phosphate 
buffer. The dialysed sample containing the TS was further purified by S-sepharose 
chromatography (Figure 26). The procedure followed for purification of mutant 
proteins was identical to that for wild-type enzyme. The purity of the mutants and 
wild-type was estimated at between 90-95%. Unsuccessful attempts were made to 
remove the high molecular weight contaminating bands (see Figure 26) by re- 
purifying the TS containing fractions on a second S-sepharose column. Changing the 
rate of the elution gradient was also unsuccessful as was further purification using a 
Mono-S column.
Fraction
A B C 14 16 18 20 22 24 26
Figure 26. Visualisation of the fractions containing purified R38G TS 
A= colum n load, B= flow  through, C= 50m M  K P 0 4 wash. Various fractions collected during the 
50-400m M  KC1 gradient are show n. Purified TS was eluted in fractions 14-21, and a TS band is 
illustrated by an arrow head.
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The mutants R38G and T39Q were analysed to determine further the role of the 
DRTG loop in catalysis. Details of determining the kinetic parameters are given in 
the materials and methods. Enzyme activity as measured by the complementation 
assay indicated these residues were essential for catalysis (Table 4). Further analysis 
on crude extracts (Table 5) confirmed that both these variants were dysfunctional. 
This dysfunction was not in their ability to bind substrate but because they could not 
turnover substrate (and thus complete the catalytic reaction). Kinetic data indeed 
confirms this conclusion as the Km for wild-type VZV TS is 5pM (Table 6) and 
variants R38G and T39Q have Km values (3 .4 7 p M  and 4 .8 jliM  respectively; table 6) 
comparable to that of wild-type. Interestingly, the debromination assay indicates that 
these mutants are somewhat impaired in their ability to participate in the partial 
reactiom, perhaps reflecting the low sensitivity of this assay.
Expresised enzyme Km for dUMP Km for CH2H4 folate
pM
Wild-type TS 5.0 ± 0.31 25.77 ± 2.20
R38G TS 3.4 ± 0.94 300.48 ±85.91
T39Q TS 4.8 ± 1.53 138.32 ±26.31
T a b l e  6 . Kra values for dUMP and CH2H4 folate of wild-type VZV TS, and 
variants with mutations in the DRTG loop region corresponding t the L. lactis TS 
A ctivities are expressed as mean ±  standard error o f  the mean
The more sensitive 3H release data is substantiated by the Km values for the folate 
cofactor. Wild-type VZV TS has a Km of 25.77pM whereas R38G has a Km of 
300.48|pM; a dramatic increase of 11-fold of that of wild-type enzyme. A less 
dramatic, but still significant, 5-fold increase in Km for the mutant T39Q (138.32;iM) 
is observed. These significant increases in the Km values for folate must play apart 
in the diminished activity of these variants.
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Kimetic data was not obtainable for the mutant G40M, because it was too inactive to 
bie detected in the spectrophotometric assay.
T h e  Km for dUMP for both mutant proteins was comparable or slightly lower than 
that; of wild-type suggesting a more open structure allowing better binding of dUMP. 
A  similar situation of reduced Km for dUMP and increased folate K m was observed 
fo r the C-terminal truncation mutant L301A, which is believed to be defective in 
effective closure of the active site (Harrison et al 1995).
1 ..4 Molecular modelling of the DRTG loop mutants
Tlhe models of the VZV TS native enzyme and ternary complex were visualised and 
rmanipulated using INSIGHT® II (Biosym technologies) run on a Silicon Graphics 
Imdiigo Workstation and an Iris Workstation. Mutations were introduced into the 
V 'ZV model using the programme SwissModeler before manipulation with 
INSIGHT® II. Output files were captured using Snapshot and converted from RGB 
to) TIFF files using XV. The TIFF images were then imported into Photoshop for fine 
turning.
Im the wild-type situation the DRTG loop appears to be somewhat unstructured, 
hcowever, it moves up towards the C-terminus upon binding of ligands. Modelling of 
thie VZV ternary complex in this region shows a very tight packing of residue side 
clhains (Figure 27).
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F i g u r e  27 The DRTG loop and C-terminus of VZV thymidylate synthase ternary 
complex
van der W aals radii are show n for the residues A rg-38, Thr-39, G ly-40, Ile-41 (DRTG loop; green) 
and for A la-300 and Leu-301 (C-terminus; blue). A lso shown is the active site cysteine (yellow ), 
leucine 247 and asparagine 248. The bottom o f  the P-sheets are shown in red, and connecting loops in 
white
That substitution of any one of the loop residues results in dramatic loss of substrate 
turnover is indicative of a functional role for this loop in the VZV enzyme, perhaps 
explaining why they have been almost fully conserved throughout the TS family. 
Throughout this section the amino acid side chains are shown for comparison of size 
and charge on the left of the page.
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NH2
1 +
c = n h 21
NH
CFb
1
c h 2|
c h 2
1
H
1
Arg Gly
R 3 8 G
In the wild-type ternary complex the 
arginine-38 side chain makes a 
hydrogen bond to the carboxylate 
group of the C-terminal leucine 
(L301). This hydrogen bond helps 
stabilise both the packing of the loop 
the C-terminus after they have moved 
towards the active site upon ligand 
binding. Arginine-38 is also one of 
four highly conserved arginines, two from each monomer, which provide a 
favourable, positively charged binding surface for the phosphate anion of dUMP. 
These four arginines as well as Serine-208 are involved in an extensive hydrogen 
bonding network around the phosphate. Each arginine forms at least one hydrogen
F i g u r e  2 8  R38G
The wild-type structure is shown on top and the mutant below . Residues 38-41 are shown in green 
and residues 300-301 in blue with their van der Waals radii, several other am ino acid are also shown.
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bond to the phosphate oxygens. Substitution of the charged arginine residue for 
glycine, an uncharged and the smallest amino acid in the mutant R38G results in lo>ss 
of this H-bond to the carboxylate group of leucine-301 (Figure 28). Without such a 
H-bond the loop does not pack tightly against the C-terminus. C-terminal packing is 
needled for tight folate binding/retention. With the exception of the mutant G40M 
this mutant is the least active in its ability to debrominate halogenated dUMP being 
approximately 65% less active than wild-type (Table 5). This suggests that this 
mutant is impaired in its ability to bind the substrate dUMP. Replacing arginine-38 
with glycine removes one of the hydrogen bonds in the network that is involved in 
stabilising substrate binding. However loss of this one hydrogen bond from a 
netw/ork of H-bonds does not appear to affect dUMP binding because its Km for 
substtrate is very similar to that of wild-type. Thus the main driving force for loss o f 
activity for this mutant must be the loss of the H-bond to the carboxylate group o f 
leuciine-301.
T39Q
Manipulation of the ternary model to examine the mutant T39Q (Figure 29) reveals 
that Ithe methyl group of threonine in the wild-type situation packs in a hydrophobic 
pockiet next to alanine 300 and its hydroxyl groups points out to the solvent.
Threonine also makes a H-bond to the 
carboxylate group of leucine-301 (as 
does arginine-38). Replacem ent o f  
threonine by glutamine results in a 
side chain that points out to solvent 
leaving a hole in the hydrophobic 
pocket. This destabilises the packing 
of the loop against the C-terminus. I t 
appears that the glutamine residue
points out to solvent in order to prevent any gross steric clashes with surrounding 
residues, particularly isoleucine-41 and alanine 300. The easiest way for a structure 
to accommodate changes is by orientating its side chains into empty space, however, 
this can best be achieved when the area containing the change (such as the DRTG 
loop) is on the surface of the protein.
c1
H O ^  x C H 3 c h 21
C H
1
c h 2
1
Thr Gin
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7 HR. t9
F i g u r e  2 9  T39Q
The w ild-type structure is shown on top and the mutant below . Residues 38-41 are show n in green  
and residues 300-301 in blue with their van der W aals radii, several other amino acid are also shown.
Each amino acid is associated with two conformational angles phi (O) and psi C1!*) 
within a peptide unit, where <I> is the angle of rotation around the N-Ca bond and V 
is the angle around the C a -C' bond from the same Ca -atom. Most combinations of O 
and V angles for an amino acid are not allowed because of steric collision between 
the side chains and the main chain. Glycine with only a hydrogen atom as a side
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chain can adopt a much wider range of conformations than the other residues.
Glycine thus plays a structurally very important role; it allows unusual main chain
conformations in proteins and is one of the main reasons why a high proportion of 
glycine residues are conserved among homologous protein sequences.
G 4 0 M
The most dramatic reduction in 
enzyme activity is for the mutant 
G40M both substrate binding and 
turnover being almost totally 
diminished (Table 5). Its activity is so 
low, that its K m was not determinable. 
Obviously this glycine residue is 
functionally or structurally important. 
Modelling of this glycine (Figure 30) 
indicates that it is crucial structurally in that it facilitates a tight turn in the loop and
CH
CH
CH
Gly Met
.rHa-i'3
V JAOT. jlfi
F i g u r e  3 0  G40M
The w ild-type structure is shown on top and the mutant below . Residues 38-41 are shown in green 
and residues 300-301 in blue with their van der W aals radii, several other am ino acid are also shown.
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keeps it in the required conformation. Mutating this residue to the L. lactis residue 
methionine, which is larger and hydrophobic, places large restrictions on the 
conformation it can adopt in this loop. It therefore kinks the loop destabilising it and 
in turn preventing correct positioning of the C-terminus.
I41A
The hydrophobic amino acid isoleucine at position 41 packs tightly against residue 
300 (alanine). It also packs neatly into a cleft created by the hydrophobic side-chains 
of tyrosine-246 and leucine-247 to form part of a flat hydrophobic surface (Figure 
31). This surface is at right angles to the orientation of the backbone carbonyl group 
of threonine-39 and methionine-299, and the carboxyl group of the C-terminal 
residue. Substitution for the much smaller, but still hydrophobic alanine in the 
mutant 141A (Figure 31) leaves a hole in this hydrophobic cleft. This gap may lead
to incorrect formation of this region of 
the protein which could disrupt the 
orientation of the surrounding  
residues. Comparison with other TS 
sequences at this position shows that 
only threonine and valine are found at 
this position (except for phage 0 3 T 
and, L. lactis both of which have an 
alanine at this position, see figure 19 
and appendix I). Both threonine and valine, like isoleucine, have a branched (3- 
carbon, one arm of which contains a lone methyl group. Both these two amino acids 
can be modelled in this position filling the cleft between tyrosine-247 and leucine- 
248, without disrupting the planar hydrophobic surface. This confirms the need for 
the presence of a methyl group in the cleft and although alanine contains a methyl 
group it is not on a branched (3-carbon and cannot reach to fit into the cleft. The 
absence of a methyl group in this cleft is probably the major factor that contributes to 
reduced enzyme activity.
c h 3
H2C\  / CH3
CH
1
c h 3
lie Ala
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F i g u r e  3 1  1 4 1 A
The w ild-type structure is shown on top and the mutant below . Residues 38-41 are show n in green 
and residues 300-301 in blue with their van der W aals radii, several other am ino acid are also shown.
Insertions within a protein can have many effects depending on the position, the size 
(one or more residues) and the properties of the amino acid (size, charge, 
hydrophobicity) inserted. The thymidylate synthase of VZV has tolerated insertions 
(or perhaps deletions) during evolution. Sequence alignments shows an insertion of 
17 amino acids at the amino terminus which is not found in the E. coli structure and 
a further two short insertions at positions 105-116 and 134-141 both of which are 
between helical regions and thus presumably loops. These extra elements are not 
modelled in the VZV structure. So extra amino acids appear to be tolerated by VZV
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TS, perhaps by being in non critical structural regions or on the surface of the 
protein.
If the DRTG loop was not functional (or structural) then insertions within it would 
most likely be tolerated as this loop would probably serve as a connection between 
a-helix A and p-strand i.
41A42
The insertion m utant 41A42 (an 
alanine between isoleucine-41 and 
glycine-42) allows us to further 
examine the role of the DRTG loop. 
The ability of this mutant to bind 
substra te , as assayed  by the 
debromination assay, indicates that
this insertion reduces by approximately 50% the ability of the mutant protein to bind 
substrate. Although, substrate dUMP is still bound albeit diminished, the ability of 
the mutant protein to turn this substrate over is almost knocked out (0 .8% of wild- 
type; Table 5). Modelling of this mutant was not possible using the programmes 
available to us. However, an insertion (even such a small one) into what appears to 
be a critical functional part of the structure would cause some gross steric clashes. 
Perhaps this results in preventing maximal packing of the loop against the C- 
terminus and also prevents the formation of the hydrogen bond between Arginine-38 
and the carboxylate group of the C-terminal leucine by moving the arginine out of 
range of efficient hydrogen bond formation.
1.5 Second-site revertants of the DRTG loop mutants
As thymidylate synthase is so highly conserved it was considered that in order for 
the L. lactis enzyme to accommodate highly variant residues in the DRTG loop there 
may be other ‘co-variant’ residues within the TS structure. These ‘co-variant’ 
residues may allow accommodation of the vastly differing residues within the overall 
structure. In order to attempt to identify co-variant positions we screened for second- 
site revertants that would restore activity to the DRTG loop mutants.
Most methods of random mutagenesis can be susceptible to mutagenic ‘hot spots’, 
that is the clustering of mutations in certain regions of the gene, whilst other regions 
may be left unmutated (McPherson 1991). The method of ‘spiked oligonucleotide’
c h 3
H 2C\  / C H 3
CH
1
c h 3 H
1
lie Ala Gly
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mutagenesis avoids such hot spots and is probably the most truly random 
mutagenesis protocol available (Blacklow and Knowles 1991).
Isolation of second-site revertants of the DRTG loop mutants which would restore 
high levels of enzyme activity was attempted using ‘spiked oligonucleotides’. These 
‘spiked oligonucleotides’ are long (-55  bases) oligos synthesised using 
phosphoramidite mixes containing 96% of the normal oligonucleotide and 1.3% of 
the other three mixes (Ner et al 1988, McNeil and Smith 1985). These should 
contain an average of two base changes per oligonucleotide. These changes are 
essentially random but since they are restricted to the region covered by the spiked 
oligonucleotide we refer to the process as “region directed mutagenesis”.
U-ssDNA was prepared for each DRTG loop mutant (as previously described). Each 
mutant uracil-enriched template was checked for efficient strand selection and 
templates that failed to give colonies in strain NM522 thy" but did for BW313 dut" 
ung" were used to attempt to generate second-site revertants via region directed 
mutagenesis. A total of 22 spiked oligonucleotides were synthesised that were 
approximately 50 bases in length and covered the whole VZV TS gene (Figure 32).
Oligo Size Region Of TS 
Gene (bp)*
Amino Acid 
Sequence*
Secondary Structures
R01 57mer 108-165 37-55 DRTG loop, p-Strand i
R05 48mer 465-513 156-171 Helix H 156-159, Loop 
160-164, p-Strand v
R 07 45mer 534-579 180-194 Helix I 179-180, loop 
181-182, p-Strand iv, 
Loop 192-194
R 08 48mer 572-620 192-207 Loop 192-196, p- 
Strand iii, Helix J 208
R010 54mer 654-708 219-237 Helix-J 219-230, Loop 
231-234, p-Strand ii 
235-237
Table 7 Spiked oligonucleotides used in the covariant studies 
* see figure 32
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K V P G F T L T G E L Q Y L K Q V D D I
AAGGTGC C GGGTTTT AC GTT AAC C GGC GAAC TTC AGT AC TT AAAAC AAGTGG ATGAT ATT 
TTCCACGGCCCAAAATGCAATTGGCCGCTTGAAGTCATGAATTTTGTTCACCTACTATAA 
, , , ,  R012 (57m er)  ...........   • • • | | | | | | , ,  , , , ,  R013 (57m er) ,
2 9 L R Y G V R K G T L S L F G
TTAAGGTATGGAGTTCGGAAACGCGATCGAACAGGAATCGGAACGTTATCTTTATTTGGA 
AATTC CAT AC C TC AAGC CTTTGC GC T AGC TTGTC C TT AGC C TTGC AAT AGAAAT AAAC C T 
, , , , , , , , , , , , , , , , , , , , , , , , 1 1 1 1 1 1 ........................... R01 (57mer)
I-SHEET i   A |
4 9 M Q A R Y N L R N E F P L L T T K  
1121 ATGCAAGCTCGATACAATTTGCGAAATGAATTTCCTCTTTTAACTACAAAGCGTGTTTTT 
1121 TACGTTCGAGCTATGTTAAACGCTTTACTTAAAGGAGAAAATTGATGTTTCGCACAAAAA 
.I I I I I I , , , , , R 0 2  ( 54m er) , , , , , , , , , , , ,
6 9
-  HELIX B E E L E
1181 TGG AGGGC C GTC GTGGAAGAGTTGTT ATGGTTTATC C GC GGGTC AAC C GATTC CAAAGAA 
1181 ACCTCCCGGCAGCACCTTCTCAACAATACCAAATAGGCGCCCAGTTGGCTAAGGTTTCTT
, , , 1 1 1 1 1 1 ................  R03 ( 42m er)  I I II I I I I I , , , , , , , , , , , , , , ,
« « « « « « « <  ( 62)
I-- HELIX D -----
C TC GC C GC TAAAGATATACACATATGGGATATATAC GGATC GAGCAAATTTC TAAATAGG 
GAGC GGC GATTTC T AT ATGTGT AT AC C C T AT AT ATGC C T AGC TC GTTT AAAGATTT ATC C 
R04 (57m er) , , , , , , , , ,  | | | | | I | | | | | | ........................... R014 (57m er) •
  HELIX G ------
109
1301
1301
129
1361
1361
149
1421
1421
169
1481
1481
189
1541
1541
209
1601
1601
229
1661
1661
249
1721
1721
H K R H T G D L G
AATGGCTTCCATAAAAGACACACGGGGGACCTTGGCCCCATTTACGGCTTCCAGTGGAGA 
TTACCGAAGGTATTTTCTGTGTGCCCCCTGGAACCGGGGTAAATGCCGAAGGTCACCTCT 
  ..............' I l l , , , , , , , , , , , , , ,  R°15 ( 57m er) , , , , , , , , , , , , , ,
I—
QC Q S N Y L Q Q G
CATTTTGGAGCGGAATATAAAGACTGTCAATCAAACTATTTACAGCAAGGAATCGATCAG 
GT AAAAC CTCGC C TTATATTTCTGACAGTTAGTTTGATAAATGTCGTTCCTTAGCTAGTC 
, , , , , , , , , , , ,  . . . . . . . . . . . .  R016 (54mer) '
L Q T V
HELIX H -  
D T
SHEET
K T N E M
CTGCAAACTGTTATAGATACAATTAAAACAAACC CAGAAAGC CGACGAATGATTATATCG 
GACGTTTGACAATATCTATGTTAATTTTGTTTGGGTCTTTCGGCTGCTTACTAATATAGC
................................................. I I I I I I , , , , , , ,  R05 ( 4 8mer) , , , , , , , 1 1 1 1 1 1« « « « « « < «  (61)
A A A A A | | --------------HELIX I --------------| | A A A A A A SHEET iv  A
S W N P K D I  P L M V L P P  *C* H T L C Q 
TCTTGGAATCCAAAGGATATCCCCTTAATGGTACTACCTCCATGTCACACGTTATGTCAG 
AGAAC CTTAGGTTTC CTATAGGGGAATTACC ATGATGGAGGTACAGTGTGCAATACAGTC
I I I I I I I I I • ' * * R06 ( 48m er) • • • • | | | | | | | | | | | | , , , , , R07( 45mer)
SHEET i i i
Y V A N G E S C Q V Y Q R S G D 4 G
TTTTACGTTGCAAACGGTGAATTATCCTGCCAAGTATACCAGAGATCGGGGGATATGGGC 
AAAATGC AAC GTTTGC C ACTT AATAGGAC GGTTC ATATGGTCTC T AGCCC C C TATAC CCG
I I  I  I  I  I .................  K08 (48m«r)  I  I  I  I  I  I  I  I  , , ,
CTTGGGGTACCGTTCAACATTGCTGGATATGCACTTCTTACCTACATAGTAGCGCATGTT 
GAAC C C CATGGCAAGTTGTAAC GAC CTATAC GTGAAGAATGGATGTATCATC GC GTACAA 
, , , , , , ,  R09 ( 54m er) , , , , , , , , , ,  I I I I I I I II I I I .............................. RO10
G L
I*
G D H
SHEET i i  A 
M G D A Y L N
ACAGGACTTAAAACCGGAGATTTAATTCATACAATGGGGGATGCACATATTTACTTGAAT 
TGTCCTGAATTTTGGCCTCTAAATTAAGTATGTTACCCCCTACGTGTATAAATGAACTTA
( 54mer) ............ | j  | | | | | | | , , , , , , , , , , , , , ,  ROll (54m er) , , , , , , , ,« « « « « « « <  (60)
|  HELIX K  1
H I D A L K V Q L A R S  P K P F P C L K  
C ATAT AGATGC TTT AAAAGTGC AGC T AGC TC GATC C C C AAAAC C TTTTC C TTGC C TT AAA 
GTATATCTACGAAATTTTCACGTCGATCGAGCTAGGGGTTTTGGAAAAGGAACGGAATTT 
I I I I I I ...............................  R017 (54roer) .........................................I | I I I I
269 I I R N V T D I N D F K W D D F Q L D G  
1781 ATTATTCGAAATGTAACAGATATAAACGACTTTAAATGGGACGATTTTCAGCTTGATGGA 
1781 TAATAAGCTTTACATTGTCTATATTTGCTGAAATTTACCCTGCTAAAAGTCGAACTACCT 
, , , , , , , , , , , ,  R018 (57 mer) , , , , , , , , , , , , , , , , , ,  I I | I | |
289 Y N P H P P L K M E M A L  
1841 T AT AATC C AC AC C C C C C C C TAAAAATGGAAATGGC TC TTT AATGGATTTTT AAATGTTGT 
1841 ATATTAGGTGTGGGGGGGGATTTTTACCTTTACCGAGAAATTACCTAAAAATTTACAACA
   ’ ’ R019 ( 57m er) ........................................ ..
, , , , , , , , ,  R020 (51m er) , , , , , , , , , , , , ,
1901 CAAGACAGTAGATGTGTTGCGAATGTAATAAAATGATATACACAGACGCGTTTGGTTGGT 
1901 GTTCTGTCATCTACACAACGCTTACATTATTTTACTATATGTGTCTGCGC AAACCAACCA
« « « « « « « <  ( 5 9 )
108
1300
1300
128
1360
1360
148
1420
1420
168
1480
1480
188
1540
1540
208
1600
1600
228
1660
1660
248
1720
1720
268
1780
1780
288
1840
1840
301
1900
1900
F i g u r e  32 Spiked oligonucleotides covering the VZV TS gene 
O ligonucleotides used for second-site revertant m utagenesis are indicated in red.
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Region directed mutagenesis on the DRTG loop mutants (R38G, T39Q, G40M and 
141 A) was performed using the spiked oligonucleotides R01, R05, R07, R08, R010 
(Table 7). These spiked oligonucleotides were chosen because they targeted surface 
areas of the structure which we thought could accommodate changes more easily 
than other more buried regions of TS.
Our selection criteria for a second-site revertant was the restoration of activity to the 
DRTG loop mutant protein. The initial mutant proteins were Thy in the in vivo 
complementation assay, thus potential second-site revertants were isolated initially 
on their ability to complement E.coli strain NM522 Thy when grown on minimal 
media without thymidine. Colonies that were now phenotypically Thy+ were selected 
and analysed by restriction digestion with EcoRI. Those giving the correct restriction 
pattern were sequenced initialy across the region that was targeted by the spiked 
oligonucleotide.
A total of 6000 colonies from the random mutagenesis were isolated on non- 
selective medium and then screened for their ability to grow on minimal media in the 
absence of thymine by patching. Only 800 of these colonies were phenotypically 
Thy+. To increase the number of Thy+ colonies obtained a different transformation 
method was tested (calcium chloride shock instead of PEG-DMSO), however the 
number of colonies that were Thy+ did not increase. Mutagenised DNA was 
transformed directly into E. coli strain %2913 to test if NM522 Thy' had reverted to a 
Thy+ strain (it only has a point mutation inactivating its TS gene) giving rise to false 
Thy+ colonies. This did not appear to be the case and the poor transformation 
efficiency of %2913 cells made its use of limited value for a first round screening 
system. Further analysis of the colonies obtained by comparison of their restriction 
profile reduced the numbers still further to 110 perhaps indicative of problematic 
filling-in reactions after primer annealing. Sequencing of these across the appropriate 
targeted region revealed that no amino acid substitutions had occurred. Interestingly, 
mutagenesis with random oligo 1 (which covers the original DRTG loop) did not 
generate any wild-type revertants. Why a previously Thy clone could acquire the 
ability to grow in the absence of exogenous thymidine after mutagenesis (indicating 
restoration of an active TS) may have been due to some sort of mis-priming event 
where the oligo has changed the promoter or copy number of the plasmid backbone. 
These changes could then have resulted in an overproduction of the weakly active 
protein which although has no second site changes can now overcome the deficiency 
of thymidine in the media.
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Failure to find covariant residues which would compensate for the L. lactis residues 
introduced into the DRTG loop may be due to several reasons. The most compelling 
reason is that residue(s) in more than one region of the enzyme may need to be 
substituted to allow accommodation of a loop mutant. Mutagenesis was performed 
using a region directed oligonucleotide targeted to a specific region of VZV TS 
(Table 7) and although these targeted regions are reasonably large (most oligos being 
50mers or bigger) they may not encompass enough of the TS gene. Perhaps the 
covariant residues needed were in two or more distinct parts of the enzyme which 
single oligos could never cover. We did not attempt to use a cocktail of no­
overlapping spiked oligonucleotides, although this approach would seem to have 
merit.
1.6 Summary
These studies have identified a highly conserved surface loop (the DRTG loop) of 
VZV thymidylate synthase and shown that the loop does have some functional role 
in catalysis. This may be mediated by close contact with the C-terminus and other 
surrounding residues perhaps helping to stabilise the C-terminus after its concerted 
movement (along with the DRTG loop) towards the active site upon ligand binding. 
This stable tightly packed region of the enzyme presumably excludes bulk solvent 
from the active site and also helps in overall stabilising of ligand binding. This is the 
first indication that DRTG loop is an important functional element that may be 
critical for active site closure. Interference with loop movement may provide a target 
for novel TS inhibitors.
The combined power of modelling, phylogentic comparisons and mutagenesis 
provide arguments as to why some residues are highly conserved and suggestions as 
to why substitutions lead to inactivation of thymidylate synthase. Many of the 
mutants are inferred to lead to' inactivation (or diminished activity) due to steric 
clashes or the creation of gaps in core regions of the protein. Such clashes must be 
overcome in order to form a stable protein structure. Inability to eliminate steric 
clashes leads to an unstable enzyme or one that attempts to repack and accommodate 
the changes but by so doing re-orientates residues that play a critical part in catalysis.
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2. The C-terminus of VZV TS
The C-terminal region of thymidylate synthase closes upon ligand binding 
effectively forming a lid over the active site which, in concert with other movements 
(the DRTG loop included), results in the adoption of a tight closed conformation of 
the enzyme (Stroud and Finer-Moore 1993). Many of the key interactions appear to 
be H-bonds between the carboxylate group of the C-terminal residue (rather than 
contributions from its side chain) and several highly conserved residues including 
arginine-21 and tryptophan-83 (E.coli TS numbering). These interactions anchor the 
cofactor in place and stabilize the closed protein conformation.
Previous studies have shown that the TS of L.casei is totally inactivated by the 
removal of the C-terminal residue by carboxypeptidase (Aull et al 1974) and this has 
recently been confirmed by site-directed mutagenesis (Climie et al 1990). It seems 
that the exact position of the carboxylate group is critical. In contrast, findings by 
Harrison (1992) and Harrison et al (1995) has shown that removal of the C-terminal 
residue from VZV TS results in an enzyme that can still complement Thy" E. coli . 
We have extended these studies to examine a variety of C-terminal modifications.
2.1 VZV C-terminus Mutants
The C-terminus of VZV TS was extended by one amino acid to examine the effect of 
moving the position of the carboxylate group upon catalysis. To prevent introducing 
gross structural constraints upon the enzyme the two smallest amino acids, glycine 
and alanine, were chosen.
Site-directed mutagenesis using the appropriate oligonucleotide was employed to 
construct the mutants A302 and G302. Colonies that yielded a restriction profile the 
same as that of wild-type (pAD768) DNA were glycerol stocked and sequenced. 
Mutations were initially identified by sequencing across the C-terminal region using 
primer 59. As before the absence of further changes introduced during the 
mutagenesis step was confirmed by sequencing the complete TS gene with primers 
59-62.
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C-terminal mutants Phenotype
A302 Thy+/'
G302 Thy+
T a b l e  8 C-Terminal mutants of VZV thymidylate synthase and their phenotype
A ll variants w ere derivatives o f  pA D 768 expressed in E. co li N M 522 Thy' cells
Complementation data reveals that both these mutants fail to inactivate VZV TS 
(Table 8), however, extension of the C-terminus with the larger alanine results in an 
enzyme that barely complements NM522 T h y  cells. Analysis of crude extracts 
shows that addition of alanine significantly reduces the overall capacity of the 
enzyme to perform the catalytic reaction. The ability of this mutant protein to 
participate in the partial reaction (and hence bind substrate) is reduced approximately 
70% and substrate turnover reduced approximately 80% when compared to wild- 
type VZV TS (Table 9) and almost certainly accounts for its much reduced Thy+ 
phenotype. Substrate turnover of 20% (of wild-type) for A302 is relatively high 
when compared with the DRTG loop mutant proteins (0.7-15%). Interestingly, the 
addition of glycine has a more profound affect on the enzyme. This mutant enzyme
Expressed
enzyme
Tritium release 
assay 
pmol/min/|ig
% Wild Type Debromination
assay
mOD/min/|ig
% Wild Type
pAD768 (WT) 160.7 ±9.8 100.0 0.19 ±0.02 100.0
A302 30.7 ± 1.2 19.1 0.06 ± 0.01 30.2
G302 74.1 ±2.3 46.0 0.69 ±0.13 363.2
T a b l e  9  Site-directed mutants of the DRTG surface loop of VZV thymidylate 
synthase
A ll variants w ere derivatives o f pA D 768 expressed in E. co li strain 2C2913. A ssays were perform ed on  
crude extracts.
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can participate in the partial reaction with a much greater efficiency than that of 
wild-type enzyme with an approximate 3-fold increase (Table 9) in its debromination 
ability. In stark contrast this mutant cannot turnover substrate at wild-type levels 
being approximately 2-fold reduced in its ability to release tritium from [5-3H] 
dUMP (Table 9).
Purification of these two C-terminal mutant proteins as previously described for the 
DRTG loop variants allowed Km values to be determined for substrate and cofactor. 
These data complement the crude extract studies. The mutant enzyme A302 has a 
Km of 7.03|iM for dUMP (table 10) representing a 1.4-fold increase over that of 
wild-type (5.0pM) indicative of its reduced ability to bind substrate. Its inability to 
complete the catalytic reaction and thus turnover substrate is also reflected in its Km 
for folate (147.47pM) which is an almost 6-fold increase. The addition of an alanine 
to the C-terminus results in an enzyme that has a reduced binding capacity for both 
the substrate and cofactor. Extending the C-terminus with a glycine residue (G302) 
has a similar effect on the Km for folate (table 10) as that of the mutant A302 in that 
it is increased approximately 7-fold (176pM). However, its ability to bind substrate 
is significantly increased, reflected in a much lower Km value (1.86pM) representing 
an approximately 2.5-fold decrease. It appears that addition of a glycine results in an 
enzyme with a greater affinity for the substrate, but a reduced affinity for the 
cofactor.
Expressed enzyme Km for dUMP Km for CH2H4 folate
|iM
Wild-type TS 5.0 ± 0.31 25.77 ± 2.20
A302 TS 7.03 ± 1.51 147.47 ±51.2
G302 TS 1.86 ± 0.88 176.00 ±22.87
T a b l e  1 0  Km values for dUMP and CH2H 4 folate of wild-type VZV TS, and 
variants with mutations in the C-terminal region.
A ctivities are expressed as mean ±  standard error o f  the mean
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2.2 Molecular modelling of the VZV C-terminal Mutants
Both the mutants A302 and G302 were not modelled on the VZV ternary structure. 
As both mutants lie at the end of the protein precise positioning of the side-chains in 
3 dimensions is difficult as there are no residues immediately in close proximity with 
which to constrain its position .
Alanine, although a small uncharged hydrophobic amino acid does affect the 
catalytic reaction of TS. This extra methyl group (and peptide backbone) presumably 
does somehow interfere with the closing down of the active site. As both folate and 
dUMP binding is affected this residue may clash with either the C-terminus and/or 
the DRTG loop. Perhaps it may exert this effect by bringing some order to the C- 
terminus in the unliganded state placing it in such a position as to sterically hinder 
binding of ligands. The solved crystal structure of this mutant will be the way 
forward in assessing what is happening at the structural level.
Glycine is much smaller than alanine, but is also uncharged. Although there is little 
difference between the two residues they have contrasting affects on the 
enzyme. A glycine at this position may interfere with the H-bond between arginine 
38 and leucine 301. This may ‘hold’ the enzyme in a more open conformation thus 
allowing more efficient binding of dUMP. However as the active site cannot readily 
close down folate binding is affected, presumably as it can leave the active site easily 
before catalysis has begun.
2.3 Folate inhibitors and phenolpthalein
Many folate based inhibitors of TS have been developed, the most notable one being 
10-propargyl-5, 8-dideazafolate (CB3717). Although CB3717 has an inhibition 
constant (Ki) of 40nM (Shoichet et al 1993) for TS, it shows liver and kidney
toxicity. This toxicity emphasises the need for more efficacious agents whether 
based on derivatives of the folate cofactor or not. Anti-TS drugs dissimilar to the 
substrate and cofactor remain attractive because they are less likely to have the side 
effects that are produced by the nucleotide and folate mimics.
The structure based approach to drug design couples critical protein and nucleic acid 
structural information with specialised computer programmes to propose novel 
enzyme inhibitors and other therapeutic agents. One such computer programme, 
DOCK (Kuntz 1992), has been developed and used on thymidylate synthase.
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From an X-ray crystallographic structure of the macromolecule, DOCK first 
characterises the surface of a localised site (the active site in the case of thymidylate 
synthase) filling it with sets of overlapping spheres. This serves as the negative 
image of the active site. The second step in the programmes algorithm searches 3D 
databases (such as the fine chemical directory) for putative ligands, matches them to 
the negative image and ranks each candidate on the basis of the best orientations for 
a particular molecular confirmation. Use of DOCK on thymidylate synthase has led 
to the discovery of a novel TS inhibitor, namely, phenolphthalein (PTH). DOCK 
finds ligands that fill the entire active site cavity, rather than analogues of substrate 
or cofactor alone. As such PTH can be considered as a substrate-folate mimic.
Three C-terminal mutants, namely L301A (Harrison et al 1995), A302 and G302 
were assayed for activity by the tritium release assay in the presence or absence of 
phenolphthalein or a series of antifolates (at 30ng/|il). The antifolates (analogues of 
CB3717) were a gift from Imperial Chemical Industries pic and were called ICI-1 to 
ICI-8. Assays were performed in triplicate on two independent extracts.
Inhibitor
Mutant L301A
% Activity
Wild-type Mutant
ICI 1 0.9 ±0.15 7.4 ±2.3
ICI 2 2.8 ± 1.1 4.4 ± 0.4
ICI 3 7.1± 1.8 4.8 ± 1.3
ICI 4 17.4 ±4 .2 6.9 ±1 .6
ICI 5 23.4 ±2.1 3.2 ± 0 .4
ICI 6 3.3± 0.6 1.3 ± 1.0
ICI 7 3.1 ± 1.7 1.5 ± 1.0
ICI 8 23.8 ±2.7 29.3 ± 4.9
PTH (50pM) 61.9 ± 2.1 87.8 ± 3 .6
PTH (100|iM) 47.0 ±5.8 79.6 ±7 .0
T a b l e  1 1  Inhibition of mutant L301A by folate analogues and phenolphthalein
A ctivities are expressed as %  o f the enzym e activity in the absence o f  inhibitor.
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Deletion of the C-terminal leucine from the VZV TS has a marked effect on the 
ability of the enzyme to resist inhibition by phenolphthalein (Table 11 and Figure 
33). At 100//M concentrations of PTH the mutant protein is 59% more active than 
that of the wild-type enzyme. All the folate analogues inhibited both the mutant 
protein (Table 11) and wild-type, however, L301A appears more resistant to ICI 1 
than wild-type (approximately 7-fold more resistant) albeit both are significantly 
inhibited. It is also slightly more resisitant to ICI 2 and 8. Interestingly, L301A is 
markedly more sensitive to folate analogues ICI 4 and 5 compared to wild-type. The 
mutant also shows greater sensitivity for analogues ICI, 3, 6 and 7 (2-fold, 0.5-fold, 
2-fold, and 2-fold respectively).
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Figure 33. Inhibition of L301A by folate analogues and Phenolphthalein
The mutant A302 shows a different response to the folate analogues (Table 12 and 
Figure 34) with no greater resistance (compared to wild-type) to the analogues. 
However, like L301A a greater sensitivity to inhibition is shown for ICI 3, 4 and 5 
indicating a similar mechanism of action on the enzyme.
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Inhibitor
Mutant A302
% Activity
Wild-type Mutant
ICI 1 1.3 ±0.5 0.8 ± 0.6
ICI 2 1.45 ±0.6 0.2 ± 0.2
ICI 3 6.4 ± 0.7 1.7 ±0.8
ICI 4 15.5 ±2.1 2.2 ± 0.25
ICI 5 23.4 ± 2.2 2.9 ± 0.6
ICI 6 3.0 ± 1.0 0.2 ± 0.2
ICI 7 1.9 ±0.8 0.3 ± 0.25
ICI 8 23.5 ± 5.0 8.4 ±2.1
Table 12 Inhibition of mutant A302 by folate analogues 
A ctivities are expressed as % o f the enzym e activity in the absence o f  inhibitor.
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Figure 34. Inhibition of A302 by folate analogues.
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G302 exhibits resistance to phenolphthalein being approximately 2-fold more 
resistant than wild-type at lOOpM (Table 13 and Figure 35). Extension of this study 
revealed that the G302 can be inhibited by phenolphthalein (17% remaining activity 
at 1mm, data not shown) but still represents a resistance to inhibition by 
phenolphthalein. This perhaps is reflected by G302’s higher affinity for the substrate 
dUMP, and thus its preference for this over the inhibitor phenolphthalein. In 
comparison, G302 is more sensitive than wild-type to inhibition by all the folate 
analogues with the exception of ICI 1 in which it shows a very slight resistance 
(Table 13). As for the other C-terminal mutant proteins, G302 shows greatest 
sensitivity to ICI 3, 4, and 5
Inhibitor
Mutant G302
% Activity
Wild-type Mutant
ICI 1 0.9 ± 0.05 1.7 ± 0 .4
ICI 2 2.7 ± 0.2 0.8 ± 0.1
ICI 3 6.4 ± 1.0 2.1 ± 0.2
ICI 4 18.2 ±5.0 3.7 ±0.8
ICI 5 22.7 ± 3.5 2.7 ± 0.7
ICI 6 4.3 ±0.1 0.9 ± 0.2
ICI 7 4.0 ±2.1 0.5 ±0.3
ICI 8 29.8 ± 3.0 8.3 ±0.8
PTH (50pM) 65.5 74.6
PTH (lOOjiM) 56.3 93.4
Table 13 Inhibition of mutant G302 by folate analogues and phenolphthalein
A ctivities are expressed as % o f the enzym e activity in the absence o f  inhibitor.
Without the structures of the folate analogues it is difficult to make any rational 
comparisons as to the differences between the inhibition by each analogue. However, 
this information when coupled to the mutagenic and enzymatic data for these 
mutants would show that a better understanding of the interactions between the 
enzyme and ligands could have positive implications for rational drug design. The 
inhibition studies presented here clearly show that removal of the C-terminal residue 
of VZV TS can for some analogues (ICI 1 , 2 , 8  and PTH) produce an enzyme more
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resistant to inhibition (Figure 35a). This leads to the speculation that these 
compounds are very similar in structure and mechanism of inhibition, and 
presumably need a tight closing down of the active site which the C-terminal leucine 
carboxylate provides. Extension of the C-terminus with a glycine or alanine renders 
the resultant protein more sensitive to the folate analogues tested (Figure 35a).
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Figure 35. Inhibition of G302 by folate analogues and phenolphthalein
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2.4 Peptide Inhibition
A series of peptides corresponding to the dimer interface of VZV TS have been 
previously characterised and shown to inhibit the VZV enzyme (R Thompson and H 
Marsden, personal communication). VZV TS is speculated to have a different 
interaction at its C-terminus compared to that exhibited by different members of the 
TS family (Harrison et al 1995). Harrison and co-workers propose that hydrophobic 
packing in this region may play a more important role in stabilising the ternary 
complex than does a hydrogen bond network. This proposed species difference in the 
C-terminal interactions allowed us to probe the potential for selectively inhibiting 
VZV TS. Based on the proposed unique interaction at the C-terminus of VZV TS we 
investigated the effect of two peptides corresponding to the last 4 (EMAL) or 5 
amino acids (MEMAL) of the C-terminus of VZV TS on enzymatic activity.
A slightly modified tritium release assay (see materials and methods) was used to 
assay peptide activity. The effect of peptide A on TS activity is given in Table 14 
(and graphically in Figure 35) and that of peptide B in Table 15 and Figure 35.
Figure 35 shows the effect of pre-incubating VZV TS with both test peptides and the 
control peptide 386. The control peptide disrupts the interface between the 2 
monomers of thymidylate synthase and its subsequent inhibition of enzyme activity 
is dramatic (inhibiting activity by 99.7%). However, in contrast both of the peptides 
to the C-terminus of VZV TS (peptide A [MEMAL] and peptide B [EMAL]) do not 
exhibit any inhibition of VZV thymidylate synthase. Indeed, both these peptides 
show a slight increase in activity. Prior to ligand binding the C-terminus is 
unordered, with no fixed location in space, to increase this disorder and perhaps 
generate a more open, accessible enzyme the peptide inhibition experiment was 
repeated at 42°C. This did not result in any change in the inhibition profile of the 
peptides.
Provision of what amounts to another C-terminal region to the reaction instead of 
inhibiting the interactions at the C-terminus actually enhances them. This is perhaps 
mediated through the peptide reducing the amount of shuffling the protein has to do 
to close down the active site as it does this for the enzyme. This could be more 
energetically stable. An analogy could be imagined, in that the peptides have an 
effect similar to that of someone pushing the door shut rather than it closing by itself.
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Concentration (mM) Tritium release assay 
pmol/min/(ig
% Wild-type
0 2072.97 100
0.5 2397.74 115
0.6 2494.58 120
0.8 2074.86 100
1.0 1939.29 93
1.2 2173.80 103
1.5 2581.53 124
2.0 2471.29 119
Positive control 7.82 0.3
Table 14 Tritium release assay showing the effect of peptide A (MEMAL)
T he positive control was peptide 386 (a peptide that disrupts the interface betw een the m onom ers o f  
T S) at 2p.M. V Z V  TS was expressed in E. coli strain BL21 using a pET8 C vector.
Concentration (mM) Tritium release assay 
pmol/min/|ig
% Wild-type
0 2072.97 100
0.5 2065.79 99
0.6 2267.05 109
0.8 2308.62 111
1.0 2490.92 120
1.2 2427.13 117
1.5 2327.86 112
2.0 2563.79 123
Positive control 7.82 0.3
Table 15 Tritium release assay showing the effect of peptide B (EMAL)
The p ositive control was peptide 386 (a peptide that disrupts the interface betw een the m onom ers o f  
T S) at 2p.M. V Z V  TS was expressed in E. coli strain BL21 using a pET 8 C vector.
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Figure 35. Inhibition of VZV TS by peptides A and B
2.5 Human thymidylate synthase C-terminus Mutants
Based on work in our lab (Harrison 1992, Harrison et al 1995) it was proposed that 
the C-terminus of human TS may well respond in a similar fashion to C-terminal 
deletion of the L. casei and E. coli enzyme, namely total inactivation. The human 
thymidylate synthase mutant V313A was made to investigate this hypothesis.
Site directed mutagenesis using the appropriate oligonucleotide was employed to 
construct the mutant V313A in NM522 T h y  cells. Screening all colonies whether or 
not they were T h y  yielded the correct mutation. Complementation data indicates a 
Thy+ phenotype for this mutant. Sequencing confirmed the desired mutation was the 
only change introduced.
V313A, like the VZV mutant L301A, can perform the partial (debromination) 
reaction at wild-type levels (Table 16) indicating that substrate binding is not 
impaired. Again, as for the VZV C-terminal truncation, V313A can turnover
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substrate (Table 16) which is in stark contrast to the L. casei and E. coli C-terminal 
deletion mutant.
Expressed Tritium % Wild Debromination % Wild
enzyme release assay Type assay Type
pmol/min/|Lig mOD/min/jig
Human WT 94.9 ±7 .6 100.0 0.15 ±0.02 100.0
V313 A 15.2 ± 1 .6 16.0 0.14 ±0.02 93.0
Table 16 Site-directed mutant of the Human TS.
A ll variants were derivatives o f pA D 876 expressed in E. co li strain %2913.
A significant difference between the response of VZV and human TS to truncation 
of the C-terminus is worthy of comment. The human mutant retains 16% of wild- 
type activity compared to 3% in the VZV C-terminal truncation.
2.5 Phenolphthalein inhibition of human thymidylate synthase
The human C-terminal mutant was tested against the TS inhibitor phenolphthalein to 
assess its sensitivity compared to that of wild-type enzyme. Deletion of the C- 
terminal valine does not make the enzyme any more or less sensitive to inhibition 
(Table 17 and Figure 36). The VZV mutant L301A and G302, in contrast, is more 
resistant (less sensitive) than the wild-type VZV enzyme.
Enzyme Phenolphthalein 
Concentration (pM)
% activity
0 100.0
WT human TS 50 68.5
100 38.1
0 100.0
V313A 50 78.9
100 25.3
Table 17 Inhibition of human TS and V 313 A by phenolphthalein
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□  WT Human TS
H  V313A (Human)
■  WT VZV TS
□  L301A (VZV)
PTH Concentration (piM)
Figure 36. Inhibition of TS C-terminal truncation mutants by phenolphthalein 
W ild-type VZV TS and the VZV mutant L301A are also shown for comparison.
2.6 Summary
Previous studies indicated the important role the C-terminal region has upon the 
function of the enzyme and the mutants A302, G302, and V313A complements an 
already interesting picture of the role of the C-terminus in both VZV and human 
thymidylate synthase.
The importance of the C-terminus is emphasised by all the mutants as they all effect 
catalysis to varying degrees. Extension of the VZV C-terminus has radically 
differing effects depending on what residue is added. Interestingly, due to the critical 
nature of this residue in the bacterial enzymes, extending this region would be 
expected to drastically inhibit catalysis. While this is true to some degree with the 
mutant A302 (a 5-fold reduction in substrate turnover), it is less adversely affected 
by addition of a glycine residue (a 2-fold reduction). As glycine is the smallest of the 
amino acids and has no charge, this perhaps is not surprising. What is unexpected is
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the effect a glycine addition has on the ability of the enzyme to bind substrate 
(increasing its ability 3-fold). Due to the difficulties in modelling such mutants it is 
near impossible to speculate as to what is happening at a structural level. One may 
think that on a surface region of a protein any insertions would be tolerated more 
readily, and in particular, in one that is relatively unordered prior to ligand binding. 
Perhaps, the importance of the DRTG loop should not be underestimated in its role 
in the catalytic function of thymidylate synthase. Any addition, particularly such 
small residues, probably can easily be orientated in surface regions as to point out to 
solvent (provided they are not hydrophobic). However, as the C-terminus becomes 
more ordered upon ligand binding and is tightly packed against the bottom of the 
active site, the DRTG loop packs against it and as such may limit the orientation the 
additional residues can adopt. Such clashes in this region have already been shown to 
have dramatic effects upon catalysis.
Analysis of folate inhibitors is useful because it can help probe the role of those 
residues in catalysis. The importance of the C-terminus is illustrated by the effects 
the folate analogues have on the different mutations. Addition of glycine or alanine 
in general makes the enzyme more sensitive to the ICI folate analogues, as does 
removal of the C-terminal leucine. Conversely, all these mutants are less sensitive to 
phenolphthalein indicative of the different nature of interaction these compounds 
have with the enzyme. The human TS C-terminal deletion mutant V313A is much 
more sensitive (3-fold) to phenolphthalein than its VZV counterpart. This adds 
weight to the suggestion that the human TS has a different interaction at the C- 
terminus than that of VZV TS.
Peptide inhibition of biologically important interactions can help in our 
understanding of the role of these interactions by providing data on the nature and 
type of interaction that occurs. It also provides a way of inhibiting such interactions 
such that new peptide like moieties can be used as anti-infectives against various 
protein-protein interactions. That VZV is an obligate dimer is elegantly illustrated by 
its inhibition with a peptide that disrupts the interaction between the two monomers. 
It binds between the dimer interface to one of the monomers thus preventing 
dimerisation. As the interaction at the C-terminus of VZV TS was speculated to be 
different to that of all the other TS enzymes (human included), it was an obvious 
target for a peptide inhibition experiment. Due to this speculated difference and that 
the C-terminus is important in catalysis it may provide a potential exploitable 
difference between the human and VZV enzymes for anti-viral agents. Despite that 
no inhibition was observed it does confirm the importance of this region. Provision
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of a peptide targeted to the C-terminus enhanced the ability of the enzyme to carry 
out its natural catalytic function.
3. Temperature sensitive mutants
Temperature-sensitive mutants are an efficient way of identifying amino acid 
positions which are critical for protein stability. We have developed a highly 
efficien t method to isolate such mutants based on the use of ‘spiked 
oligonucleotides.
3.1 Construction and screening of temperature-sensitive mutants
Oligonucleotides targeted to buried regions in the protein structure were chosen 
(Table 19) for random mutagenesis as these would have more effect on the structure 
of the protein. Mutant dsDNA was transformed using the PEG/DMSO method into 
E. coli strain NM522 T hy . Colonies that were ampicillin resistant were patched on 
to minimal media (M9) alone or minimal media supplemented with thymidine and 
incubated overnight at either 30°C, 37°C or 42°C. Temperature-sensitive isolates 
were selected on their ability to grow in the absence of exogenous thymidine at low 
but not high temperatures (Figure 37). Phenotype was assigned on the basis of 
growth on minimal media (M9) in the absence of thymidine, where strong growth is 
Thy+, no growth T h y  and weak growth Thy+yL.
Sequencing of the temperature sensitive mutants was carried out using the 
appropriate oligonucleotide and the mutations obtained are detailed in table 20 along 
with the areas of TS secondary structure they affect.
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OLIGO SIZE REGION OF 
TS GENE
AMINO ACID 
SEQUENCE
SECONDARY
STRUCTURES
R09 54mer 613-667 205-223 |3-Strand iii 205, 206 
Helix-J 207-222
R010 54mer 654-708 219-237 p-Strand ii 235-237 
Helix-J 219-230
R011 54mer 698-752 234-252 p-Strand ii Helix-k 252
R015 57mer 339-396 114-133 Helix-G
R016 54mer 416-470 140-158 Helix-H
T a b l e  1 9  Random oligonucleotides and the region of VZV TS they targeted
Mutant 31°(- 37°<; 42°c Mutant 31°<* 37°c 42°c
FJ 1 □ □ FJ 10 1 1 __ I ■ □
FJ 2 □ □ FJ 11 □ □
FJ 3 I__ | □ □ FJ 12 1 1 n J □ L— l□
FJ 4 □ □ FJ 13 I__i □ □
FJ 5 □ □ FJ 14 1 j1 1 □
FJ 6 □ □ FJ 15 □ □ □
FJ 7 □ □ FJ 16 □ ■ □
FJ 8 ■ □ FJ 17 □ □ □
FJ 9 □ □
Weak growth 
□  No growth
F i g u r e  3 7  Phenotypes of the isolated temperature-sensitive mutants of VZV TS
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Mutant Gene
position
Nucleotide
change(s)
Amino acid 
change(s)
Secondary 
structure(s) affected
FJ 1§ 621 1 base deletion Frame shift
657 GCA -> GCG Ala 219—> Ala Helix J
FJ2§ 626 1 base deletion Frame shift
649 GGA -> GAA Gly 217 —> Glu Helix J
FJ 3 615 GGG GGT Gly 205 -»  Gly p-strand iii
625 CTT - » TTT Leu 209 —» Phe Helix J
FJ 4* 646 GCT -»  TCT Ala 216 —> Ser Helix-J
FJ 5 647 GCT -> GAT Ala 216 —> Asp Helix-J
FJ 6 693 CTT -> CTC Leu 231 —> Leu Loop between Helix 
J and p-strand ii
FJ 7 678 GCG -> GC Ala 226 —» Ala Helix J
687 ACA GCA Thr 229 -> Ala Helix J
FJ 8$ 653 TAT -> TNT Tyr 218 ? Helix J
FJ 9t 753-754 70 base insertion Frame shift Before Helix K
FJ 10 714 CAT -> CAG His 238 -> Gin p-strand ii
FJ 11 381 TGG TGT Trp 127 —» Cys Helix G
386 CAT -> CCT His 129 —> Pro Loop between Helix 
G and Helix H
FJ 12 350 GGG -> GAG Gly 117—> Glu Loop between Helix 
D and Helix G
354 CAG - » GAG Gin 126 -> Glu Helix G
367 TAC AAC Tyr 123 —> Asn Helix G
370 GGC -> AGC Gly 124 -> Ser Helix G
FJ 16 390 TTT -> TTA Phe 130 —» Leu Loop between Helix 
G and Helix H
T a b l e  2 0  Sequence changes found in temperature-sensitive mutants 
§ The single base deletion results in a stop codon at position 670 (lie  224)
* A  double-priming event occurs in w hich the sequence loops back to position 593 (C ys 198) until 
position 664 (Thr 222) where it continues out o f  frame until a stop codon at position 670  
$ N ucleotide change undetermined
t  A  double-priming event resulting in a 70  amino acid insert (16 bases o f  unknown origin plus the 
original random o ligo ) and a fram eshift culm inating in a stop codon at position 799 (Leu 267)
FJ 13, FJ 14, FJ 15 and FJ 17 sequence data not determinable
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Use of the spiked oligonucleotides towards buried regions of VZV TS was 
successful in that it generated several temperature sensitive proteins. However, table 
20 illustrates one drawback such an approach to mutagenesis has because in addition 
to the temperature sensitive mutants, several unexpected variants were found. These 
comprised mainly of single base deletions, but one FJ 9 contained a 70 base 
insertion. One explanation could be that due to the degenerate nature of the spiked 
oligonucleotides, mis-priming events are more common than for site-directed 
mutagenesis. Indeed, this may explain why many of the clones examined for 
covariant residues of the DRTG loop exhibited a Thy+ phenotype but had no changes 
in the TS gene. Subsequent studies in our lab (J Boffey, personal communication) 
using spiked oligonucleotides targeted to different regions of VZV TS have 
produced similar findings. This does not make this approach to mutant generation 
invalid because overall the number of useful mutants outweighs the erroneous ones.
The generation of temperature sensitive mutants illustrates that such an approach to 
generate covariant residues which would revert the phenotype of the DRTG loop 
mutants was justified.
3.2 Molecular modelling of temperature-sensitive mutants
Molecular modelling was performed on a selection of the temperature sensitive 
mutants. Those that had undetermined sequence or contained frame shifts (and hence 
stop codons would result in truncated proteins) were not modelled due to the 
difficulties these would pose, as would FJ 9 with a 70 base insertion. Mutations were 
introduced into the VZV model using the programme SwissModler and visualised 
using the programme O on an Iris Indigo 2. Final output files were labelled using 
Showcase and saved as RGB images with Snapshot, converted to TIFF format for 
manipulation in Photoshop.
The temperature sensitive mutants have been illustrated with the original wild-type 
residue superimposed onto the new variant residue. For clarity the wild-type amino 
acid is shown in light blue. However, the original or mutant side chain is not always 
visible due to size differences or near perfect superimposition.
Mutation FJ 3 contains the substitution L209F, which is one of the highly conserved 
residues involved in van der Waal radii contacts with the PABA ring of folate. 
Phenylalanine 213 also plays a role in formation of this hydrophobic pocket for the 
PABA ring. L209F appears be a direct substitution of a like residue for like (in terms
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of function) as both can form the hydrophobic pocket which surrounds the PABA 
ring. The model indicates that there is a big space that the phenyalanine could 
occupy, perhaps facilitated by methionine 297 and 299 moving slightly out of the 
way. It may also be the case that the phenyalanine protrudes slightly more into the 
hydrophobic pocket reducing the cofactor binding.
F i g u r e  3 7  Temperature sensitive mutant FJ 3, showing the mutation L209F
The original w ild-type residue is shown in light blue, next to the mutated residue. Several other amino
acids are shown for reference.
Substitution of alanine with aspartic acid (A216D) in the mutant FJ 5 is illustrated in 
figure 38. The bigger, charged aspartic acid is easily accommodated by pointing out 
towards the surface despite this substitution occurring in the buried J-helix. This 
region undergoes segmental accommodation during ligand binding and thus may be
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able to tolerate changes more freely because it is not a fixed structural part of the 
protein.
F i g u r e  38 Temperature sensitive mutant FJ 5, showing the mutation A216D
The original w ild-type residue is shown in light blue, next to the mutated residue. Several other amino
acids are shown for reference.
The central J helix appears to tolerate amino acid substitutions more readily than 
anticipated. Due to its helical nature and the fact that its buried within the TS 
structure, substitutions in this region were thought to be more disruptive. However, 
disruption of protein stability is a consequence of such tolerance as exhibited by the 
temperature sensitive phenotype of mutant FJ 7 (Figure 39). The much smaller 
alanine can easily be accommodated, but it does not have the branched methyl or
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hydroxyl groups of threonine. Presumably these are important for stabilising this 
region of the protein.
F i g u r e  3 9  Temperature sensitive mutant FJ 7, showing the mutation T229A
The original w ild-type residue is shown in light blue, next to the mutated residue. Several other amino  
acids are shown for reference.
The almost fully conserved histidine at position 238 is located at the beginning of p- 
strand i and can be substituted for a tryptophan (E . coli), a tyrosine (L. lactis), and a 
phenylalanine (phage T4 and <F3T). TS can also tolerate other substitutions at this 
position, as FJ 10 has a glutamine at this position. Its position at the beginning of the
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j3-strand allows it to position the variant residues such that they point out to solvent 
(Figure 40).
IM240 T239
H238Q
(
V
Q50 /
1237
F i g u r e  4 0  Temperature sensitive mutant FJ 1 0 ,  showing the mutation H238Q 
The original w ild-type residue is shown in light blue, next to the mutated residue. Several other amino 
acids are shown for reference.
Mutant FJ 11 has the substitution W127C, a residue located at the end of P-strand ii, 
and as like FJ 10 can position any unfavourable side chains into solvent. 
Interestingly, Tryptophan at position 127 is over 80 % conserved throughout the TS 
family.
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F i g u r e  4 1  Temperature sensitive mutant F J 11, showing the mutation W127C 
The original w ild-type residue is shown in light blue, next to the mutated residue. Several other amino 
acids are shown for reference.
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The temperature sensitive mutant FJ 11 also contains the substitution H129P. This 
proline residue may disrupt the protein backbone at this position (Figure 42), 
implicating this residues role in protein stability.
F i g u r e  4 2  Temperature sensitive mutant FJ 11, showing the mutation H129P
The original w ild-type residue is shown in light blue, next to the mutated residue. Several other amino
acids are shown for reference.
The mutant FJ 12 contains four substitutions G117E, Q126E, Y123N, and G124S. 
All are located in helix G with the exception of G117E which is located in the loop 
before helix G. Amino acid tyrosine 123 and glycine 124 are fully conserved 
throughout the TS family, illustrating the conservation paradox. Clearly these fully 
conserved residues can be substituted for different amino acids without total loss of
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function. The substitution G117E is shown in figure 43 and illustrates that in surface 
loop areas, variant side chains are more easily accommodated.
F i g u r e  4 3  Temperature sensitive mutant FJ 12, showing the mutation G117E
The original w ild-type residue is shown in light blue, next to the mutated residue. Several other amino
acids are shown for reference.
The substitution of glutamine with the almost identical glutamic acid does not appear 
to perturb the local structure (Figure 44). Perhaps this mutant alone would not lead to 
a temperature sensitive phenotype.
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F i g u r e  4 4  Temperature sensitive mutant FJ 12, showing the mutation Q126E
The original wild-type residue is shown in light blue, next to the mutated residue. Several other amino
acids are shown for reference.
As for the previous mutation (Q126E) within FJ 12, replacement of tyrosine 123 
with asparaginie can easily be accommodated because asparagine is much smaller 
than tyrosine (Figure 45). However, reduction in the volume occupied by the 
asparagine residue may account for the phenotype of FJ12.
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1122 H184
Y123N
W127
F i g u r e  4 5  Temperature sensitive mutant FJ 12, showing the mutation Y 123N 
The original wild-type residue is show n in light blue, next to the mutated residue. Several other amino 
acids are shown for reference.
The last substitution in FJ 12 is G124S. Gylycine 124 is fully conserved and may be 
important in maintaining the overall structure of the helix G. Figure 46 illustrates this 
mutation within VZV TS. The extra CH2OH group that is different in serine 
compared to glycine may cause small distortions in this tiny helix, although it can be 
orientated so it points out to solvent.
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Figure 46 Temperature sensitive mutant FJ 12, showing the mutation G124S
T he original w ild-type residue is shown in light blue, although cannot be seen because it
superim poses exactly below  the mutant residue. Several other amino acids are shown for reference.
The final temperature sensitive mutant examined contains the substitution F130L (FJ 
16). Leucine can easily be accommodated in this position with no gross structural 
changes (Figure 47). However, phenylalanine at this position is implicated in 
maintaining a stable TS structure by virtue of this mutants temperature sensitive 
phenotype.
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Figure 47 Temperature sensitive mutant FJ 16, showing the mutation FOOL
The original w ild-type residue is shown in light blue, next to the mutated residue. Several other amino
acids are shown for reference.
3.3 Summary of temperature-sensitive mutants
A notable feature of the temperature sensitive mutants is that most of the 
substitutions have occurred in regions which appear not to be important in catalysis 
and can tolerate change. Perhaps these are the natural ‘hot spots’ of VZV which can 
tolerate variation. They also illustrate elegantly the conservation paradox as mutant 
FJ 3 has a mutation in a fully conserved leucine residue (209). Similarly FJ 12 also 
has conserved residue changes (Y123N and G124S), yet have produced proteins that
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tolerate these substitutions. How the enzyme accommodates these substitutions at the 
lower temperature (30°C) and not the higher temperatures is not fully understood. 
Two plausible theories may explain this temperature sensitivity. Firstly, the enzyme 
is a more rigid less fluid structure at 30°C and at this temperature variant side chain 
residues may be more easily positioned such that they either point out to solvent or 
pack in to the structure with the least disruption. Raising the temperature to 37 °C or 
42°C gives rise to a much more fluid enzyme, and as such positioning of the side 
chains where no other residue will come into contact with it is more problematic. 
Secondly, such variants may be the result of two TS genes within the host bacteria, 
one wild-type and the other a variant. Mutant homodimers would be inactive, but 
heterodimers consisting of one monomer of wild-type enzyme and one monomer of 
variant enzyme may be sufficiently active.
The generation of many temperature sensitive mutants using the randomly ‘spiked’ 
oligonucleotides vindicates their use in a targeted mutagenesis protocol to search for 
covariants of the DRTG loop mutant proteins.
4. Final discussion and future work
This discussion outlines the original aims of the work and contrasts them with our 
findings with suggestions for some future research.
4.1 Is a highly conserved surface loop important?
The original aim of this study was to examine the role of the highly conserved 
surface DRTG loop and to provide a possible explanation as to why this loop was 
not conserved in the L. lactis phage 0 3 T  enzyme. Mutagenesis of the DRTG loop 
does impair the ability of thymidylate synthase to catalyse the formation dTMP 
without significantly affecting substrate binding. Detailed examination of these 
mutants on the VZV model has provided some insight into what may be happening 
at the structural level. Furthermore, kinetic characterisation of the mutants does show 
that the DRTG loop is important for catalysis. Much work has centred on the C- 
terminus, because it has been implicated heavily in catalysis and closing down the 
active site.
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This is the first study implicating the DRTG loop as an important functional element 
in catalysis. The DRTG loop in VZV TS may be critical for effective active site 
closure.
4.2 Can covariant accommodation restore the DRTG loop mutants 
activity?
Based on these studies, there does not appear to be any covariant residues for the L. 
lactis residues. However, it was by no means a fully exhaustive search and problems 
with the experimental approach hindered any real progress. The fact that region 
targeted random mutagenesis generates many temperature sensitive mutants shows 
that this approach is feasible. Mis-priming events were problematic and probably 
helped to mask any real covariants. Furthermore, it may be that to accommodate 
such drastic changes in an important loop, there needs to be more than one covariant 
residue. These residues are probably in different regions of the protein making a 
mutagenesis protocol difficult, if not unfeasible. Perhaps when a crystal structure of 
the VZV enzyme becomes available along with that of the L. lactis enzyme such 
residues may be more easily detected. Determination of the crystal structure of VZV 
TS is in progress (R. Thompson, personal communication). The L. lactis enzyme can 
be considered to be the result of an elegant yet ‘natural’ mutagenesis experiment that 
has shown that a large number of conserved amino acids can be substituted en masse 
without inactivating the enzyme. Perhaps it is this en masse substitution of residues 
that allows it to accommodate its ‘novel’ DRTG loop.
We have discovered novel structural plasticity in VZV TS that has not been 
previously reported and shown that VZV TS can tolerate amino acid substitutions 
(R38G, T39Q, G40M, 141 A) and insertions (41A42, A302, G302). This plasticity 
has been extended throughout the protein with the temperature sensitive mutants 
(e.g. L209F, A216S, A216D, T229A, F130P, T123N, G124S) and with the VZV 
model we have been able to predict the manner in which these changes may have 
been accommodated. In summary, these observations show that VZV TS, like 
several other proteins possesses inherent structural plasticity. Our studies and those 
of others (Climie et al 1990, Michaels et al 1990) have revealed that highly 
conserved residues are not always resistant to substitution.
The conservation paradox that exists for TS may be explained by the fact that it is 
not the precise residue that is important but maintenance of the ‘core structure’ of the 
protein. It is around this core that the majority of changes are more easily
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accommodated. Conservation of the core residues may be the result of fine-tuning to 
give the most efficient protein. Substituting one of these conserved residues does not 
have a catastrophic effect upon catalysis but results in a slightly less efficient variant 
of the protein which still has the same core structure.
4.3 Is the VZV TS unique in its C-terminal interactions?
Previous work has led to the notion that the interactions at the C-terminus of VZV 
were unique. This was primarily based on sequence alignment data and computer 
modelling. Based on this premise, it was predicted that all the other TS family 
members, including the human TS would interact differently in this region. It was 
proposed that the bacterial and human thymidylate synthase would be inactivated if 
their C-terminal residue was removed because this would disrupt the crucial 
hydrogen bond network within this region that helps maintain the closed ternary 
conformation.
Work presented in this thesis shows that the C-terminal mutant V313A of the human 
TS behaves in a similar fashion to VZV TS, namely it it not inactivated by C- 
terminal truncation. V313A exhibits 16% of wild-type activity compared to 3% for 
VZV L301 A. Since the human enzyme is not inactive as predicted the uniqueness of 
the VZV enzyme in this region is open to question.
Changes within the C-terminus of the VZV and human TS result in proteins that 
respond differently to folate inhibitors. Mutations in the C-terminus of VZV TS 
result in an enzyme that is more resistant to the folate-substrate mimic 
phenolpthalein reflecting the need of this inhibitor to have a fully closed active site. 
The C-terminal mutants cannot form a tight closed conformation upon ligand (or 
inhibitor) binding as reflected in their folate Km values. In contrast, the C-terminal 
mutant proteins show a greater sensitivity to ICI inhibitors 4 and 5 compared to the 
wild-type protein. This is reflected in their dUMP Km which indicates that these 
proteins are in a more open conformation. This allows the inhibitors better access to 
the active site and once there they can form irreversible ternary complexes. That 
these mutants do not close down the active site is not important for inhibition.
Peptides targeted against the C-terminus of VZV TS were tested for inhibition 
wihout success, perhaps reflecting an unrewarding target. Given the crucial role of
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the DRTG loop presented in this thesis peptides generated against this region may 
meet with more success.
Generation of temperature sensitive mutants using the spiked oligonucleotides 
validated this approach in the search for covariant residues of the DRTG loop 
mutants. They also provide information about which residues are important in 
protein stability and help to illustrate that TS is a fluid structure only accommodating 
many changes at lower temperatures when there is more order to its structure.
4.4 Future work
We have shown that the DRTG loop of VZV TS is crucial for catalysis by 
introducing single L. lactis residues into this region. It would be of further interest to 
replace the VZV DRTG loop with combinations of the L. lactis residues until the 
whole loop was identical to that of L. lactis. Similarly, other covariant residues may 
still be needed for accommodation of the new residues which may include the 7 base 
insertion located immediately before the loop. Covariant residues could be identified 
by using cocktails of the spiked oligonucleotides, while yielding many temperature 
sensitive mutants along the way.
Crystallisation of the VZV TS is under way and the elucidation of its structure will 
be of great value to these studies.
141
REFERENCES
Ablashi DV, Berneman ZN, Kramarsky B, Whitman J Jr, Asano Y, Pearson JR 
(1995). Human herpesvirus 7 (HHV7): current status. Clinical and Diagnostic Virol. 
4, 1-13
Ackermann M, Braun DK, Pereira L, Roizman B (1984). Characterization of herpes 
simplex virus 1 a  proteins 0, 4 and 27 with monoclonal antibodies. J. Virol. 52, 108- 
118.
Alford CA and Britt WJ (1993). Cytomegalovirus. In The Human Herpesviruses 
227-255. B Roizman, RJ Whitley and C Lopez (eds). Raven Press, New York.
A llen  JR, Reddy GPV, Lasser GW, Mathews CK (1980). T4 ribonucleotide 
reductase. J. Biol. Chem. 255, 7583-7588
Alm eida JD, Howatson AF, Williams MG (1962). Morphology of varicella 
(chickenpox) vims. Virology 16, 353-355
Arvin AM (1996). Varicella-Zoster Virus. In Fields Virology (3nd ed) 2, 2547- 
2585. BN Fields, DM Knipe et al (eds). Raven Press, New York
Arvin AM, Kushner JH, Feldman S, Baehner RL, Hammond D, Merigan TC (1982). 
Human leukocyte interferon for the treatment of varicella in children with cancer. N. 
Engl. J. Med. 306, 761-765
Aull JL, Lyon JA, Dunlap RB (1974). Gel electrophoresis as a means of detecting 
ternary complex formation of thymidylate synthetase. MicroChemistry Journal 19, 
210-218
Averett ER, Pahwa S, Swenson P, Stanat SC Biron KK (1987). Varicella-zoster 
virus clinical isolate resistant to acyclovir. In Proceedings of the 87th annual 
meeting of the American society of microbiology. Abstract No. A94
Ayusawa D, Shimizu K, Koyama H, Kaneda S, Takeishi K, Seno T (1986). Cell- 
cycle-directed regulation of thymidylate synthase messanger RNA in human diploid 
fibroblasts stimulated to proliferate. J. Mol. Biol. 190, 559-567
142
References
Bachmann B and Follmann H (1987). Deoxyribonucleotide biosynthesis in green 
algae-C haracterisation of thym idylate synthase-dihdrofolate reductase in 
Scenedesmus obliquus. Archives Biochem. 256, 244-252
B ach m an n  BJ (1983). Linkage map of Escherichia coli K-12, edition 7. 
Microbiological Reviews 47, 180-230
Balestrazzi A, Branzoni M, Carbonera D, Parisi B, Celia R (1995). Biochemical 
evidence for the presence of a bifunctional dihydrofolate reductase-thymidylate 
synthase in plant species. J. Plant Physiol. 147, 263-266
Balzarini J and DeClercq E (1982). 5-substituted-2’-deoxyuridines: correlation 
between inhibition of tumour cell growth and inhibition of thymidine kinase and 
thymidylate synthase. Biochemical Pharnacol. 31, 3673-3682
Barr PJ, Nolan PA, Santi DV, Robins MJ (1981). Inhibition of thymidylate 
synthetase by 5-alkynyl-2’-deoxyuridylates. J. Medicinal Chem. 24, 1385-1388 
Becker Y, Dym H, Sarov I (1968). Herpes simplex virus DNA. Virology 36, 184- 
192
Ben-Porat T and Rixon FJ (1979). Replication of herpesvirus DNA. IV. Analysis of 
concatamers. Virology 94, 61-70
Bird OD, Vaitkus JW, Clark J (1970). 2-amino-4-hydroquinazolines as inhibitors of 
thymidylate synthetase. Mol. Pharmacol. 6, 573-575
Bisson L and Thorner J (1977). Thymidine 5’-mono-phosphate-requiring mutants of 
Saccharomyces cerevisiae are deficient in thymidylate synthetase. J. Bacteriol. 132, 
44-50
Blacklow SC and Knowles JC (1991). In Directed Mutagenesis: A Practical 
Approach. 177-198. MJ McPherson (ed). Oxford University Press, New York.
Blakely RL (1963). The biosynthesis of thymidylic acid. IV. Further studies on 
thymidylate synthetase. J. Biol. Chem. 238, 2113-2118
B rou gh ton  CR (1966). V aricella-zoster in Sydney. I. V aricella and its 
complications. Med. J. Aust 2, 392-397
143
References
Brunell Pa, Ross A, Miller LH, Kuo B (1969). Prevention of varicella by zoster 
immune globulin. N. Engl. J. Med. 280, 1191-1194
Briinger A, Kuriyan J, Karplus M (1987). Crystallographic R factor refinement by 
molecular dynamics. Science 235, 458-460
Bullow a JGM and Wishik SM (1935). Complications of varicella. I. Their 
occurrence among 2,534 patients. Am. J. Dis. Child. 49, 923-926
B u n n i M, Doig MT, Donato H, Kesavan V, Priest DG (1988). Role of 
methylene-tetrahydrofolate depletion in m ethotrexate-m ediated intracellular 
thymidylate synthase inhibition in cultured L1210 cells. Cancer Res. 48, 3398-3404
B urdeska A, Ott M, Bannwarth W, Then RL (1990). Identical genes for 
trimethoprim-resistant dihydrofolate reductase from Staphylococcus aureus in 
Australia and Central Europa. FEBS Letters 266, 159-162
Burns JC, Newburger JW, Sundell R, Wyatt LS, Frenkel N (1994). Seroprevalence 
of human herpesvirus 7 in patients with Kawasaki disease. The Pediatric Infectious 
Disease J 4, 168-169
Cabirac GF, Mahalingam R, Wellish M, Gilden DH (1990). Trans-activation of 
viral tk promoters by proteins encoded by varicella zoster virus open reading frames 
61 and 62. Virus Res. 15, 57-68
Cameron JM (1993). New antiherpes drugs in development. Medical Virology 3, 
225-236
Capco Gr, Krupp TL, Mathews CK (1973). Bacteriophage-coded thymidylate 
synthetase: characteristics of the T4 and T5 enzymes. Archiv. Biochem. Biophys. 
158, 726-775
Carreras CW and Santi DV (1995). The catalytic mechanism and structure of 
thymidylate synthase. Ann. Rev. Biochem. 64, 721-762
Carreras CW, Climie SC, Santi DV (1992) Thymidylate synthase with a C-terminal 
deletion catalyses partial reactions but is unable to catalyse thymidylate formation. 
Biochemistry 31, 6038-6044
144
References
Chang Y, Cesarman E, Pessin M, Lee F, Culpepper, J Knowles D, Moore P (1994). 
Identification of herpesvirus-like DNA in AIDS-associated Kaposi’s sarcoma. 
Science 266, 1865-1869
C h iu  CS, Cook KS, Greenberg GR (1982). Characteristics of a bacteriophage 
T4-induced complex synthesising deoxyribonucleotides. J. Biol. Chem. 257, 15087- 
15097
C h u  E, Drake JC, Boarman D, Baram J, Allegra CJ (1990). Mechanism of 
thymidylate synthase inhibition by methotrexate in human neoplastic cell lines and 
normal human myeloid progenitor cells. J. Biol. Chem.265, 8470-8478
Chu E, Koeller DM, Casey JL, Drake JC, Chabner BA, Elwood PC, Zinn S, Allegra 
CJ (1991). Autoregulation of human thymidylate synthase m essenger RNA 
translation by thymidylate synthase. Proc. Natl. Acad. Sci. USA. 88, 8977-8981
Chu E, Voeller D, Koeller DM, Drake JC, Takimoto CH, Maley GF, Maley F, 
Allegra CJ (1993). Identification of an RNA binding site for human thymidylate 
synthase. Proc. Natl. Acad. Sci. USA. 90, 517-521
Chung CT and Miller RH (1988). A rapid and convienient method for the 
preparation and storage of competent bacterial cells. Nucl. Acids Res. 16, 3580
Clements JB, Watson JR, Wilkie NM (1977). Temporal regulation OF herpes 
simplex virus type 1 transcription: location of transcripts on the vural genome. Cell 
12, 275-285
Climie S, Ruiz-Perez L, Gonzalez-Pacanowska D, Prapunwattana P, Cho SW, 
Stroud RM, Santi DV (1990). Saturation site-directed mutagenesis of thymidylate 
synthase. J. Biol. Chem. 265, 18776-18779
Cohen EA, Gardreau P, Brazeau P, Langelier Y (1986). Specific inhibition of 
herpesvirus ribonucleotide reductase by a nonapeptide derived from the carboxy 
terminus of subunit 2. Nature 321, 441-443
Cohen JI and Straus SE (1996). Varicella-Zoster Virus and its replication. In Fields 
Virology (3nd ed) 2, 2525-2545. BN Fields, DM Knipe et al (eds). Raven Press, 
New York
145
References
Collier NC, Knox K, Schlesinger MJ (1991). Inhibition of onfluenza virus formation 
by a peptide that corresponds to sequences in the cytoplasmic domain of the 
haemaglutinin. Virology 183, 769-772
Conley AJ, Knipe DM, Jones PC, Roizman B (1981). Molecular genetics of herpes 
simplex virus. VII. Characterization of a temperature-sensitive mutant produced by 
in vitro mutagenesis and defective in DNA synthesis and accumulation of y  
polypeptides. J. Virol. 37, 191-206.
Conrad AH (1971). Thymidylate synthetase activity in cultured mammalian cells. J. 
Biol. Chem. 246, 1318-1323
Cosentino G, Lav alee P, Rakhit S, Plante R, Gaudette Y, Lawetz C, Whitehead PW, 
Duceppe J-S, Lepine-Frenette C, Dansereau N, Guilbaut C, Langelier Y, Gaudreau 
P, Thelander L, Guidon Y (1991). Specific inhibition of ribonucleotide reductases by 
peptides corresponding to the C-terminal of their second subunit. Biochem. Cell 
Biol. 69, 79-83
Croen KD and Straus SE (1991). Varicella-zoster virus latency. Annu Rev 
Microbiol. 45, 265-282
Croen KD, Ostrove JM, Dragovic LJ, Smialek JE, Straus SE (1987). Latent herpes 
simplex virus in human trigeminal ganglia: detection of an immediate-early gene 
“antisense” transcript. N. Engl. J. Med. 317, 1423-1432
Croen KD, Ostrove JM, Dragovic LJ, Straus SE (1987). Characterisation of herpes 
simplex virus type 2 latency associated transcription in human sacral ganglia and in 
cell culture. J. Infect. Dis. 163, 23-28
Croen KD, Ostrove JM, Dragovic LJ, Straus SE (1988). Patterns of gene expression 
and sites of latency in human nerve ganglia are different for varicella-zoster and 
herpes simplex viruses. Proc. Natl. Acad. Sci. USA 85, 9773-9777
Crusberg TC, Leary R, Kisluik RL (1970). Properties of thymidylate synthetase 
from dichlromethatrexate-resistant Lactobacillus casei. J. Biol. Chem. 245, 5292- 
5296
Danenberg PV and Lockshin A (1982). Tight-binding complexes of thymidylate 
synthase, folate analogues and deoxyribonucleotides. Adv. Enz. Reg. 20, 99-110
146
References
Danenberg PV, Langenbach RJ, Heidelberg C (1974). Structures of reversible and 
irreversible complexes of thymidylate synthetase and fluorinated pyrimidine 
nucleotides. Biochemistry 13, 926-933
Danenberg PVand Danenberg KD (1978). Effect of 5, 10-methylenetetrahydrofolate 
on the dissociation of 5-fluro-2’-deoxyuridylate from thymidylate synthase: evidence 
for an ordered mechanism. Biochemistry 17, 4018-4024
Davison AJ (1984). Structure of the genome termini of varicella-zoster virus. J. 
Gen. Virol. 65, 1969-1977
Davison AJ (1991). Varicella-zoster virus. The fourteenth Fleming Lecture. J. Gen. 
Virol. 72,475-486
Davison AJ and Scott JE (1986). The complete DNA sequence of varicella-zoster 
virus. J. Gen. Virol. 67, 597-611
Davison AJ and Wilkie NM (1981). Nucleotide sequence of the joint between the L 
and S segments of herpes simplex virus types 1 nd 2. J. Gen. Virol. 55, 315-331
Davison AJ, Walters DJ, Edson CM (1985). Identification of the products of a 
varicella-zoster virus glycoprotein gene. J. Gen. Virol. 66, 2237-2242
Dayringer HE, Tramontano A, Sprang SR, Fletterick RJ (1986). Interactive program 
for visulization and modelling of proteins, nucleic acids and small molecules. J. 
Mol. Graphics 4, 82-87
de Moragas JM and Kierland RR (1957). The outcome of patients with herpes 
zoster. Arch. Dermatol. 75, 193-196
Dealty AH, Spivack JG, Lavi E, O’Boyle DR, Fraser NW (1988). Latent herpes 
simplex virus type 1 transcripts in peripheral and central nervous system tissues of 
mice map to similar regions of the viral genome. J. Virol. 62, 749-756
Defechereax P, Melen L, Baudoux L, Merville-Louis M-P, Rentier B, Piette J 
(1993). Characterization of the regulatory functions of varicella-zoster virus open 
reading frame 4 gene product. J. Virol. 67, 4379-4385
147
References
Dev IK, Yates BB-Leong J, Dallas WS (1988). Functional role of cysteine-146 in 
Escherichia coli thymidylate synthase. Proc. Natl. Acad. Sci. USA. 85, 1472-1476
Disney GH, McKee TA, Preston CM, Everett RD (1990). The product of varicella- 
voster virus gene 62 autoregulates its own promoter. J. Gen. Virol. 71, 2999-3003
Donato H Jr, Aull JL, Lyon JA, Reinsch JW, Dunlap RB (1976). Formation of 
ternary complexex of thymidylate synthetase as followed by absorbance, 
fluorescence and circular dichroism spectra and gel electrophoresis. J. Biol. Chem. 
251, 1303-1310
Dumas AM, Geelen JLMC, Maris W and van der Noordaa J (1980). Infectivity and 
molecular weight of varicella-zoster virus DNA. J. Gen. Virol. 47, 233-235.
Dumas AM, Geelen JLMC, Weststrate MW, Wertheim P, and van der Noordaa J 
(1981). Xbal, Pstl and Bghl restriction enzyme maps of the two orientations of the 
varicella-zoster virus genome. J. Virol. 39, 390-400.
Dutia BM, Frame MC, Subak-Sharpe JH, Clark WN, Marsden, HS (1986). Specific 
inhibition of herpesvirus ribonucleotide reductase by synthetic peptides. Nature 321, 
439-441
Ecker JR and Hyman RW (1982). Varicella-zoster virus DNA exists as two isomers. 
Proc. Natl. Acad. Sci. USA 79, 156-160
Ellis RW, Keller PM, Lowe RS, Zivin RA (1985). Use of a bacterial expression 
vector to map the varicella-zoster virus major glycoprotein gene, gC. J. Virol. 53, 
81-88
Evans RM, Laskin JD, Hakala MT (1981). Effect of excess folates and deoxyinosine 
on the activity and site of action of 5-flurouracil. Cancer Res. 41, 3288-3295
Everett RD (1984) Trans activation of transcription by herpes virus products: 
requirement for two HSV-1 immediate early polypeptides for maximum activity. 
EMBO J. 3,3135-3141
Everett RD and Orr A (1991). The Vmwl75 binding site in the IE-1 promoter has 
no apparent role in the expression of VmwllO during herpes simplex virus type 1 
infection. Virology 180, 509-517.
148
References
Fauman EB, Rutenber EE, Maley F, Stroud RM (1994). W ater-m ediated 
substrate/product discrimination: the product complex of thymidylate synthase at 
1.83A. Biochemistry 1502-1511
Feldman S, Hughes WT, Daniel CB (1975). Varicella in children with cancer: 
seventy-five cases. Pediatrics 56, 388-397
F e lse r JM, Straus SE, Ostrove JM (1987). Varicella-zoster virus complements 
herpes simplex virus type 1 temperature-sensitive mutants. J. Virol. 61, 225-228.
Fenwick ML and Everett RD (1990). Inactivation of the shutoff gene (UL41) of 
herpes simplex virus types 1 nd 2. J. Gen. Virol. 71, 2961-2967
Finer-M oore JS, Fauman EB, Foster PC, Perry KM, Stroud RM (1993). Refined 
structures of substrate-bound and phosphate-bound thymidykate synthase from 
Lactobacillus casei. J. Mol. Biol.
Finer-M oore JS, Montfort WR, Stroud RM (1990). Pairwise specificity and 
sequential binding in enzyme catalysis: thymidylate synthase. Biochemistry 29, 
6977-6986
Frenkel N, Schirmer EC, Wyatt LS, Katsafanas G, Roffman E, Danovich RM, June 
CH. (1990). Isolation of a new herpesvirus from human CD4+ T cells. Proc. Natl. 
Acad. Sci. USA 87, 748-752
Friedkin M, Crawford E, Humphreys SR, Goldin A (1962). The association of 
increased dihydrofolate reductase with amethopterin resistance in mouse leukemia. 
Cancer Res. 22, 600-606
Galivin JH, Maley GF, Maley F (1975). The effect of substrate analogues on the 
circular dichroic spectra of thymidylate synthetase from L.casei. Biochemistry 14, 
3338-3344
Garret C, Wayata Y, Santi DV (1979). Thymidylate synthetase. Catalysis of 
dehalogenation of 5-bromo-and 5-iodo-2’-deoxyuridylate. Biochemistry 18, 2798- 
2804
149
References
G eiser CF, Bishop Y, Myers M, Jaffe N, Yankee R (1975). Prophylaxis of varicella 
in children with neoplastic disease: comparative results with zoster immune plasma 
and gamma globulin. Cancer 35, 1027-1030
Gelb LD (1993). Varicella-zoster virus. In The Human Herpesviruses 257-308. B 
Roizman, RJ Whitley and C Lopez (eds). Raven Press, New York
Gershon AA, LaRussa, Steinberg SP (1993). In The Human Herpesviruses 357- 
366. B Roizman, RJ Whitley and C Lopez (eds). Raven Press, New York
Gershon AA, Steinberg S, Brunell PA (1974). Zoster immune globulin: a further 
assessment. N. Engl. J. Med. 290, 243-245
Ghose C, Oleinick R, Mathews RG, Dunlap RB (1990). Kinetic studies on 
thymidylate synthase from Lactobacillus asei. In Chemistry and Biology of 
Pteridines 1989, 860-865. Curtius H-CH, Chisla S, Blau N (eds). Walter de Gruyter 
and Company, Berlin
Gilden DH, Rozenman Y, Murray R, Devlin M, Vafai A (1987). Detection of 
varicella-zoster nucleic acid in neurons of normal humsn thoracic ganglia. Ann. 
Neurol. 22, 377-380
Goodrich JA, Hoey T, Thut CJ, Admon A, Tjian R (1993). Drosophila TAFn40 
interacts with both a VP16 activation domain and the basal transcription factor 
TFIIB. Cell 75, 519-530
Greaves RF and O’Hare P (1990). Structural requirements in the herpes simplex 
virus typel transactivator Vmw65 for interaction with the cellular octamer-binding 
protein and target TAATGARAT sequences. J. Virol. 64, 2716-2724
Guess HA (1986). Population-based studies of varicella complications. Pediatrics 
78, 723-727
Haigh A, Greaves R, O’Hare P (1990). Interference with the assembly of a virus- 
host interaction complex by peptide competition. Nature 344, 257-259
Hardy LW, Finer-Moore JS, Montfort WR, Jones MO, Santi DV, Stroud RM 
(1987). Atomic structure of thymidyalte synthase: target for rational drug design. 
Science 235, 448-455
150
References
Harrap KR, Jackman AL, Newell DR, Taylor GA, Hughes LR, Calvert AH (1989). 
Thymidylate synthase: A target for anticancer drug design. Adv. Enz. Reg. 29, 161- 
179
Harrison PT (1992). Mutagenic studies of the varicella-zoster virus thymidylate 
synthase. PhD Thesis, University of Glasgow.
Harrison PT, Scott JE, Hutchinson MJ, Thompson R (1995). Site-directed 
mutagenesis of varicella-zoster virus thymidylate synthase- Anaylsis of 2 highly 
conserved regions of the enzyme. European J. Boichem. 230, 511-516
Hattori M and Sakaki Y (1986). Dideoxy sequencing method using denatured 
plasmid templates. Analytical Biochem. 152, 232-238
Hayakawa Y and Hyman R (1987). Isomerisation of the U l region of varicella- 
zoster virus DNA. Virus Res. 8, 25-31
Hayes S and O’Hare P (1993). Mapping of a major surface-exposed site in herpes 
simplex virus protein Vme65 to a region of direct interaction in a transcription 
complex assembly. J. Virol. 67, 852-862
Helene C and Toulme J-J (1990). Specific regulation of gene expression by 
antisense, sense and antigene nucleic acids. Biochimie et Biophysica Acta 1 0 4 9 ,  99- 
125
Hidaka Y, Okada K, Kusuhara K, Miyazaki C, Tokugawa K and Ueda K (1994). 
Exanthem subitim and human herpesvirus 7 infection. The Pediatric Infectious 
Disease J 1 3 ,  1010-1011
Honess RW (1984). Herpes simplex and ‘the herpes complex’: diverse observations 
and a unifying hypothesis. J. Gen. Virol. 65, 2077-2107
Honess RW and Roizman B (1974). Regulation of herpesvirus macromolecular 
synthesis I. Cascade regulation of the synthesis of three groups of viral proteins. J. 
Virol., 1 4 ,  8-19.
Honess RW and Roizman B (1975). Regulation of herpesvirus macromolecular 
synthesis: sequential transition of polypeptide synthesis requires functional viral 
polypeptides. Proc. Natl. Acad. Sci. USA 72, 1276-1280.
151
References
Honess RW, Bodemer W, Cameron KR, Niller HH, Fleckenstein B, Randall RE 
(1986). The A+T-rich genome of herpesvirus saimiri contains a highly conserved 
gene for thymidylate synthase. Proc. Natl. Acad. Sci. USA 83. 3604-3608
Hope-Simpson RE (1965). The nature of herpes zoster: a long-term study and a new 
hypothesis. Proc. R. Soc. Med 58, 9-20
H o u g h to n  JA, Maroda SJ, Philips JO, Houghton PJ (1981). Biochemical 
determinants of responsiveness to 5-fluorouracil and its derivatives in human 
colorectal adenocarcinoma xenografts. Cancer Res. 41, 144-149
Hyman RW, Ecker JR, Tenser RB (1983). Varicella-zoster virus RNA in human 
trigeminal ganglia. Lancet 2, 814-816
Inchauspe G and Ostrove JM (1989). Differential regulation by varicella-zoster 
virus (VZV) and herpes simplex virus type-1 rrarcs-activating genes. Virology 173, 
710-714
Inchauspe G, Nagpal S, Ostrove JM (1989). Mapping of two varicella-zoster virus- 
encoded genes that activate the expression of viral early and late genes. Virology 
173, 700-709
Ivanetich KM and Santi DV (1990). Thymidylate synthase-dihydrofolate reductase 
in protozoa. Exp. Parasitol. 70, 367-371
Jackers P, Defechereux P, Baudoux L, Lambert C, Massaer M, Merville-Louis M - 
P, Rentier B, Piette J (1992). Characterization of regulatory functions of the 
varicella-zoster virus gene 63-encoded protein. J. Virol. 66, 3899-3903
Jackson RC, Jackman AL, Calvert AH (1983). Biochemical effects of a quinazoline 
in h ib ito r of thym idy la te  synthase, N -(4 -(N -((2 -am in o -4 -h y d ro x y -6 - 
quinazolinyl)methy])prop-2-ynylamino)benzoyl)L-glutamic acid (CB3717) on 
human lymphoblastoid cells. Biochemical Pharmocology 32, 3783-3790
Jacob RJ, Morse LS, Roizman B (1979). Anatomy of herpes simplex virus DNA. 
XII. Accumulation of head-to-tail concatamers in nuclei of infected cells and their 
role in the generation of the four isomeric arrangements of viral DNA. J. Virol. 29, 
448-457
152
References
Jazwinski SM and Edelman GM (1984). Evidence for participation of a multiprotein 
complex in yeast DNA replication in vitro. J. Biol. Chem. 259, 6852-6857
Jenh CH, Geyer PK, Johnson LF (1985). Control of thymidylate synthase messenger 
RNA content and gene transcription in an overproducing mouse cell line. Mol. Cell. 
Biol. 5, 2527-2532
Johnson DC and Feenstra V (1987). Identification of a novel herpes simplex virus 
type 1-induced glycoprotein which complexes with gE and binds immunoglobulin. 
J. Virol. 61, 2208-2216
Johnson DC, Frame MC, Ligas MW, Cross, Stow ND (1988). Herpes simplex virus 
immunoglobulin G Fc receptor activity depends on a complex of two viral 
glycoproteins, gE and gl. J. Virol. 62, 1347-1354
Jones TR, CAlvert AH, Jackman AL, Brown SJ, Jones M, Harrap KR (1981). A 
potent antitumour quinazoline inhibitor of thymidylate synthetase: synthesis, 
biological properties and therapeutic results in mice. European J. Cancer 17, 11-19
Kamb A, Finer-Moore JS, Calvert AH, Stroud RM (1992b). Structural basis for 
ecognition of polyglutamyl folates by thymidylate synthase. Biochemistry 31, 9883- 
9890
Kamb A, Finer-Moore JS, Stroud RM (1992a). Cofactor triggers the conformational 
change in thymidylate synthase: implications for an ordered binding mechanism. 
Biochemistry 31, 12876-12884
Keller PM, Davison AJ, Lowe RS, Bennett CD, Ellis RW (1986). Identification and 
structure of the gene encoding gpll, a major glycoprotein of varicella-zoster virus. 
Virology 152, 181-191
Keyomarsi K and Moran RG (1988). Mechanism of the cytotoxic synergism of 
fluoropyrimidines and folinic acid in mouse leukemic cells. J. Biol. Chem. 263, 
14402-14409
Keyomarsi K and Moran RG (1990). Qinazoline folate analogues inhibit the 
catalytic activity of thymidylate synthase but allow binding of 5-flurodeoxyuridylate. 
J. Biol. Chem. 265, 19163-19169
153
References
Kieff ED, Bachenheimer SL, Roiznam B (1971). Size, composition and structure of 
the DNA of subtypes 1 and 2 herpes simplex virus. J. Virol. 8, 125-129
Kinchington PR, Hougland JK, Arvin AM, Ruyechan WT, Hay J (1992). The 
varicella-zoster virus immediate-early protein IE62 is a major component of virus 
particles. J. Virol. 66, 359-366
Kinchinton PR, Reinhold WC, Casey TA, Straus SE, Hay J, Ruyechan WT (1985). 
Inversion and circularisation of the varicella-zoster virus genome. J. Virol. 5 6 ,  194- 
200
Kisliuk RL, Gaumont Y, Baugh CM (1974). Polyglutamyl derivatives of folate as 
substrates and inhibitors of thymidylate synthetase. J. Biol. Chem. 2 4 9 ,  4100-4103
Kost RG, Kupinsky H, Straus S (1995). Varicella-zoster virus gene 63- Transcript 
mapping and regulatory activity. Virology 2 0 9 ,  218-224
Krugman S, Ward R, Katz SL (1977). Varicella-zoster infections. In Infectious 
diseases of children (6th ed) 451-471. St. Louis: Mosby
Kiinkel TA (1985). Rapid and efficient site-specific mutagenesis without phenotypic 
selection. Proc. Natl. Acad. Sci. USA 82, 488-492
Kiinkel TA, Roberts JD and Zakour RA (1987). Rapid and efficient site-specific 
mutagenesis without phenotypic selection. Methods in Enzymology 5 4 ,  367-382 
Kuntz ID (1992). Structure-based strategies for drug design and discovery. Science 
2 5 7 ,  1078-1082
Kwong AD, Kruper AJ, Frenkel N (1988). Herpes simplex virus virion host shutoff 
function. J. Virol. 62, 912-921
Lagosky PA, Taylor GR, Haynes GR (1987). Molecular characterisation of the 
saccharomyces cerevisiae dihydrofolte-reductase gene (DFR1). Nucl. Acids Res. 
1 5 ,  10355-10371
LaPat-Polasko L, Maley GF, Maley F (1990). properties of T4-phage thymidylate 
synthase following mutagenic changes in the active site region. Biochemistry 2 9 ,  
9561-9572
154
References
Lawerence GL, Chee MS, Craxton MA, Gompels UA, Honess RW, Barrell BG 
(1990). Human herpes virus 6 is closley related to human cytomegalovirus. J. Virol. 
6 4 ,  287-299
Lazar G, Hong Z, Goodman HM (1993). The origin of the bifunctional 
dihydrofolate reductase thymidyalte isogenes of Arabidopsis thaliana. Plant Journal 
3, 657-668
Leary RP, Beaudette, Kisliuk RL (1975). Interaction of deoxyuridylate with 
thymidylate synthetase. J. Biol. Chem. 2 5 0 ,  4864-4878
Lewis CA and Dunlap RB (1981). Thymidylate synthase and its interaction with 5- 
fluro-2’-deoxyuridylate. In Tpoics in Molecular Pharmacology, 170-219. Burgen 
ASV and Roberts GCK (eds). Elsevier/North Holland Biomedical Press
Lim WA and Sauer RY (1991). The role of internal packing interactions in 
determining the structure and stability of a protein. J. Molec. Biol. 2 1 9 ,  359-376
Ling P, Kinchington PR, Ruyechan WT, Hay J (1991). A detailed analysis of 
transcripts mapping to varicella-zoster virus gene 14 (glycoprotein V). Virology 
1 8 4 ,  625-635
Ling P, Kinchington PR, Sadeghi-Zadeh M, Ruyechan WT, Hay J (1992). 
Transcription from varicella-zoster virus gene 67 (glycoprotein IV). J. Virol. 66, 
3690-3698
Lockshin A and Danenberg PV (1980). Hydrdynamic behaviour of human and 
bacterial thym idylate synthetases and thym idylate synthetase-5-fluro-2’- 
deoxyuridylate-5, 10-methylenetetrahydrofolate complexex. Evidence for large 
conformational changes during catalysis. Biochemistry 1 9 ,  4244-4251
Lopez C (1993). Human herpesviruses 6 and 7: Molecular biology and clinical 
aspects. In The Human Herpesviruses 309-316. B Roizman, RJ Whitley and C 
Lopez (eds). Raven Press, New York
Lorenson MY, Maley GF, Maley F (1967). The purification and properties of 
thymidylate synthetase from chick embryo extracts. J. Biol. Chem. 2 4 2 ,  3332-3344
155
References
Lu Y-Z, Aiello PD, Mathews RG (1984). Studies on the polyglutamate specificity of 
thymidylate synthase from fetal pig liver. Biochemistry 23, 6870-6876
M aguire HF andHyman RW (1986). Polyadenylated cytoplasmic transcripts of 
varicella-zoster virus. Intervirology 26, 181-191
Maley GF, Maley F, Baugh CM (1979). Diferential inhibition of host and viral 
thymidylate synthase by folyl-polyglutamates. J. Biol. Chem. 254, 7485-7487
Maley, G and Maley F (1988). Properties of a defined mutant of Escherichia coli 
thymidylate synthase. J. Biol. Chem. 263, 7620-7627
M a n a v a la n  P, M ittelstaedt DM, Schimerlink MI, Johnson WC (1986). 
Conformational analysis of thymidylate synthase from amino acis sequence by 
circular dichroism. Biochemistry 25, 6650-6655
M arsden HS (1987). Herpes simplex virus glycoproteins and pathogenesis. In 
Molecular Basis of Virus Disease. SGM 40, 259-288. Cambridge University Press.
M arsden HS (1992). Disruption of protein-subunit interactions. Seminars in Virol. 
3, 67-75
M athews CK, Moen LK, Wang Y, Sargent RG (1988). Intracellular organisation of 
precursor biosynthetic enzymes. Trends in Biochem. Sci. 13, 394-397
M athews CK, North TW, Reddy GPV (1978). Multienzyme complexes in DNA 
precursor biosynthesis. Adv. Enz. Regulation 17, 133-156
M athews DA, Appelt K, Oatley SJ, Xuong NH (1990b). Crystal structure of 
Escherichia coli thymidylate synthase containing bound 5-fluro-2’-deoxyuridylate 
and 10-propargyl-5,8-dideazafolate. J. Mol. Biol. 214, 923-936
M athews DA, Villafranca JE, Janson CA, Smith WW, Welsh K, Freer S (1990a). 
Stereochemical mechanism of action for thymidylate synthase based on the x-ray 
structure of the covalent inhibitory ternary complex with 5-fluro-2’-deoxyuridylate 
and 5, 10-methylenetetrahydrofolate. J. Mol. Biol. 214, 937-948
156
References
M cG eoch DJ and Davison AJ (1986). Alphaherpesviruses possess a gene 
homologous to the protein kinase gene family of eukaryotes and retroviruses. Nucl. 
Acids Res. 14, 1765-1777
M cG eoch  DJ, Barnett BC, MacLean CA (1993). Emerging functions of 
alphaherpesvirus genes. Seminars in Virology 4, 125-134
McGeoch DJ, Dalrymple MA, Davison AJ, Dolan A, Frame MC, McNab D, Perry 
LJ, Scott JE, Taylor P (1988). The complete DNA sequence of the long unique 
region in the genome of herpes simplex virus type 1. J. Gen. Virol. 69, 1531-1574
M cGeoch DJ, Dolan A, Donald S, Brauer DHK (1986). Complete DNA sequence of 
the short repeat region in the genome of herpes simplex virus type 1. Nucl. Acids 
Res. 14, 1727-1745
McGeoch DJ, Dolan A, Donald S, Rixon FJ (1985). Sequence determination and 
genetic content of the short unique region in the genome of herpes simplex virus type 
1. J. Mol. Biol. 181, 1-13
McLauchlan J, Addison C, Craigie MC and Rixon FJ (1992). Noninfectious L- 
particles supply functions which can facilitate infection by HSV-1. Virology 190, 
682-688
M cNeil JB and Smith M (1985). Saccharomyces cerevisiae CYC1 mRNA 5’-end 
positioning by in vitro mutagenesis, using synthetic duplexes with random mismatch 
base pairs. Mol. Cel. Biol. 5, 3545-3551
McPherson MJ (1991). Directed mutagenesis. Oxford University Press, New York. 
Meek TD, Garvey EP, Santi DV (1985). Purification and characterisation of the 
bifunctional thymidylate synthase-dihydrofolate reductase from methotrexate- 
resistant Leishmania tropica. Biochemistry 24, 678-686
Meier JL and Straus SE (1992). Comparative biology of latent varicella-zoster virus 
and herpes simplex virus infections. J. Infect. Dis. 166 (Suppl. 1), 13-23.
Michaels ML, Mathews DA, Miller JH (1990). Escherichia coli thymidylate 
synthase: amino acid substitutions by suppression of amber nonsense mutations. 
Proc. Natl. Acad. Sci. USA. 87, 3957-3961
157
References
Miller FA, Dixon GJ, Arnett G, Dice JR, Rightsel WA, Schabel FM, McLean JW 
(1968). Antiviral activity of carbobenzyoxy di and tripeptides on measles virus. 
Appl. Microbiol. 16, 1489-1496
Miller G (1990). Epsein-Barr Virus: Biology, pathogenesis and medical aspects. In 
Virology (2nd ed) 2, 1921-1958. BN Fields, DM Knipe et al (eds). Raven Press, 
New York
Montfort WR, Perry KM, Fauman EB, Finer-Moore JS, Maley GF, Hardy L, Maley 
F, Stroud RM (1990). Structure, m ultiple site binding, and segm ental 
accommodation in thymidylate synthase on binding dUMP and an anti-folate. 
Biochemistry 29, 6964-6977
Morgan C, Rose HM, Mednis B (1968). Electron microscopy of herpes simplex 
virus. I. Entry. J. Virol. 2, 507-516
Moriuchi H, Moriuchi M, Smith HM, CohenJI (1994). Varicella-zoster virus open 
reading frame 4 protein is functionally destinct from and does not complement its 
herpes simplex virus type 1 homolog, ICP27. J. Virol. 68, 1987-1992.
Myers CE, Young RC, Johns DG, Chabner BA (1974). Assay of 5- 
flurodeoxyuridylate and deoxyuridylate pools following 5-flurouracil. Cancer Res. 
34, 2682-2688
Myers MG and Connelly BL (1992). Animal models of varicella. J. Infect. Dis. 166 
(Suppl. 1), 48-50
Myers MG, Kramer LW, Stanbery LR (1987). Varicella in a gorilla. J. Med. Virol. 
23,317-322
Nagpal S and Ostrove JM (1991). Characterization of a potent varicella-zoster 
virus-encoded trans-repressor. J. Virol. 65, 5289-5296
Navalgund LG, Rossana C, Muench AJ, Johnson LF (1980). Cell cycle regulation of 
thymidylate synthetase gene expression in cultured mouse fibroblasts. J. Biol. 
Chem. 255, 7386-7390
158
References
Neipel F, Ellinger K, Fleckenstein B (1991). The unique region of the human 
herpesvirus 6 genome is essentially colinear with the U l  segment of human 
cytomehalovirus. J. Gen. Virol. 72, 2293-2297
Ner SS, Goodin DB, Smith M (1988). A simple and efficient procedure for 
generating random point mutations and for codon replacements using mixed 
oligonucleotides. DNA 7, 127-134
Nicolaides E, deWald H, Westland R, Lipnik M, Posler J (1968). Potential antiviral 
agents. Carbbenzyoxy di and tripeptides active against measles and herpes viruses. 
J. Medicinal Chem. 11, 74-79
Nielson E and Celia R (1988). Thymidylate synthase in plant cells: kinetic and 
molecular properties of the enzyme from Daucus carota L. cell cultures. Plant and 
Cell Physiol. 29, 503-508
O'Hare P (1993). The virion transactivator of herpes simplex virus. Semin. Virol. 4, 
145-155
Ohyama K (1976). A basis for bromodeoxyuridine resistance in plant cells. Env. 
Exp. Botany 16, 209-216
Ostrove JM (1990). Molecular biology of varicella zoster virus. Advan. Virus Res. 
38, 45-98
Ostrove JM, Reinhold W, Fan CH, Zorn S, Hay J, Straus SE (1985). Transcription 
mapping of the varicella-zoster virus genome. J. Virol. 56, 600-606
Para MF, Bauckle RB, Spear PG (1980). Immunoglobulin G (Fc)-binding receptors 
on virions of herpes simplex virus type 1 and transfer of these receptors to the cell 
surface by infection. J. Virol. 34, 512-520
P a rk  JS, Cheng CT-C, M ertes MP (1979). 5 -[(4 -m e th y l-l, 2, 3, 4- 
tetrahydroquinoxalyl)m ethyl]-2’-deoxyuridine-5’-phosphate: an analogue of a 
proposed intermediate in thymidylate synthetase catalysis. J. Medicinal Chem. 22, 
1134-1137
Paryani SG and Arvin AM (1986). Intrauterine infection with varicella-zoster virus 
after maternal varicella. N. Engl. J. Med. 314, 1542-1546
159
References
Perera LP, Mosca JD, Ruyechan WT, Hay J (1992a). Regulation ofvaricella-zoster 
virus gene expression in human T lymphocytes. J. Virol. 66, 5298-5304
Perera LP, Mosca JD, Sadeghi-Zadeh M, Ruyechan WT, Hay J (1992b). The 
varicella-zoster virus immediate early protein, IE62, can positively regulate its 
cognate promoter. Virology 1 9 1 ,  346-354
Perry KM, Fauman EB, Finer-Moore JS, Montfort WR, Maley GF, Maley F, Stroud 
RM (1990). Plastic adaptation toward mutations in proteins: structural comparison of 
thymidylate synthases. Proteins: Struct. Funct. Genet. 8, 315-333
Perry KM, Fauman EB, Finer-Moore JS, Montfort WR, Maley GF, Maley F, Stroud 
RM (1990). Plastic adaptation toward mutations in proteins- Structural comparisons 
of thymidylate synthases. Proteins: Struct. Funct. and Genet. 8, 315-333
Perry LJ, McGeoch DJ (1988). The DNA sequences of the long repeat region and 
Adjoining parts of the long unique region in the genome of herpes simplex virus type 
1. J. Gen. Virol. 69, 2831-2846
Piggot PJ and Hoch JA (1985). Revised linkage map of Bacillus subtillus. 
Microbiological Reviews 49, 158-179
Pogolotti AL Jnr, Danenberg PV, Santi DV (1986). Kinetics and mechanism of 
interaction of 10-propargyl-5, 8-dideazafolate with thymidylate synthase. J. 
Medicinal Chem. 2 9 ,  478-482
Pogolotti ALJ, Danenberg PV, Santi DV (1986). Kinetics and mechanism of 
interaction of 10-propargyl-5, 8-dideazafolate with thymidylate synthase. J. Med. 
Chem. 2 9 ,  478-482
Preston CM (1979). Control of herpes simplex virus type 1 mRNA synthesis in cells 
infected with wild-type virus or the temperature-sensitive mutant tsK. J. Virol. 2 9 ,  
275-285.
Prober CG, Kirk LE, Keeney RE (1982). Acyclovir therapy of chickenpox in 
immunosuppressed children: a collaborative study. J. Pediatr. 101, 622-625
Reinhold W, Straus SE, Ostrove JM (1988). Directionality and further mapping of 
varicella-zoster virus transcripts. Virus Res. 9 ,  249-261
160
References
Reyes P and Heidelberger C (1965). Fluorinated pyrimidines. Mol. Pharmacol. 1, 
14-30
R ich ard so n  CD and Choppin PW (1983). Oligopeptides that specifically inhibit 
membrane fusion by paramyxoviruses: studies on the site of action. Virology 1 3 1 ,  
518-532
R ic h a r d s o n  CD, Scheid A, Choppin PW (1980). Specific inhibition of 
paramyxovirus replication by oligopeptides with amino acid sequences similar to 
those at the N-termini of the F] or HA2 viral polypeptides. Virology 1 0 5 ,  205-222
Richter J, Puchtler I, Fleckenstein B (1988). Thymidylate synthase gene of 
herpesvirus ateles. J. Virol. 62, 3530-3535
Rickinson AB, Kieff E (1996). Epsein-Barr Virus: In Fields Virology (3rd ed) 2, 
2397-2446. BN Fields, DM Knipe et al (eds). Raven Press, New York
Rixon FJ, Campbell ME, Clements JB (1984). A tandemly reiterated DNA sequence 
in the long repeat region of herpes simplex virus type 1 found in close proximity to 
immediate early mRNA-1. J. Virol. 5 2 ,  715-718
Roizman B (1979). The structure and isomerization of herpes simplex virus 
genomes. Cell 1 6 ,  481 -494
Roizman B (1993). The family herpesviridae: A brief introduction. In The Human 
Herpesviruses 1-9. B Roizman, RJ Whitley and C Lopez (eds). Raven Press, New 
York
Roizm an B (1996). Herpesviridae. In Fields Virology (3nd ed) 2, 2221-2230. BN 
Fields, DM Knipe et al (eds). Raven Press, New York
Ross AH (1962). Modification of chicken pox in family contacts by administration 
of gamma globulin. N. Engl. J .  Med. 2 6 7 ,  369-376
Ross P, 0;G ara F, Condon S (1990). Cloning and charcterisation of the thymidylate 
synthase gene from Lactococcus lactisl subsp. lactis Applied and Env. Microbiol. 
56,2156-2163
161
References
Sani BP, Vaid A, Cory JG, Brockman RW, Elliot RD, Montgomery JA (1986). 5 ’- 
haloacetam ido-2’-deoxythymidines: novel inhibitors of thymidylate synthase. 
Biochimie et Biophysica Acta 8 8 1 ,  175-184
Santi DV and Danenberg PV (1984). Folates in pyrimidine nucleotide biosynthesis. 
In Folates and Pterins Vol 1- Chemistry and Biochemistry of Folates 345-398. RL 
Blakley and SJ Benkovic (eds). John Wiley and Sons, New York
Sartorius C and Franklin RM (1991a). Hybridisation arrest of cell-free translation of 
the malarial dihydrofolate reductase/thymidylate synthase mRNA by anti-sense 
oligodeoxyribonucleotides. Nucl. Acids Res. 1 9 ,  1613-1618
Sartorius C and Franklin RM (1991b). The use of anti-sense oligonucleotides as 
chemotherapeutic agents for parasites. Parisitology Today 7, 90-93
Schalling M, Ekman M, Kaaya E, Linde A, Biberfeld P (1995). A role for a new 
herpes virus (KHSV) in different forms of Kaposi’s sarcoma. Nature Medicine 1, 
707-708
Schiffer, CA, Davisson VJ, Santi DV, Stroud R (1991). Crystallisation of human 
thymidylate synthase. J. Mol. Biol. 2 1 9 ,  161-163
Seither RL, Trent DF, Mikulecky DC Rape TJ, Goldman ID (1991). Effect of direct 
suppresion of thymidylate synthase at the 5, 10-methylene-tetrahydrofolate binding 
site on the interconversion of tetrahydrofolate cofactors to dihydrofolate by 
antifolates: influenve of degree of dihydrofolate reductase inhibition. J. Biol. Chem. 
266,4112-4118
Shoichet BK, Stroud RM, Santi DV, Kuntz ID, Perry KM (1993). Structure-based 
discovery of inhibitors of thymidylate synthase. Science 259, 1445-1450
S m ib ert CA and Smiley JR (1990). Differential regulation of endogenous and 
transduced (3-globin genes during infection of erythroid cells with herpes simplex 
virus type 1 recombinant. J. Virol. 64, 3882-3894
Smith RF and Smith TF (1989). Identification of new protein kinase-related genes in 
three herpesviruses, herpes simplex virus, varicella-zoster virus, and Epstein-Barr 
virus. J. Virol. 63, 450-455
162
References
Spear PG (1992). Membrane fusion induced by herpes simplex virus. In Viral fusion 
mechanisms. J Bentz (ed). CRC press, Boca Raton, USA
Stevens JG, Wagner EK, Devi-Rao GB, Cook ML, Feldman LT (1987). RNA 
complementary to a herpesvirus alpha gene mRNA is prominent in latently infected 
neurons. Science 2 3 5 ,  1056-1059
Stevenson D, Colman KL, Davison AJ (1992). Characterization of the 
varicella-zoster virus gene 61 protein. J. Gen. Virol. 73, 521-530
Storms RK, Ord RW, Greenwood MT, Mirdamadi B, Chu FK, Belfort M (1984). 
Cell cycle-dependant expression of thymidylate synthase in Saccharomyces 
cerevisiae. Mol. Cell. Biol. 4 ,  2858-2864
Stow ND and Davison AJ (1986). Identification of a varicella-zoster virus origin of 
DNA replication and its activation by herpes simplex virus type 1 gene products. J. 
Gen. Virol. 6 7 ,  1613-1623.
Straus SE, Aulakh HS, Ruyechan WT (1981). Structures of varicella-zoster virus 
DNA. J. Virol. 40, 515-525
S tra u s  SE, Owens J, Ruyechan WT (1982). Molecular cloning and physical 
mapping of varicella-zoster virus DNA. Proc. Natl. Acad. Sci. USA 7 9 ,  993-997
Stroop WG, Rock DL, Fraser NW (1984). Localization of herpes simplex virus in 
the trigeminal and olfactory systems of the mouse central nervous system during 
acute and latent infections by in situ hybridisation. Lab Invest. 5 1 ,  27-38
Stroud RM and Finer-Moore JS (1993). Stereochemistry of a multistep/bipartite 
methyl transfer reaction: thymidylate synthase. The FASEB Journal 7 ,  671-677
Stroud RM and Finer-Moore JS (1993). Stereochemistry of a multisterp/bipartite 
methyl transfer reaction: thymidyalte synthase. The FASEB J. 7, 671-677
Takahashi M, Okuno Y, Otsuka T et al (1975). Development of a live attenuated 
varicella vaccine. Biken J. 1 8 ,  25-33
163
References
Takahashi M, Otsuka T, Okuno Y, Assano Y, Yazaki T, Isomura S (1974). Live 
vaccine used to prevent the spread of varicella in children in hospital. Lancet 2 ,  
1288-1290
Tanaka K, Kondo T, Torigoe S, Okada S, Mukai T, Yamanishi K (1994). human 
herpesvirus 7: another causal agent for roseola (exanthem subitim). The journal of 
pediatrics 1 2 5 ,  1-5
Tatman JD, Preston VG, Nicholson P, Elliot RM, Rixon FJ (1994). Assembly of 
herpes simplex virus type 1 capsids using a panel of recombinant baculoviruses. J. 
Gen. Virol. 75, 1101-1113
Telford EAR, Watson MS, Aird HC, Perry J, Davison AJ (1995). The DNA 
sequence of Equinine herpesvirus-2. J. Molec. Biol. 2 4 9 ,  520-528
Thompson R, Honess RW, Taylor L, Morran J, Davison AJ (1987). Varicella-zoster 
virus specifies a thymidylate synthetase. J. Gen. Virol. 68, 1449-1455
Toth I, Lazar G, Goodman HM (1987). Purification and immunochemical 
characterisation of a dihydrofolate reductase-thymidylate synthase enzyme complex 
from wild-carrot cells. The EMBO Journal 6, 1853-1858
Ueda K, Kusuhara K, Okada K, Miyazaki C, Hidaka Y, Tokugawa K Yamanishi K 
(1994). Primary human herpesvirus 7 infection and exanthem subitim. The Pediatric 
Infectious Disease J 13, 167-168
Vafai A, Murray RS, Wellish M, Delvin M, Gilden D (1988). Expression of 
varicella-zoster virus and herpes simplex virus in normal trigeminal ganglia. Proc. 
Natl. Acad. Sci. USA 85, 2362-2366
Veda T, Dutschman GE, Broom AD, Cheng Y-C (1986). Interactions o f human 
thymidylate synthetase (TS) with bisubstrate analogues. Proc. American. Assoc. 
Cancer Res. 27, 998
Voeller DM, Changchien L-M, Maley GF, Maley F, Takechi T, Turner R, Montfort 
WR, Allegra CJ, Chu E (1995). Characterization of a specific interaction between 
Escherichia coli thymidylate synthase and Escherichia coli thymidylate synthase 
mRNA. Nucl. Acids Res. 23, 869-875
164
References
Wagner EK (1985). Individual HSV transcripts: characterization of specific genes. 
In The Herpesviruses. 3, 45-104. B. Roizman (ed). Plenum press, New York/London
Ward RL and StevensJG (1975). Effect of cytosine arabinoside on viral-specific 
protein synthesis in cells infected with herpes simplex virus. J. Virol. 15, 71-80.
W atson RJ and Clements JB (1980). A herpes simplex virus type 1 function 
continuously required for early and late virus RNA synthesis. Nature 2 8 5 ,  329-330.
Wayata Y, Matsuda A, Santi DV (1980). Interaction of thymidylate synthetase with 
5-nitro-2’-deoxyuridylate. J. Biol. Chem. 2 5 5 ,  5538-5544
W eller TH and Witton HM (1958). The etiologic agents of varicella and herpes 
zoster. Serologic studies with the viruses as propagated in vitro. J. Exp. Med. 1 0 8 ,  
869-890.
Whitley R, Hilty M, Haynes R, Bryson Y, Conner JD, Soong SJ, Alford CA Jr 
(1982). NIAID Collaborative antiviral study group. Vidarabine therapy of varicella 
inimmunosuppressed patients. J. Pediatr. 101,125-131
Whitley RJ and Alford CA (1981). Parenteral antiviral chemotherapy of human 
herpes viruses. In The Human Herpesviruses : an interdisciplinary perspective. 478- 
490. Nahmias AJ, Dowdle WR, Schinazi RF (eds). Elsevier, New York
Whitley RJ and Gnann JW Jr (1993). The epidemiology and clinical manifstations 
of herpes simplex virus infections. In The Human Herpesviruses 69-105. B 
Roizman, RJ Whitley and C Lopez (eds). Raven Press, New York
Wittels M and Spear PG (1991). Penetration of cells by herpes simplex virus does 
not require a low pH-independent endocytic pathway. Virus Res. 1 8 ,  271-290
Yang F-D, Spanevello RA, Celiker I, Hirschmann R, Rubin H, Cooperman BS 
(1990). The carboxyl terminus heptapeptide of the R2 subunit of mammalian 
ribonucleotide reductase inhibits enzyme activity and can be used to purify the R1 
subunit. FEBS Lett. 272, 61-64
Zaia J, Levin M, preblud S, Leszcynski J, Wright G, Ellis r, Curtis A, Valerio MA, 
LeGore J (1983). Evaluation of varicella-zoster immune globulin: protection of
165
References
immunosuppressed children after house-hold exposure to varicella. J. Infect. Dis. 
1 4 7 ,  7 3 7 - 4 3
aSGOW 
iivxp.srr?
166
I f  g s sa H a
P  4-1
d
I i f  s'
UJ UJ UJ UJ 
& & & &
b
i—I 7T *H
59 ft “
0 ) <D <u tj ti a: d
. ts ti ti ts c  d  * 6
O l d d d d c o d <0 J d l d l J d l j J hqd l  
01 T ) 01 ID
4 4  4 4  4 4  4 4
^  □  n  n  ^  nco <0 <0 nS i—i i—i i—i 4-i
O’ C T d ’ O 'G ’ O ' a c og s s e a a c o a -  • • • • a a a a  uOOOOOr t r t i d l c f
> > > > .-h ,-h >
E-* Eh 
0 0 
-H -H
4 4  ^  <d
0 0 0
cn cn UJ UJ UJ UJ UJ UJ UJ UJUJ UJ,y
Eh Eh Eh E" Eh Eh
0 0 0 0 0 0 0 0
-  t  *> *-> *-> *-> *-> *-> j-j r i  , i Ti z>
| p | | | | | S S 8 8 B 8 ^ B
H G 1 j rP ^ ^ M l5 C5 rO^ ^ ^ ^ 0 i,C-U'*.UJ-l->rn m 4_i 
c £ £  [ 0 W I 4 4 1 H 4 4 4 4  > 1 4 4 J 4 4 l t l 4 4 - 5 S P l* 4 lH S S  5
o 1 co
 B #
. o i  o> .
Oi x  ^  <u aiw d 01 w
S ,  4-4 4-4 4-4 4-1 4 4  rrj
m m
d  >i >i x i  
0 0 0 0 0 0 0 0  
s  s  a  5  a  & a S
CO CO CO C/1 CO
•H rH ,Eh Eh Eh Eh 
0 0 0 0 
U  4 J  4J  4J
% % % 8 g
g g g g
4-1 4-4 V4 I I  f i l l  N  S |  1 1 1 1  | H  I I L  -4 - 4 4 - 4  a)  (1) 01 01 rH H  K, . r-| - H d  d  1-4 d - U  <11 01 4-1 m  2  ^  d  <
i l i ' H rH 5 S « « » ^ ^ ^ ^ ^ l 2 d T 3 Q i < i i ' C Wferg ra lrH & *H *H *H - H  i  i  i g  g  g  g  fc: ._i _ i  __i —i ___ i k  , U _i _
' O d £ o ’ 2 o i <Doi,2r2&
2 d r ; c o c o O i d d T 5 T 5 d rO
m & m g M & B—i .—i dd r* t-*  i  i  i m
w  w  ^01 <D u  
-u rd x :  
h-j a  4_) 
4-1 4-1 S  
4-1 <11 &
Ol <0
t f4-> 5
P
o
U J
rH
T>
i1
rH rH i—1w w w
0 01 0
rd d!a d O’
& a<0 a<0a di ai
<D <0 4-1
<d U J d
Ti
d
iH
O’ &
<11 O1 O’
O1 10 <0«s T) Ol
<0 U J U Ja 0* O1a
r-H
&
da
rH i— 4 1— 1
di dl dl
U J U J CO
Oi Oi Ol
> 1 d>>
& rHg rHg
Cn to
>,—i i—• >—i i—i
Cn 0) <U <U
£  £  £  53^  P o  cx a  a  
> , > , d  d  d  d(Sa w w w w w<u <u <u ai a> ai
d  d  <0 d  d  d
-  . i i i i i i
f t r O O l H O H H r l .  . , . .  -
C m n ^ i ’ i M r o n c o N i N f o  
« l < N C N ( N 0 4 C N C M O J C N n n C N  
H. I I I 1 I I I I I I I
y C N C N 0 4 C N 0 4 C N ( N C N ( N 0 4 0 4
| S S I S S l g S § § §
3
TI
*H
4-1
<0
4-1
g
oi t i ts
C/1 U J <0 cn
0 0 0 0
% % 6 g
d) T)
Hr  H  H  -H  KhS'Kw-vfii 'OOico w y,
& i, £ i  £ # £ § fi &o i o i a b < Q a 5 5 ' s  "a '<0 cx o> cx
. ^ g u m - s f  S t a s i sT)(0
>.
4-1
g
W  44 44
a  d 1 o 1
m
Q  C X  
i
W
g  6
00 04
ai CO <0
(0
•H UJ 1
>H
<0
4-1
<0
CO
-H §
•H
■H I i <0
1-1
d> u d o •H •H 4-1 u
dl •r) *r4 44 rH rH o -H
d JQ d o (d d CO
dl rH <0 d ) d d <0 <0U <0 o d 4-1 4-> o 44
UJ U a ci < < d d
«5 T)
U T)
U  44 Ol U
pq CQ CQ UJ Xa  ex. cn cq
4-4 0) P i  Q) <D (I)
X  M 0) Ti <U Q)
at a) > o’ O’ a: O’ g
i—I i—I 4-1 i—I 44  44  44
w ' y '  u i  u i  u i  kji u* u i  u i  rn
G Id r l  r l  r l  r l  H  £  rH . j
Ol G AJ .A CO 01 01 42 ^  m
aJ c d T S T i ' O T i T i T S ' O r t f
D T) 
G Jh
cn cn cn cn
G u 
cn cn cn cn
dl 04 01 04 04 d>
dl 0) AJ AJ 4-4 AJu
di T^
G
04
C
0)
G
04
B
<14
4-> 4-4 4-4 4-) 4-4 4-4
iH 1—1 i—1 i—1 rH i—1
Ol Oi Ol Oi Ol O)
■r4 *H G i-i u G
Oi cn in cn cn cn
T) Ti TS Ti Ti Ti
i—1 i—i i—1 i—i rH i—i
J>i 44 44 44 44
cd 04 04 d> 0) 0)
G G G >4 G V4
cn cn cn cn cn cn
id Ol Ol Oi Ol a
> > > aioi <u ai aih b hi >ix  x  x  ai*4-i >+-i a  jj
x  x  
1 1
G 0) 
G M 
cn cn 
Ti Ti
oi a;
G G 
4-) 4-4 
>
g a g g cG o> d) d) ai
cn T3 'O T) T)
Oi cd ttJ cd ccd
i
CD 
O’
&il 
5 &
Q. M-t 
G cn
S a
rH cn
3 XJ 
cd a: 
cd d-t
S
cd 04 
(0 G
44 44  
04 CD
rS* r£ T) TiAJ O’
O’ O’
cn cn
i! £
O) Oi 
4-1 4-1 
Ti Ti 
4-> 4-)% I
& ^
>1 > 1  
04 Ti 
Ti Ti 
cn cn a: O’
&
m T) Ti(U cu a>ai Ol ai
■* 'oi ^  'trt O’ 6 * <u ® « %x  ^  >i
1
^y' oioioiDiDigiaioioiO)2!SOi )CnOiOiOiOi>Oird(d(cJ( cdp) 0)<cJcciy H
I l l l l I i I I l l ! I I ? I I I I f y ? I ! l ! I ! I I f ? l i f
T) OiOiOiOiOiOiOiOiOic X 4-i g (d cn aj a; a: O’ aj b „—. ^  ^cdi-icdcdcdcncncnaiai^rnQidiaiT) cdcncncncdcncncncncn^t/ iq’ O’^i d
cucuiDaicuQiaicurH-H AJGGAJAJAJAJAJGAJ
—  cn cn cn cn cd id cd cn
S i l l
D i O i O i O i T i T l ' O T J  
Ti Ti TJ
(d cti 4-4
- - „  a  ij J■H |> i—I i—I i—I. X £ O’ O’ O’
<d <d (d (d (d <d
33dl G
Oi Ol G X X G 
CD Ti 04
O) Oi G G G C 
d> dl 04
3 3 S S2$
X. U) X  M
I I I !
6 6 1 1 5 5 5 5 = 5 5> > J j  -H
S g g g g g g g
cn cn cn
O O OG AJ G
cn cn cn cn 
O O O O4 AI A! A!
'rH *r
Ol w
O’ O’
ISIS S l i p i l i l l  111 I I P  111! I l l l i  i
I I  I | | | | | £  I t  3 3 a ............  . . . . . . . . .  . s aj j9 oi a; £ 3 aj
u j  i u  ^  t  ^  . u_i u_i •>$&&&&£•§
J  j  hi J
J  J  J  41
Pi Pi Pi Pi
a  a  fL, a
X UX U U
S 41 in -rl H
4-1 4-1 4-1 4-| CM 
>. >. >  >G G
P  S ^ P  P
J  41 4
Oi Pi Pi
i   ^ I   ^  ^ ^ ^
■ ■ ■ "■  44  44 44  44  44
_ cn cn cn cng g aj g m . : . :  .. ^  ,.
t> i—I S  ?  H  44 44 H  "S ^
44 44 44 4 4 G G G G  CG
ti fe H [4 (4 Pi 
44 44 41
Oi Ol
a  Dl, a
a  A  <n
00 <N
04 cn
cd
*H cn % ^d
cn
•H §
•H
*H I § § cd
> u G o -H *H 4-4
04 *H -H 44 i—1 rH o
W XI G O <d rd G
<14 T--1 cd d> rC g j 3
O id o G 4-4 44 O
C/4 u a a < < p
id T3 ido o a  -h
•H (d -H  -H
a  X) o t) 
o  <d rH  g
G  ,G  cd
44 a  44
ih a  a  a  a
cnG
a;
*H
o
cd
44
04
& . H  
-H  M 
rH 0)
5 s
P<ap*P, OiOiOip4
a  a  a  a  > > a a
N
0 201 o
•H JJ
o ■§ 
o cn
d4 44  i-l G
44 -H
cn
•H
•H  r o
cn 
G 
04 4J
!■§ cd cn
u G i j a a a ^ E - i w m m c o m s a G i w m
E-*
d)
Ol
cd
x:
a
a 3   ^ a D °g a a a a t f - y w mo i o o u o S S a S o i d i G i d i t j i &o i
(0 (d nj
> > >
B S S 1 1 S
o i  o i  o i  c o  J g  o i
T S  T ) T S  T S  T I  
C 4  d i  C X
T S  T J
11 i  I
T S  T
£ £ £ 
d 1 >
J  i J  J
n  Q  JSJ 0)P  111 4-1 rr-<
a s  a
W 0)
4J iH 0) -U 4-> 4-> 4-> 4-1 AA
T i T S  d l  T S  c  t s  t s  t s  a 3
H  H  M H  H
> i T )  O' O' U X  X  &  T S  
oi g  a4 a*; w  ty ts1 a; d1
• j  j  P  J  P  J .  P  h r )  * - 5^  ^  ^  J .  ^  J  ^  ^  »-l h   | J  *H *H *H -H J  J  J  *H -H *H *H -H ^ l_H
■ t I l ! S I I I ! I I I I I I I ! I I ! I I I I I I I § td i  _ _ _d 1 t?  d 1 as
ts1 di di diH 4J h ASJ? ^G TS TJ TJ 
01 aS 4-> G
d 1 T> AA dl 
u  (d oi '
TS TS TS 
A*
. . . 
as <d id
as aS aS
di di di
d i d i  b i  d i  d i  d i  _
d i d , d ' d , d 1 d 1 AS d 1 d* d 1 as as as as
d i d i d i d i d i d i d i d i d i d i T J  d i d i d i  
P 1 0 1 0 1 4 - 1 4 J - H A S 4 J 4 J 0 1  • rd r6 ' 631 £ji ^  rji Jg ?jt Jji Jg I>i !>i l>i r~
TS T) TS TS TS G T) TS TS Tl  G G G G T Soiwcn[doi4JGi(d(d(dSfd(8r3(d 
m , g ' 3 T ! T 3 A : T ) G X G T )  as as asa s
Eji di 'u  ^  ^
' P1 H -*
^
as as as
id <d (d 
di  di  cn
u  u  u
_  4-> TS T i 
X  X  X
£ £  * *
<d 6  6  6  0-1 M-t
t 3  t s  t S  t s  d i  d i
4J 4J 4) 4J A A
£ £ £
as as as as as aS
d 1 d* m as as m m
d i  d i  d i  d i  d i  d i  d >
4 J  T S  T J  T I  T S  t )  c>i  >i  a  <d <d a -  S
t s  G  - * - >  d i  d i  4 - i
1 1 1 1 1  I f
£  < §  s  s  < s  *
i s s *
d i  ^  S  o 1  d 1  ‘  
X   ^ 1 >1 > ,  & '
* 2 3 I  2 3  J,
 ^g § § s' s' 
s  ■ §  a  a  & >
'S . S  as as 
d s  S ’ d i  d i  
*  S  c  GA< rH  ■—I
4 J  4S A  4S
r “"i !>i £>1 £>i
as as cd <d
as as aS aS
d i  d i  C n  d i
0-4 4-4 4-4 4-4 §■&&£&!
4-1 4-1 4-1 4-10  (9
_ _ _ o»
X  o s  o i  ^c t ' i ' y y y y y y y y y y o u o u o u u u u O O t J C i t i r t Q r i i r i o r i i  m i
I l l l i lSl l iSl I l s I s l ss l l sss l s l^l s i l i - :
S 3 3 S 3 3 S S S S 3 S S 3 S S 3 3 S S S 3 3 S S S 3O a a O O O n p p p p 3 p P P P P P g g g p g p  ^
O O O O 0 O O O 6 6 S 6 3 3 O 6 O O 0
01 01
d i  d i
P  Q  Q 
O  O  O
o  a  a  oi a
111 A  44 144 A  I
O P  C5 o  O O
>< >4
■w ■H I
S3 X! X  ^  ^
0  o  5  3
-H  -H  P  P
p  is 4J u  as p‘ " o o u o
0 0  C N
as 01as
-H 01 § 3 as01
■rl 1 -H*H | § § as
> o G o •rH •H 4-1as *H •rl 4-4 f-H r—1 ou X! sh O (TJ (d Has i—1 as as X X aS
u a) o G 4-» 4J O
U1 O a 6 < < P
as
4J
as
I—I
G
0  G 
•H O
01 -r-i
O  P
-H g
01 3 m
G •H u 01
as as TS OS •H
G u G a • rl rH
o ■rH OS •H -H •H •H
N a  m o TS N  -H 4-1
| oG
OS
-G
rH
OS
G
O 2  *3 •3
.
4-1 u 4-1 d i u  u 01
p P a , a E-i W t o
a s  S  
a s  3
N  -H  
G  c  - h  
h  o j  a s  n s  i n
> i  a s  m  £ i—i G
0 1  r H  
G  - H
h  4 - »  a s  a s  4 J
G  O  0 1  M  A 3
a s  a s  a s  G  3
d i  h  o  a s  o i
4 - i  ’ d *m E-i 
O S
d i  d i
ol as* * * * *  t~{
S  P  P  o  p q  p  p
•H -H -H -H -H -rl >  >  -rH -rl -rl . H -H -rl !
^ o j ,0 d a ^ ^ ^ o o ^ a j ^ ^ ro r7 a> oj ai oj b1 d $0 0 0 0 0 0 0 0 0 0 0 ^ 0 0 0  $ 0 0 $  <« id y S
d  ^  H  H  r l  r l  H  g  S r H i J r H r H i H  *  ,-H rH —i ,-H r-H r-l ,Oi Oi Cn d - _4J 4J U 4J 4J 4J 4J 4J  ^  ^
Pm Pm ■
0 0
C n  C n  d i
4-1 4-> 4J  
( 0  ( 0
2 2
0) Oi 171 0  Cn 
o  u
O’ o’
d  m
rH 1—I 1—I 1—I g  1—I 4J 1—If—| 1—|
T) OiOi Oi 'O’O T J T l ' O T i ' d  . .   „  ” 0 0
f i i s sssasss^*
H  E h  E - I  E h  H  t n  E - *J  iJ J  hI iJ J  J  
P  P  P  P  P  J  _q
c n  d  d  d  d  d  d
X  X  X  X  > i  > •  X
t o  c o  c o  c n  c n  c n  c n
r f j  < c  < c  < <  < c  < < c
S i —I S *H
m i
C n  c n
C n i ? C n C n C n 0 C n C n
g g g g g g g g
P P P
9
P P P P
C n C n C n d O l C n C n
C O C O C O C O C O C O C O C O
o; oi Pi 0; O i Pi o i o i
cn a o» cn 0 1 a c n a
> H > H > H > H > H > H > H > H
£
1 - - - 1 r H r H r H r H r H r H
O ’ O ’ O ’ O ’ O ’ O ’ O ’
u 0 0 0 0 u 0 0
C O C O C O C O C O C O C O C O
p
q j
p
q j
p
a > 5 3 3
p
0 )
p
0
p
Q J
l i S S 8 f i S S g S S “ s S s l ^ ® ® “ 3 | ,iS ' S t lS | S g . ' S . ,S i6 | a 9 9 § , s § , e e e e s 9 9 S 9 e l e e e H i § 6 e 9 9 9 iWWWcoWWWCOCOCOCOcoCOCOCo R cocOw WWWm WWm & w ^ WMGt f & & « £ r t t f t f * t f « o s o ; o i o ; £ o ; o i £ r t p i o i $ o i o i 3 2 2 K 3 o « ? S l ^ ? 9 l ? 9 ? ? ? ? , o| Pl P, 0 l a 0 , S S S a a o i S a S r t a 0 , a a ‘li
> H  > H  r
i l l
O  u  o  o
j  p  p
u  2  qj
s s  &
f i > O l S i C n 0 )
g g g 1— 1 H
P P p P p
O O 0 0 0
C O C O C O C O C O
05 o i 0 5 05 o i
a o o i cn 01
> H > H > H > i > H
' - - - 1 H 1 — 1 a a
a a g - H • r H
0 u 0 O 0
C O C O C O C O C O
p
C D
p
0
P
a i 3 3
O ’
£
C n  O i  O i  O )  01
a a a a a a a a a a a o i d i o i o i
o o o c n c n o o u c n o u u d d d
r H r - H t —l r - 1  r—l i —I r H i —I 4-1 44  4-4 4H 4-4 4H 4H
a s K x s s i s c K s i i i i i
g g g K K K K g S i K S i S K I i SPi P< P< A Pi Pi Pi 0i n- n, n. n. n. n. n. 
P  P  P  P  -
O i  O i  O '  0 )  O i  O )< 0  T ) d d d a d d d
4 - 1  4 - 1
a  a
1—I rH r-H rH
4-1 4H 4-1 
rH r—I 1—I 4-H rH rH 4-H
* K W X X X X
K « &2 B Si K SOi Oi Oi to Oi Oi d
ft 0,0ft W ft ft O ’  T I  T l  T J  T J  T )  T 3  H1—I .—1 __I 1 ____ I . _i .
Cn Cn
QJ Tl
B  £  g  cj1 jj B
Q J c n
d
• H c n
C
9
c n
■rl §
•rl
■rH 1 §
> 0 G 0 •rl
d ) ■rl •rl 4H 1— 1
a j G X I JH O d
0 1 d > 1— 1 d d ) - G
o 4 - 1 O d 0 G 4 - 1
0 d •
g Pi C O 0 C 4 0 2
c n
d - H £
4-1 c n 3 m
d G • H U c n
i —1 Q J d T > d •H0 G 0 d a •rH 1—1
O G 0 •H d •rH •rl •rl
■rl O N a J S O T I  -rl 4-)
c n • 0 d 0 d 1 — 1 G  <—1 £ 1
d d g Ph A d O  O d4H a . 4 - 1 O 4H C n  0 c n
U p P P C 4 a Eh W «
H  o
C Q C O K g P P C O C Q
0 0  - - - - - - -  r H  J > 1 0  ( 0
i d  c d
^ & &i a  i i i i i i g  ec n  c n
M M H  H  H
a  ( 0  a  c d  a ;  a :  u
il
D l  D l c o  ( 0
d i  x
n  O *  V. 
% £  £
( 0  ( 0
£ £ 5  £ £ £ £ £ £  S £ g* P i  P < D )  t n  r |
_  I  H i  i  1 1  i  i  & i
a  a a  a  a  a  x  x  a
£ £ £ £ £ SS
&  S .  D i
a  a  a a  w
T )  T !  t ! Ti 0 )
T I  T l  T J  n
H
T )  T !Dl Dl tJ)
O '  D 1  O' Q J  0 )  d
W  IH IH IW IH IHQ Q Q Q
0 )  0 )  O J  4->
a j  Sd. i j  a ;
0 )  ( 1 ) A J  0 )
14-1 M - l  M _ |
4-1
c n
^  ^  ^  ^  ^ ^ %
a )  q j  < d  < u  q j  t v  V
H  H
‘ • h  >1  o n  >1  d  d  a i
a j
a  c o
a >  o i
0 )  T J  T l  T l T I  T )  T l  T J  
M  H  
4 - >  4 - >  T l
T l  T l  T l 4-1 4-c
c n  T l  u D 1  T )  T l c n  c n  c n
( 1 )  ( 1 )  T J  T J  < D  C O
& £  £ £ * •" 5
> h  d  H  a  c n
( 0  ( 0  x  c  a :
44 -H 44 44 -rl .H
d )  
A C
« i  &  &  d  a :  a j  a j  a :  a' d '  c
-i4 -r4 -H 44 44 44 44 rH H  -H
>  - H  >  - H  A i  A I
J  J  O  J  O  J
d l  Q J
a  4 J a  a
D 1  X
d )  d )
( 0  c d
g & & & &£•''>
a  a  >  >  a  a  - u
>  d l  T )  T )  0 )  Q J  - U
a  a  a  a
S  in  d) 4J
£  £  o  0 1
0 )  0 )
CT D1 a  a
d >  q j
b 1  A T  c d  
I )  T l  T l
o  o
c n d ) c n c d d ) Q J Q J A J A J 4 - i  
> ^  ^  & t> tj tj A* d  -H AJ AJ 2  QJ d  d  14 J4  -rl -r-1l4CAIAJA:AlTSdJincnaJ(UDi<lidid)did)T!v n d d J n d d d d J i H n a a c n A J d J c u o j a a
I d  i d  r H  1— I  r H  A ^  A J  C
4 4  4 4  - H  - H  - r l  - H  - r l
> h  a :  i n  a j  m  a j  >
a a a a a a a a a a a a a a & a a a a a a a a a a a a f t a
44444444444444444444444444444444444444444444
£ & & & & & & & & £ & ' £ £ £ £  £ 2 2 2  g g &
a a a a a a a a a a a a a a a a a a a a i V a
4-J CO 4-1
a  a  a
a a o a o i ^ o i o i o i o i o i o i o i ^ i n  a  a  <§ <§ <  ^ di  c i
b !  t !  d )  * h  - h  - h  o j  d )  D ] - u  ( U d J  c u  q j  c d  i d  c d  ^ - r i  o iin a; 4-i a j a j a j a j a ; b 1 a : d , d , 4 4 A J a j a j a j
c d  a  a  c d  c d
T )  Q J  0 1  T l  T l
•r l  - H  >  -r l  >
CN
a  a  a  i d  c d  c d  a
d )  Q J  Q J  T )  T )  0 )  Q J
•r l  - r l  - r l  “r l  - r l  “A  J>M  M  M  M  M  M  M3 3 3 3 3 3 3
rH rH rH rH 
}H >4 >4 >4 >4
•r l  - r l  -H >  >
5 5 5 5 5
§ 0 8 § § 8 § § 8
4-1 4-1 4J 4J 4-1 4JM M M M M M
MH 44  MM 4-< 4-1 I-Ih
cn cn 
> 4
c d  i d  i d  c d  
< u  T )  T )  T l  
> >
r H
0
• H
p
0
* H
4 - 1
O
r H
O
1—1
> > C O - U 4 J
X X X X X
a  c rc n  i d
T )  Q J
X X X > 44 X X
5 5 3 5 5
o o o £ o
4 4  44  Dl  - r l  rH
4J  4-1 4-1 AJ 4-1
X  X  5  X  X fi a44 44 cn 1 44 X
CX) CN
qj cn cd -rl
p >< >4 4-1 cn•rl in s cd P cd C
cn
■rl §
-rl
•rl g S  g cd
1—1 
P
qj
d
cd
u
> 0 c 0 •H *H 4-1 0 in 0 •H
0) •H -rl 44 rH 1—1 0 *H 0 N ad) >H A Ih O cd cd cn •n 33 0in QJ rH cd QJ X  X cd P (3P 4-1 CJ cd 0 c 4-1 4-1 u 44 g c3 4-10 id • « •X a CO u a u <  < Q u A j
cn44 d
g  0J qj g  cn
3  X  3  cd 3  d
• r l  M W O ’ - r l  N  - r l  W OJ
T i cd - r l  - r l  J4  D  f-H - r l  W
P  a  - h  rH  1 i di dj cd c n  in  h  p  4 1 C
(d - r l  - r l  - r l  - r l  O  d  D  4-1 - r l  - r l  D  - r l  OO E4 O
,lQ U  T l  M - H 4 - l r H  X . —I - r l  4-1 QJ QJ 4-1 -©- CJ
C d r H d p r H ^ > , d ) 4 4 C O C n d - Q  ®  ®^ j c d o d o ^ g r H d S c d c d p p  Di Di
0 4 4 D i o u c n i o 4 4 - r i b i r H o c d c n  cd id• ■ • • • • • • • • • • • a  (~| fH
a a t H t H w m f f l u J X X c P c - i c o m a a

